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ABSTRACT

The bioflavonoid hesperidin and its aglycone hesperetin are promising candidates for the
treatment of diabetic retinopathy and diabetic macular edema because of their pharmacological
properties. The objective of this project was to characterize the biopharmaceutic and
pharmacokinetic characteristics of hesperidin and hesperetin for ocular delivery, especially with
respect to the distribution of these compounds to the posterior segment of the eye.

Hesperidin and hesperetin were found to be water insoluble compounds. Although they
demonstrated good permeability across the ocular tissues, hesperetin’s permeability was found to
be higher than that of hesperidin. Hesperidin demonstrated symmetrical transcorneal and
transretinal permeation whereas hesperetin exhibited asymmetrical transcorneal and symmetrical
transretinal transport. However, none of the influx or efflux transporters, expressed on the
cornea, were involved in hesperetin’s corneal transport. It was concluded that hesperetin’s
physicochemical properties, ultrastructure of the cornea and components of the diffusion media
play a major role in the passive asymmetric transport.
Results from the intravitreal kinetic studies of hesperidin, hesperetin and glucosylhesperidin (a water soluble derivative of hesperidin), following intravitreal injection, revealed
that all three compounds have relatively short half-lives (< 8h) in the vitreous humor. Hesperetin
demonstrated the shortest half-life, consistent with its physiochemical characteristics. All three
compounds exhibited linear pharmacokinetics, within the dose range tested. This information
will be critical in the design of ocular drug delivery systems for these compounds.
ii

The ocular bioavailability studies following systemic administration suggested that
vitreal bioavailability is negligible because of rapid conversion of both hesperidin and hesperetin
into their hydrophilic metabolite, hesperetin-glucuronide, in the plasma. In contrast, topical
instillation produced significant concentrations of hesperidin and hesperetin in the ocular tissues.
Hesperetin’s diffusion into the ocular tissues, in vivo, was high compared to hesperidin; however,
very low levels were observed in the vitreous humor. Inclusion of benzalkonium chloride, as a
penetration enhancer/preservative, significantly improved the vitreal levels of hesperetin.
In conclusion, topical administration would be ideal for the delivery of hesperetin to the
deeper ocular tissues. Development of a controlled release drug delivery system and specialized
ophthalmic formulations will reduce the frequency of administration needed to sustain the levels
at the target site.
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CHAPTER 1 : OVERVIEW OF THE RESEARCH PROJECT

INTRODUCTION

Eye, the organ of sight, has a very unique structural and biochemical organization. Age
and certain disease conditions, however, can affect the function of this vital organ. A report from
the World Health Organization (WHO) in 2002 estimated that approximately 161 million people
were suffering from visual impairment worldwide, out of which 37 million face blindness while
124 million suffer from low vision. Age seems to be a causative factor in blindness as 82% of the
population with blindness are aged above 50 years (1). In the United States, in 2002, among
civilian non-institutionalized adults, 19.1 million people were suffering from visual impairment
including 0.3% with blindness (2). Although, blindness is necessarily associated with ageing, the
leading causes of blindness are cataract, refractive error, glaucoma, age-related macular
degeneration, trachoma, childhood blindness and diabetic retinopathy (1, 3).
With regard to diseases affecting the posterior segment of the eye, it is estimated that
about 1.47% (1.75 million) of the population in the age group of 40 years and older in the US is
diagnosed with AMD and this number may reach 3 million by 2020 (4). Further, approximately
4.1 million US adults aged above 40 are suffering from diabetic retinopathy and one out of every
12 persons with diabetes mellitus, in this age group, faces vision threatening retinopathy (5).
Although significant progress has been made in the identification of molecular mechanisms
involved and in the development of therapeutic agents, drug delivery to the posterior segment of
the eye, or back-of-the eye, remains a formidable challenge for the pharmaceutical scientists.
1

Pathophysiology of diabetic retinopathy involves the process of physiological or
pathological angiogenesis. Oxidative damage to the retinal neuronal cells as a result of free
radical generation, a complication associated with diabetes, is considered to be a principal factor
responsible for the initiation and progression of diabetic retinopathy (6). Decreased retinal blood
supply, as a consequence of long term diabetes is another major contributor to the progression of
this disease. In patients with diabetes, proliferative diabetic retinopathy is the neovascular result
wherein ischemia induced angiogenesis on the surface of the retina, and into the vitreous, is
postulated to occur. Increased permeability in these vessels can lead to diabetic macular edema,
the major factor responsible for vision loss (6).
Currently, these disorders are maintained by preventive care or treatment of the disease
(7). Preventive care is aimed at controlling the metabolic abnormalities. Laser photocoagulation,
vitrectomy or pharmacologic intervention, with the drugs targeting the pathophysiology of the
disease, are the various treatment options available. However, laser photocoagulation and
vitrectomy, which are surgical interventions, are indicated only during sight threatening
conditions of the disease. Drugs used for treatment include, anti-inflammatory agents, antiVEGF agents, PKC-β inhibitors and antioxidants. However, none of these agents act on the
multiple pathways associated with the initiation and progression of the disease.
Hesperidin (hesperetin 7-rutinoside) is a flavanone glycoside, comprising of an aglycone,
hesperetin, and an attached disaccharide, rutinose. Hesperidin is abundantly found in citrus fruits
(family Rutaceae) and has also been reported to occur in many plants other than Citrus, such as
in genera Fabaceae, Betulaceae, Laminaseae and Papilionaceae. What makes hesperidin and
hesperetin particularly attractive for the treatment of diabetic retinopathy or macular
degeneration is their potential effect on the ocular blood flow and vascular permeability, two
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important factors leading to the initiation and progression of diabetic retinopathy. It has been
demonstrated that these compounds can support retinal function recovery subsequent to retinal
ischemia (8). Hesperidin’s effect on ocular blood vessels has not been studied. However, this
compound was initially referred to as ‘Vitamin P’ to indicate that it could decrease capillary
permeability and fragility, although subsequently the term vitamin P has been discontinued (9).
Literature suggests that these compounds can prevent microvascular leakage by virtue of their
vasoprotective action through the inhibition of the enzyme hyaluronidase which is reported to
regulate the permeability of capillary walls and supporting tissues (10). Additionally, it has been
demonstrated that they can decrease blood cell and platelet aggregation, believed to be beneficial
in cases of capillary permeability and fragility (9).
Besides their effect on vascular permeability and ocular blood flow, both hesperidin and
hesperetin demonstrate strong antioxidant properties (11). This antioxidant activity is through
their ability to quench oxidative radical chain reactions (capable of oxidizing and nitrating
cellular proteins, nucleic acids and lipids) and can thus help preserve neuronal health. These
compounds also exhibit significant anti-inflammatory activity by modulating the prostaglandin
synthesis and COX-2 gene expression pathways (12). Ayalasomayajula et al.,(13) reported that,
in diabetic rat retina, up-regulation of COX-2 is responsible for the production of prostaglandin
E2, a pro-angiogenic factor implicated in vascular permeability and leakage. This prostaglandin
up-regulation was inhibited by celecoxib (13), a selective COX-2 inhibitor.
Hesperidin and hesperetin has been reported to possess analgesic (14), hypolipidemic
(15), anti-hypertensive and diuretic activity (16). Another potential therapeutic application of
hesperidin is its anticancer activity mediated through the suppression of cell proliferation (17,
18). Thus, both hesperidin and hesperetin appear to be capable of modulating multiple pathways
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(Fig. 1.1) identified in the genesis and progression of diabetic retinopathy and diabetic macular
edema. It can also be used in other ocular diseases because of its varied pharmacological actions.

Decreased retinal
blood flow *

Retinal
Hypoxia

Free radical
mediated damage
of retinal blood
vessels. *

Transcription
factor
activation e.g.
NK-κβ *

Arachidonate *

PGG2

PGH2

COX-2 *
Prostaglandins
VEGF

Hyperglycemia

NO *

PGE2, PGI2, PGF
Angiogenesis,
vascular permeability.

Figure 1.1: Schematic representation of some of the currently identified pathways involved in
the development and progression of diabetic retinopathy and macular degeneration. * Indicates
pathways which hesperidin and hesperetin can potentially inhibit.
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STATEMENT OF THE PROBLEM

Currently hesperidin is used as a dietary supplement for improving the blood flow and for
its vasoprotective properties and is available as an oral dosage form. Ameer et al., (19) reported
that following oral administration, hesperidin is absorbed across the gastrointestinal tract, but
cumulative urinary recovery indicates low bioavailability (<25%). Several factors limit oral
bioavailability of hesperidin, including poor water solubility and precipitation in an acidic
environment (20). Moreover, hesperidin and hesperetin are substrates of the intestinal efflux
protein, P-glycoprotein (P-pg), (21-23) and intestinal and hepatic drug metabolizing enzymes
CYP450 (24). These factors, acting together, severely restrict systemic bioavailability of the
orally administered drug. Furthermore, hesperidin possesses poor transmembrane permeability
and is believed to be absorbed primarily by the paracellular pathway (25, 26). Thus intestinal
tight junction proteins would limit intestinal absorption. Additionally, reports indicate that
hesperidin needs to be converted to hesperetin, by the beta-glycosidase secreted by the intestinal
flora (27), for absorption to occur. Thus, currently, it is unclear as to what fraction of the orally
administered hesperidin can reach the systemic circulation.
With respect to ocular drug delivery, the eye is a secluded organ protected by various
physiological barriers that prevent unrestricted entry of xenobiotics into the ocular tissues from
the external environment or systemic circulation. In case of hesperidin and hesperetin, over and
above all the barriers to oral bioavailability, in order to exert a therapeutic effect in diabetic
retinopathy they must reach the neural retina, the target site of action.
In general, drug delivery to the internal ocular tissues can be achieved by topical,
systemic or intravitreal administration routes. Delivery and maintenance of therapeutic
concentrations by any of these routes depends on several factors: biopharmaceutic (solubility,
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log P, pKa and permeability characteristics across the ocular barriers) and pharmacokinetic
(absorption, distribution and elimination from ocular tissues).
Till now no one has investigated the ocular delivery of hesperidin and its aglycone
hesperetin through any route of administration. This research project explores two critical
aspects in ocular delivery; biopharmaceutic (solubility, log P, pKa and permeability across ocular
barriers) and pharmacokinetic (absorption, distribution and elimination following topical,
systemic and intravitreal delivery) characteristics.
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SPECIFIC OBJECTIVES

1. Biopharmaceutic Characterization:
i.

To evaluate solubility, stability, physicochemical properties and in vitro
permeability of hesperidin across the ocular tissues - cornea, sclera and retinal
pigmented epithelium (RPE).

ii.

To evaluate solubility, stability, physicochemical properties and in vitro
permeability of hesperetin across the ocular tissues - cornea, sclera and RPE.

2. Pharmacokinetic Characterization:
i.

To investigate the ocular bioavailability and to simultaneously evaluate systemic
pharmacokinetics following intravenous administration.

ii.

To investigate distribution of these compounds into the posterior segment of the eye
following topical instillation.

iii.

To determine ocular kinetics and disposition characteristics of these molecules
following intravitreal administration.
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CHAPTER 2 : LITERATURE REVIEW

ANATOMY OF THE EYE

The structure of the eye can be described in terms of different tissue layers and fluid
compartments, as comprised of (Figure 2.1).
External layer

: Cornea and sclera,

Intermediate layer

: Iris-ciliary body, lens and choroid

Internal layer

: Retina

Fluid compartments : Aqueous humor and vitreous humor

From a drug delivery perspective, the eye can be broadly divided into anterior and
posterior segments. Anterior segment consists of the cornea, the conjunctiva, the iris-ciliary
body, the lens and the aqueous humor. Posterior segment consists of the sclera, the choroid, the
retina and the vitreous humor.
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Figure 2.1: Schematic illustration of parts of the eye and its biological barriers. (1: Tear film
provides the foremost physiologic impediment against installed drugs
drugs. 2: The cornea is the main
route for drug transport to the ante
anterior chamber. 3: The conjunctival and scleral route provides a
passage for macromolecules
ecules and hydrophilic drugs
drugs. 4: Small compounds penetrate from the iris
blood vessels into the anterior chamber after systemic administration. 5: One of the elimination
pathways for drugs from the anterior cha
chamber - by aqueous humor outflow or 6: by venous blood
flow after diffusing across the iris surface. 7: The retinal pigment epithelium and the retinal
capillary endothelium are the main barriers for systemically administered drugs. 8: Intravitreal
injection to reach the vitreous. 9: Drugs can be removed from the vitreous through
rough the blood–
blood
retinal barrier or 10: through diff
diffusion into the anterior chamber.)

Courtesy: Figure was adapted and modified from National Eye Institutes (NEI), National
Institutes of Health (NIH).
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The following section briefly describes the anatomy of the different tissue layers and fluid
compartments of the eye.

Cornea
The cornea is an optically transparent avascular tissue, which allows light to reach the
retina. The structure of the cornea is complex and is mainly composed of five layers of tissues:
the epithelium, the Bowman’s membrane, the stroma, the Decement’s membrane, and the
endothelium. The epithelium is the outermost layer of the cornea and is composed of 5-6 layers
of epithelial cells which are tightly packed together and is hydrophobic in nature, which makes it
an important barrier to drug delivery. The Bowman’s membrane separates the epithelium and the
stroma. The stroma comprises around 90% of the corneal thickness and is hydrophilic in nature
because 85% of the stroma is water. The stroma acts as a barrier to the delivery of lipophilic
compounds. The Decement’s membrane lies between the stroma and the endothelium. The
endothelium is a monolayer in thickness with loose intercellular junctions. It is in contact with
the aqueous humor and is responsible for controlling corneal hydration. Nutrients and oxygen to
the corneal cells is supplied by the lachrymal fluid and aqueous humor as well as by the blood
vessels located at the junction between the cornea and the sclera (28).
There are two major pathways of drug penetration across the corneal epithelium,
transcellular and paracellular. Transcellular diffusion can take place by the partitioning of the
drug into the cell membrane or by diffusion through the cellular pores. Paracellular pathway
involves diffusion through the intercellular space. The delivery of therapeutic agents across the
cornea primarily depends on the physicochemical properties of the compound and on the
involvement of any functional nutrient transporters expressed on the cornea (29, 30).
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Sclera
The sclera is the opaque outer tunic of the eye. It extends from the outer ring of the cornea
to the optic foramen, and is perforated by the optic nerve. It is usually referred to as the “white of
the eye” and is a protective layer. The scleral tissue possesses considerable viscoelastic
properties and consists of the tenon’s capsule, the episclera, the stroma, the spur and the lamina
fusca (31). The tenon’s capsule and the episclera are the two outermost vascularized layers of the
sclera. The stroma is composed of collagen and elastic fibers. The lamina fusca forms the outer
portion of the choroid and is a component of both the uveal tract and the sclera (31, 32). The spur
is a rigid ring like structure formed by the abridgment of the deep scleral fibers with the fibers of
the limbus. The sclera is mainly made up of collagen fibrils, predominantly Type I collagen,
embedded in a glycosaminoglycan (GAG) matrix. In addition, collagen Types III, V, VI, VIII
and XII are also found in the human sclera. Based on the structure and composition of the sclera
it is believed that hydrophilic drugs are better suited for transscleral diffusion. (32)
Iris-ciliary body
The iris is the opaque ring visible through the cornea, in front of the lens and is made up
of connective tissues and muscles with a circular opening, called the pupil. Pigmentation of the
iris gives a characteristic color to the eye. The ciliary body is a complex, highly specialized
vascular tissue comprising of several cell types. Contraction or relaxation of the ciliary muscle
alters the tension on the lens causing it to alter shape and thus shift focus. The surface of the
ciliary body is elaborated into a series of ridges named ciliary processes, which are short, black
tissues arranged radially. The ciliary body secretes the aqueous humor. In the iris-ciliary body
there are two types of muscles, radial and circular. They change the pupil size to control the
amount of light entering the eye. (33)
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Choroid
The choroid is another vascular tissue of the eye, sandwiched between the outer sclera
and the retina. It is light to dark brown in color and continues anteriorly into the ciliary body and
iris, and ends posteriorly at the optic nerve. The choroid is classically divided into four or five
layers by light microscopy; the epichoroid, the vessel layer, the choriocapillary layer and the
Bruch’s membrane. It is opaque and deeply pigmented with melanin in order to absorb excessive
light; otherwise internal reflection would form multiple images on the retina. The principal
functions of the choroid are to nourish the outer retina and to provide a pathway for blood
vessels that supply the anterior part of the eye (33). The choroidal region of the eye has the
highest per unit blood volume (34). Thus, for compounds traversing across this region, the
choroid is considered to act as a sink because of the huge network of blood capillaries: the
choroidal capillaries.
Retina
The retina is the light sensitive part of the eye and is a thin film of tissue covering most of
the inner wall of the eye. Histologically, the retina is an extremely well‐organized tissue in which
10 layers are classically recognized. The inner limiting membrane (ILM), a basement membrane,
forms the boundary with the vitreous humor and the outermost layer of the retina, retinal
pigmented epithelium (RPE). The layers in between these two layers include, the retinal nerve
fiber layer, the ganglion cell layer, the inner plexiform layer, the inner nuclear layer, the outer
plexiform layer, the outer nuclear layer and photoreceptor layer (33).
The RPE, a single epithelial cell layer under the choroid, plays a vital role in the support
and maintenance of neural retina viability. RPE cells can be differentiated into an apical portion,
facing the neural retina, and a basolateral portion, facing the choroid. These cells are polarized
12

and express several nutrient transporters on the apical and basolateral membranes. The macula is
the central part of the retina that provides fine central vision and color perception. The fovea is a
depression at the center of the macula. The RPE is an important physical barrier to drug delivery
to the posterior segment of the eye (35).
Vitreous humor
Vitreous humor fills the region between the lens and the retina. It occupies nearly 80% of
the eye globe. The main component of the vitreous humor is water (98-99% w/w), with a
microstructure of collagen and glycosaminoglycans (hyaluronan, chondroitin sulphate and
heparin sulphate) conferring viscoelastic properties. The alignment of collagen and
glycosaminoglycans plays a key role in the maintenance of rigidity and stability of the vitreous
gel. Importantly, it also acts as a molecular barrier to diffusion. (33, 36)
Aqueous humor
Aqueous humor, a clear colorless liquid, is produced by the ciliary body by ultrafiltration.
The production rate of aqueous humor is 2-3 µL/min and is responsible for the maintenance of
the shape of anterior chamber and nourishment of various ocular tissues. It is slightly acidic (pH
7.2), hypertonic and has less protein content compared to the plasma. A major function of the
aqueous humor is maintenance of intraocular pressure (IOP) and providing nutrients (glucose,
oxygen, electrolytes) to meet the metabolic requirements of the avascular cornea. The aqueous
humor also aids in the elimination of metabolic products (lactate, pyruvate, carbon dioxide).
Elimination of aqueous humor takes place via the trabecular meshwork into the canal of
Schelmm and finally into the systemic circulation (37).
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OCULAR DRUG DELIVERY

Drug delivery to the eye poses significant challenges due to the presence of the unique
anatomical and physiological barriers. Ocular drug delivery can be broadly categorized into
anterior segment and posterior segment drug delivery. Treatment of anterior segment diseases is
relatively less problematic compared to the posterior segment diseases. The following section
briefly discusses various routes of administration for ocular delivery.

Figure 2.2: Routes of drug administration to the eye

Courtesy: Figure was adapted and modified from National Eye Institutes (NEI), National
Institutes of Health (NIH).
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Topical Route
It is the most common and convenient method for ocular drug delivery and, importantly,
is the most effective route for the treatment of anterior segment diseases. The corneal route
represents the major pathway of absorption following topical administration of a medication. The
major advantage of this route is ease of application, noninvasiveness and very little, if any,
systemic exposure. However, only 1-7% of the instilled dose reaches the aqueous humor. Several
factors e.g. formulation (aqueous solubility and stability) and permeability/delivery (precorneal
drainage, corneal ultrastructure and drainage through the conjunctival vasculature or
nasolacrimal duct) issues, limit bioavailability of the administered drug by this route (28, 38, 39).

Systemic or Oral Administration
These are other options for delivering therapeutic agents to the ocular tissues. However,
these routes are challenged by physiological barriers like the blood-aqueous-barrier (BAB) and
the blood-retinal-barrier (BRB) for the anterior and posterior ocular segments, respectively. The
BAB is composed of two discrete cell layers located in the anterior segment of the eye, the
endothelium of the iris-ciliary blood vessels and the nonpigmented ciliary epithelium. Both cell
layers prevent the entry of solutes from the systemic circulation into the aqueous humor because
of presence of the tight intercellular junctions. The BRB restricts the entry of therapeutic agents
from the blood into the posterior segment of the eye. It is composed of two types of cells, the
retinal capillary endothelial cells and the RPE cells known as the inner and outer blood-retinal
barriers, respectively. Following oral or systemic administration drug can easily permeate into
the choroid, due to its high vascularity. However, the outer BRB restricts the entry of drugs from
the choroid to the retina, through the RPE tight junctions. Moreover, these routes are associated
with unnecessary systemic exposure to the drug. Physicochemical properties of the compounds
15

and any specificity towards the nutrient transporters expressed on the ocular barriers plays an
important role in drug diffusion across the BAB and BRB (28).

Periocular Administration
It includes subconjunctival, subtenon, retrobulbar, peribulbar and posterior juxtascleral
routes. It is a more effective but minimally invasive route of drug administration for the posterior
segment of the eye. The physical barriers associated with this route are the sclera, the choroidBruch’s membrane, and the RPE. Following periocular administration drug can reach the
posterior segment by three main routes; the first constitutes direct diffusion wherein the
compound traverses across the underlying tissues into the vitreous humor. An alternative
pathway could be absorption into the aqueous humor followed by diffusion into the vitreous
humor. Thirdly, the drug moiety could be absorbed into the general systemic circulation, through
the scleral, conjunctival and soft tissue vasculature and lymphatics, and could then diffuse across
the BRB into the vitreous humor. Lee and Robinson evaluated the contribution of each of these
three pathways and found that only the first contributes significantly to the overall vitreal
bioavailability of the administered drug.

Although the periocular route does deliver the

compound into the aqueous humor and the systemic circulation, the contribution of these routes
to drug penetration into the vitreous humor is minimal (28, 35).

Intravitreal Administration
Unlike the periocular route, intravitreal administration delivers the drug directly into the
vitreous humor. It is the most effective method of drug administration for posterior segment
diseases; however it is invasive in nature. Vitreous humor acts as a diffusional barrier and is
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dependent on various factors like molecular weight, size and lipophilicity of the administered
compound and pathophysiological conditions. (28)

Overall, ocular delivery of a therapeutic agent depends on the physicochemical properties
viz. solubility, log P, pKa and molecular weight of the administered compound. Maximum
corneal permeability was observed for compounds with log octanol-water partition coefficient
(logP) in the range of 2-3. Thus, for efficient ocular tissue permeation, compounds should neither
be too lipophilic nor too hydrophilic. Solubility is important in the design of the ophthalmic
dosage forms. Tear film and corneal pH is approximately 7.4, thus percent ionized or unionized
at this pH, depending on the drug’s pKa, will influence partitioning of the drug across the ocular
barriers. Besides these factors interaction with membrane influx and efflux transporters and
hydrogen bond donors/ acceptors of the molecule is another important determinant of ocular
tissue diffusion. (39-41)
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MICRODIALYSIS

The unique nature of the eye presents various challenges in the development of tools for
evaluating drug disposition. Microdialysis is an invasive sampling technique, which involves
surgical implantation of a probe into the organ/tissue of choice. Recently, this sampling
procedure has attracted a lot of attention and has been effectively used in characterizing
intraocular disposition of drugs in both the anterior and posterior chambers of the eye. For
posterior segment microdialysis, the probe is placed in close proximity to the retina in the
vitreous humor (42, 43). Several research publications have demonstrated the utility of the
microdialysis technique for characterizing intravitreal kinetics of drugs (42, 44-47).

(A)

(B)

Figure 2.3: Schematic drawing depicting the dialysis in an in vitro setting. The perfusion fluid
(perfusate) enters the probe through the inlet tubing. The dialysate is transported to a microvial
via the outlet tubing (A). Enlarged section of the same probe (B).
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A microdialysis system consists of pump, probe, and a microvial in which the sample is
collected (Fig 2.3). A variety of probes with different design (linear and concentric), membrane
and shaft length combinations are available. The molecular weight cut-off of commercially
available microdialysis probes covers a wide range of approximately 20-100 kDa. The probe
consists of a thin dialysis tube and a semipermeable membrane at the tip of the probe. A
perfusion fluid enters the probe through the inlet tubing at a constant flow rate, passes through
the microdialysis probe and is then transported through the outlet tubing and collected in a
microvial (dialysate), see Figure 2.3. In general the perfusate is an aqueous solution that mimics
the composition of the surrounding medium (e.g. IPBS, pH 7.4). This way it prevents excessive
movement of molecules into or out of the periprobe fluid due to osmotic differences. The
direction of the diffusion process is dependent on the concentration gradient. While the perfusion
fluid passes the membrane, molecules up to a certain molar mass diffuse into (recovery) or out of
(delivery) the perfusion fluid. Thus, microdialysis can be used both for collecting a substance in
the dialysate as well as for delivering it into the periprobe fluid. (42, 48)
During the process of microdialysis, the probe is implanted into the tissue or other
matrices, e.g. aqueous humor or vitreous humor. For example, in the case of vitreal microdialysis
a concentric probe is placed in the vitreous humor and in the case of anterior chamber
microdialysis a linear probe in place in the anterior chamber of the eye (Fig 2.4).
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Figure 2.4: Diagrammatic representation of the microdialysis probes implanted in the anterior
and vitreous chambers of the eye. The design of the probe in the anterior chamber is linear and in
the vitreous humor is concentric.

Courtesy: Reproduced with kind permission from Elsevier BV (Ref 42).
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OCULAR DISEASES/DISORDERS

The following section briefly describes the pathophysiology of various ocular diseases
that are related to this project.

Diabetic Retinopathy and Diabetic Macular Edema
Diabetes is considered to be the primary causative factor in the development of diabetic
retinopathy (DR). The disease can be broadly categorized into three stages; background DR, preproliferative DR and proliferative DR (PDR). In the first stage of DR, hyperglycemia initiates
thickening of the capillary basement membrane and causes death of pericytes that support the
vessel wall. Following this, microaneurysms and vascular leakage takes place leading to
blockage of retinal capillaries and induction of local hypoxia. Subsequently, endothelial cells die
resulting in closure of capillaries and increased areas of non-perfusion. Pre-proliferative DR is
identifiable by the areas of increased retinal hypoxia and multiple hemorrhages because of loss
of vascular patency. Increased areas of non-perfusion stimulates the generation of angiogenic
factors leading to the formation of new blood vessels, a characteristic feature of PDR.
Subsequently retinal detachment may take place causing vision loss or blindness. Hyperglycemia
and hypoxia are the two principal factors in the initiation and progression of DR. Production of a
variety of local agents in the ocular tissues such as vascular endothelial growth factor (VEGF),
prostaglandins, cyclooxygenase-2 (COX-2) and nitric oxide (NO) is indicated in the process, all
of which contribute to vascular permeability and angiogenesis. Increased permeability in these
vessels can lead to diabetic macular edema (DME), the major factor responsible for vision loss
(6, 49). It is also reported that oxidative stress, associated with diabetes, is responsible for the
initiation of retinopathy (7, 50).

21

Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is another leading cause of vision impairment
and blindness, especially in the western countries (4). The well known risk factor for AMD is
age. Retinal tissues most affected in this disease are the photoreceptors and the RPE. There are
two types of AMD: an atrophic form, which is associated with pigmentary changes in the macula
without hemorrhage or scar formation, and disciform macular degeneration, which is
characterized by exudative mound formation and sub and intra-retinal hemorrhage. However,
leakage of vascular content from small blood vessels in the macula following breakdown of the
blood-retinal barrier can lead to macular edema and can endanger vision. Besides age, macular
pigmentary change, hypertension, smoking and obesity are other risk factors. Importantly, in
AMD, like in diabetic macular edema, free radicals and reactive oxygen intermediates are
implicated in the initiation and progression of the disease (51-53).
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MANAGEMENT AND PREVENTION OF DR/DME: CURRENT APPROACHES

Primary Prevention
The management options are aimed at controlling metabolic abnormalities. Stringent
control of glucose levels to near normal values, the tight control of high blood pressure, and the
treatment of hyper-lipidemia can delay the appearance and thus progression of diabetic
retinopathy by several years (54-56). Good quality diet, exercise, and weight loss, which control
the incidence and prevalence of diabetes, can also mitigate its complications.

Treatment
Two approaches are available under treatment option; non-pharmacological intervention
and pharmacological intervention.
Non-pharmacological Intervention
Laser photocoagulation and vitrectomy are the non-pharmacological interventions. The
goal of laser photocoagulation is to control the vascular leakage through a series of focal laser
burns at leaking microaneurysms or grid laser burns in regions of diffuse breakdown of the
blood-retinal barrier and macular areas with capillary non-perfusion. The basis of laser treatment
is to reduce the leakage and to reduce the macular area in the inner retina that is ischemic and
hypoxic, and perhaps to allow oxygen from the choriocapillaries to diffuse into the hypoxic inner
retina near it. In the case of vitrectomy, primarily recommended for treating proliferative DR,
vitreous humor is surgically removed. In this procedure, the aim is to improve vision by taking
out any blood in or behind the vitreous and reattaching detached area of the retina. However,
both laser photocoagulation and vitrectomy are only indicated in advanced stages of the disease
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and are associated with an additional risk of vision loss, and neither is effective in bringing
vision back to normal (54-57).
Pharmacological Intervention
The multi-factorial nature of DR and DME has made these complex diseases difficult to
treat with the limited treatment options available, in addition to the limitations of nonpharmacological treatment options. Currently, available treatment regimens mainly target the
underlying biochemical mechanisms that cause DR/DME. Following are the various options
available (7, 57, 58).
1. Vascular Endothelial Growth Factor (VEGF) Inhibitors: Clinical studies have indicated an
increase in the levels of VEGF in patients as they progress from non-proliferative DR to
proliferative DR. Currently three major anti-VEGF compounds are being used for the
management of DR/DME; bevacimuzab, pegaptanib sodium and ranibizumab.
2. Anti-inflammatory agents: Corticosteroids are capable of reducing vascular permeability and
blood-retinal barrier breakdown, down-regulating VEGF production and inhibiting
inflammatory mediators. Currently, intravitreal triamcinolone acetonide, dexamethasone and
fluocinolone acetonide are being investigated and used for the management of DR/DME.
3. Protein Kinase C (PKC) Inhibitors: Activation of PKC-β may play a role in the pathogenesis
of DR. Its activation regulates VEGF expression. One drug studied in this category, in
clinical trials, is ruboxistaurin. However, its use in humans is still unknown.
4. Antioxidants: Oxidative stress is believed to play an important role in the pathogenesis of
DR/DME. Thus, strategies to prevent the deleterious effects of free radicals were considered
as a potential prevention or treatment option. Several antioxidants like vitamin E, lipoic acid,
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green tea and benfotiamine (thiamine derivative B1) were shown to be effective in animal
models. However, outcomes of some clinical trials have been ambiguous.

In summary, various treatment options discussed above act on any one of the multiple
biochemical pathways associated with the initiation and progression of DR and DME. A
compound that acts on multiple pathways associated would be an ideal candidate for further
explorations.
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HESPERIDIN AND HESPERETIN

Structure and Chemistry
Hesperidin (hesperetin-7-rutinoside) is a flavanone glycoside, comprising of an aglycone,
hesperetin, and an attached disaccharide, rutinose. The structures of hesperidin and hesperetin
are illustrated in Figure 2.5. The rutinose (C12H22O10) is composed of one molecule each of
rhamnose and glucose. In hesperidin, glucose is attached to hesperetin and rhamnose is attached
to the glucose. Hesperetin (C16H14O6) chemically is 3', 5, 7-trihydroxy-4'-methoxy flavanone.
Hesperidin is thus 3', 5, 7-trihydroxy-4'methoxyflavanone-7-(6-α-L-rhamnopyranosyl-β-Dglucopyranoside or -7-rutinoside (Calomme et al., 1996).

A

B

Figure 2.5: Chemical structure of Hesperidin (A) and Hesperetin (B)
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Physical Properties

Hesperidin
Molecular Formula

: C28H34O15

Molecular Weight

: 610.57 g/mole

Exact Mass

: 610.18977 g/mole

Physical nature

: Long hair-like needles

Color

: Tan or pale yellow

Taste

: Tasteless (In general, rutinosides are non-bitter)

Melting Point

: 258-262°C (softens at 250°C)

Hesperetin
Molecular Formula

: C16H14O6

Molecular Weight

: 302.27 g/mole

Exact Mass

: 302. 079038 g/mole

Physical nature

: Crystalline

Color

: Slight yellow powder or pale yellow powder

Melting Point

: 227-232 ˚C
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Source
Hesperidin is abundantly found in citrus fruits (family Rutaceae) and has also been
reported to occur in many plants other than Citrus, such as in genera Fabaceae, Betulaceae,
Laminaseae and Papilionaceae. Hesperidin is one of the major flavonoids found in the oranges
and mandarins. It occurs in greatest concentration in green fruit and its concentration in the fruits
increases on storage. Its distribution in the epicarp, mesocarp, endocarp and juice of Citrus fruits

has been reported in the literature (9).

Commercial Products
In traditional medicine it is used as dietary supplement for its beneficial effects on the
vascular system. It is used alone and also as a combination product. Some of the commercially
available products are listed in Table 2.1

Table 2.1: Commercially available products of hesperidin as a dietary supplement.

Product

Contents

Diosvein

Diosmin – 500mg,
Hesperidin – 100mg

Hesperidin

Hesperidin – 500mg

Life Extension

Hesperidin Complex Powder
Hesperidin – 150mg

Natural Factors
Citrus Bioflavonoids powdered extract – 500mg
Vitamin C complex

Rutin and Hesperidin

500-C Methoxyflavone

Vitamin C with Hesperidin
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Pharmacology
The following section briefly describes various pharmacological activities of hesperidin
and hesperetin that may be useful in the prevention or treatment of diabetic retinopathy or
diabetic macular edema.

Antioxidant Activity
Generally, antioxidants act by scavenging the free radicals directly, because of their low
redox potential (i.e. high reactivity of the hydroxyl groups) (59). A number of researchers have
studied antioxidant activity or radical scavenging properties, both in vitro and in vivo, of
hesperidin and hesperetin using a variety of assay systems (60-67). Findings from these studies
indicate that both hesperidin and hesperetin possess strong antioxidant activity and also
neuroprotective properties arising from their antioxidant characteristics. However, results from
different assays varied considerably with respect to the effective concentration. Several studies
however indicate that the aglycone hesperetin’s antioxidant potential is greater compared to
hesperidin (68-71).
Hesperidin is reported to be capable of inhibiting, in vitro, free radicals (hydroxyl,
superoxide and nitric oxide free radicals) in a concentration dependent manner (72). In a study
by Kalpana et al., the IC50 of the antioxidant activity was found to be 5.23 µg/mL, which was
comparatively lower than that observed with standards like trolox and ascorbic acid. The
antioxidant activity was attributed to the aromatic hydroxyl group present on the B ring, which
donates hydrogen and electron to free radicals, stabilizing them and forming a relatively stable
flavonoid radical. Balakrishnan et al., (63) reported that hesperidin treatment (25 mg/Kg BW) in
rats improved the antioxidant status in the lungs and reversed the changes induced by nicotine
treatment. Rao et al., (73) evaluated the antioxidant activity of hesperidin by studying its
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potential to inhibit the DPPH radical and its superoxide anion scavenging activities and reported
an IC50 of 11 µM.
Hirata et al., (12) studied the free radical scavenging capabilities of hesperidin and
hesperetin. The authors found the stoichiometric factor (the number of free radicals trapped by
one mole of antioxidant) in the order of trolox (2.0) > hesperetin (0.8) > hesperidin (0.2) in the 2,
2’ azobisisobutyronitrile (AIBN) system, whereas in the benzoyl peroxide (BPO) system, the
order is hesperetin (0.9) > trolox (0.1) > hesperidin (0.0). Additionally, hesperidin and hesperetin
showed potent inhibition of lipopolysaccharide induced expression of COX-2 gene,
demonstrating anti-inflammatory activity. Cos et al., (74) studied hesperetin’s ability to inhibit
ascorbate-induced microsomal lipid peroxidation and estimated IC50 of 22 µM for this inhibition.
In a study by Aranganathan et al., (69, 75) hesperetin supplementation in the rats (20 mg/Kg
BW) significantly improved the antioxidant defense system of the body.

Effects on Vascular System

a. Ocular blood flow
A decrease in the ocular blood flow can lead to a number of diseases like glaucoma,
diabetic retinopathy and macular degeneration (76). Literature suggests a significant effect of
bioflavonoids on ocular blood flow (77-79). In 1996, Liu et al., reported that hesperetin was able
to increase the blood flow in iris, ciliary body and choroid (77). Further investigations using
different flavonoids revealed that this activity is dependent on the number of hydroxyl groups
present in the flavones and flavanones and on the dihydrogenation of the flavone molecules (7880). Topical administration of hesperetin in the rabbits exhibited highest activity, among the
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several flavonoids tested, with respect to increasing ocular blood flow. Additionally, it showed a
marked increase in retinal function recovery following ischemic insult (79, 81).

b. Effect on Retinal Cells
In a recent study, Xiaoting et al., (82) studied the effect of hesperidin on the expression
of iNOS (inducible nitric oxide synthase) in cultured rabbit RPE cells. Hesperidin was able
protect the retinal cells by inhibiting nitric oxide (NO) production, through iNOS inhibition, in
the concentration range of 10-80 µg/mL.

c. Angiogenesis and Vascular Leakage
Angiogenesis is the process of formation of new blood vessels and is characterized by
early degradation of the extracellular matrix followed by migration and proliferation of the
endothelial cells and, finally, maturation of the new blood vessels. Several factors are associated
with the pathophysiology of angiogenesis, e.g. matrix metalloproteases (MMP-2 and MMP-9),
and pro-angiogenic factors expressed in response to local injury, ischemia or inflammation, such
as hypoxia-inducible factor-1α (HIF-1α), epidermal growth factor (EGF), vascular endothelial
growth factor (VEGF), tumor necrosis factor-α (TNF-α), and interleukin-1, 6 and 8 and others
(83, 84). The newly formed blood vessels are leaky in nature and this hyper-permeability causes
interstitial edema, which leads to physical compression of the capillaries resulting in a no-reflow
phenomenon. Retinal vascular hyper-permeability is observed in the later stages of diabetic
retinopathy and age related macular degeneration (53). Thus, treatment with agents capable of
decreasing capillary hyper-permeability and inhibiting angiogenesis is highly desired. Hesperidin
and hesperetin have been reported to exhibit these properties by inhibiting various mediators
associated with angiogenesis and thus hyper-permeability.
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A study by Choi et al., (85) demonstrates hesperetin’s (1-100 µM) anti-angiogenic
activity through the inhibition of the expression of PECAM-1 (platelet-endothelial cell adhesion
molecule-1), a cell adhesion molecule, which has been implicated in vasculogenesis and
angiogenesis. In another study by Calderone et al., (86) on the vasorelaxing effects of flavonoids,
hesperetin showed a strong vasorelaxing effect and hesperidin exhibited a partial effect among
the several flavonoids tested. Hesperetin was found to be acting through calcium activated
potassium channels.
Furthermore, recently, it has been reported that hesperidin (at concentrations of 10 and
100 µM) is capable of inhibiting the expression of HIF-1α and inflammatory cytokine production
in the human mast cell line (HMC-1) in addition to inhibition of TNF-α. HIF-1α an important
mediator of inflammatory response, and one of the major transcriptional activators of VEGF
gene expression, plays a critical role in the process of angiogenesis (87).
The micronized purified flavonoid fraction (Daflon® 500mg) (MPFF) and its individual
flavonoid components (diosmin, hesperidin, linarin, and isorhoifolin) were evaluated for their
anti-leakage effect in a hamster cheek pouch animal model, where hyper-permeability was
induced by ischemia-reperfusion. The activity displayed by hesperidin, linarin, and isorhoifolin
was similar to or greater than that of diosmin, the major component (90%) of MPFF. MPFF
activity was greater than that of any single flavonoid, indicating synergetic activity (88).
Few other reports also substantiate activity of hesperetin and hesperidin on various proangiogenic factors (89-91).
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d. Ischemia/Reperfusion (IR)
Ischemia reperfusion is capable of generating reactive oxygen species (ROS), which can
induce arrhythmia. In a study by Gandhi et al.,(92) hesperidin effectively reduced tissue levels of
the antioxidant enzymes like SOD, CAT, and GSH and also reduced tissue MDA levels in a rat
model of IR induced myocardial injury. Additionally, hesperidin, by prolonging the QTc interval
action potential duration, and subsequent refractoriness, improved IR-induced arrhythmia.

e. Other Vascular Effects:
In a recent 4 week clinical trial with healthy human volunteers undertaken by Morand et
al., (93), oral consumption of orange juice or pure hesperidin (292 mg) significantly decreased
the diastolic blood pressure and increased endothelium-dependent microvascular reactivity. This
was speculated to be because of the positive effects of hesperidin on the cyclooxygenase
pathway.

Anti-inflammatory Activity
Some of the mediators that are activated in certain inflammatory conditions are nitric
oxide (NO), prostanoids and leukotrienes, cytokines and adhesion molecules (94). NO is
produced from L-arginine by three nitric oxide synthase (NOS) enzymes; endothelial NOS
(eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS). The iNOS is responsible for the
production of larger amounts of NO for longer durations. Prostanoids and luekotrienes are also
involved in inflammation. Prostaglandins and thromboxan A2 are produced by the
cyclooxygenases (COX-1, COX-2 and COX-3). Generally COX-1 is expressed in most tissues
(acts in response to hormones and other stimuli) whereas COX-2 is highly expressed in
inflammatory cells. Leukotrienes are generated by lipooxygenases (LOX) and 5- and 12-LOXs
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are associated with the inflammatory processes. Moreover, different cytokines are involved in
inflammation and can be pro-inflammatory (interleukins; IL-1β, IL-2, IL-6, IFN-γ or TNF-α) or
anti-inflammatory (IL-10, TGF-β). Adhesion molecules also play a role in inflammation. Blood
vessel endothelial cells characteristically respond to pro-inflammatory stimuli and recruit
leukocytes by selectively expressing adhesion molecules on the surface, such as vascular cell
adhesion molecules (VCAM-1), intercellular adhesion molecules (ICAM-1) and endothelial cell
selectin (E-selectin) (94). Hesperidin/hesperetin can act on multiple pathways in the
inflammation process as summarized in Table 2.2. Additionally several reports also document
the anti-inflammatory activity of hesperidin and/or hesperetin, in vivo (95, 96).

Table 2.2: General mechanisms by which hesperidin/hesperetin exert their anti-inflammatory
activity.
Inhibition of iNOS expression

Hesperidin (97)

Inhibition of COX-2 expression

Hesperidin (12, 97); Hesperetin (12)

Inhibition of VCAM-1

Hesperidin (98)

Inhibition of IL-1β

Hesperetin (91)

From the above discussion it is apparent that both hesperidin and hesperetin appear to act
on the multiple pathways associated with the initiation and progression of DR and DME.
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CHAPTER 3 : SOLUBILITY, STABILITY, PHYSICOCHEMICAL
CHARACTERISTICS AND IN VITRO OCULAR TISSUE PERMEABILITY
OF HESPERIDIN

ABSTRACT

The aim of this study, constituting the first step towards efficient ocular delivery of
hesperidin, was to determine its physicochemical properties and in vitro ocular tissue
permeability. Aqueous solubility and stability were investigated as a function pH following
standard protocols. Permeability of hesperidin across excised rabbit cornea, sclera, and sclera
plus retinal pigmented epithelium (RPE) was determined using a side-bi-side diffusion apparatus.
Hesperidin demonstrated poor, pH independent, aqueous solubility. Solubility improved
dramatically in the presence of 2-hydroxypropyl-beta-cyclodextrin (HP-β-CD) and the results
supported 1:1 complex formation. Solutions were stable in the pH and temperature (25, 40 ºC)
conditions tested, except for samples stored at pH 9. Transcorneal permeability in the apicalbasal and basal-apical directions was 1.11±0.86x10-6 and 1.16±0.05x10-6 cm/s, respectively. The
scleral tissue was more permeable (10.2±2.1x10-6 cm/s). However, permeability across
sclera/choroid/RPE in the sclera to retina and retina to sclera direction was 0.82±0.69x10-6,
1.52±0.78x10-6 cm/s, respectively, demonstrating the barrier properties of the RPE. Our results
suggest that stable ophthalmic solutions of hesperidin can be prepared and that hesperidin can
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efficiently permeate across the corneal tissue. Further investigation into its penetration into the
back-of-the eye ocular tissues is warranted.

INTRODUCTION

For a topically administered drug, penetration into the posterior chamber tissues, such as
the RPE, may be through corneal or noncorneal routes. Transcorneal absorption represents the
major route of penetration for most therapeutic agents. However, several studies demonstrate that
the noncorneal route is also a significant pathway, wherein the drug molecule is supposed to
penetrate into the intraocular tissues via diffusion across the conjunctiva and sclera (99).
Physicochemical properties and permeability across the ocular tissues are important
characteristics that need to be determined for any compound targeted for ocular delivery. This in
vitro information obtained from these studies will be the starting step in understanding the
behavior of the compound upon in vivo administration and also helps in the design of dosage
form.
Thus, the objective of this project, constituting the first step towards efficient ocular
delivery of hesperidin, was to determine hesperidin’s solubility, stability, physicochemical
properties and in vitro permeability across the ocular tissues - cornea, sclera and RPE.
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MATERIALS AND METHODS

Materials
Hesperidin, hesperetin and 2-hydroxypropyl beta cyclodextrin (HP-β-CD) (1300 MW 0.6
substitution) were purchased from Sigma-Aldrich (St. Louis, MO, USA). [14C]Mannitol was
purchased from American Radiolabelled Chemicals Inc. (St. Louis, MO, USA) and
[3H]diazepam was obtained from PerkinElmer Life and Analytical Sciences (Boston, MA, USA).
All other chemicals and solvents were obtained from Fisher Scientific, USA.
Ocular Tissues
Ocular tissues were isolated from euthanized adult male New Zealand albino rabbits
weighing between 2-2.5 kg (Myrtle’s Rabbitry, Thompson Station, TN, USA). Experiments
using rabbits conformed to the tenets of the Association for Research in Vision and
Ophthalmology statement on the Use of Animals in Ophthalmic and Vision Research and
followed the University of Mississippi Institutional Animal Care and Use Committee approved
protocol (07-024). Each experiment was conducted at least in quadruplicates.
Solubility Studies
Aqueous solubility of hesperidin was determined following standard shake flask method
wherein excess quantity of drug was added to 5mL of solvent in a tightly capped glass vial. To
achieve uniform mixing, samples were constantly agitated at 75 rpm at room temperature (25 ºC)
for 24 h in a reciprocating water bath (Fisher Scientific, USA). At the end of 24h, samples were
centrifuged (accuSpin 17R, Fisher Scientific, USA) and the supernatant was analyzed for drug
content. Solubility was determined in water and in buffers with pH values ranging between 1.2
and 9. Additionally, effect of surfactants and HP-β-CD on the solubility of hesperidin, was also
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evaluated. HP-β-CD concentrations used for the phase solubility studies were 1, 2.5, 5, 7.5, 10,
15 and 20 %w/v in water.

Differential Scanning Calorimetry (DSC) Studies
DSC analysis of hesperidin, HP-β-CD, physical mixture of hesperidin and HP-β-CD (1:1
molar ratio) and the complex were carried out using a Diamond Differential Scanning
Calorimeter (PerkinElmer Life and Analytical Sciences, Shelton, CT, USA). Samples, 2-3 mg,
were heated in hermetically sealed aluminum pans at a heating rate of 10 °C/min (25-280 °C
range) under a nitrogen atmosphere (flow rate 20 mL/min). An empty aluminum pan was used as
the reference.

Fourier Transform Infrared Spectroscopy (FTIR) Studies
FTIR spectra were obtained using a Perkin Elmer FTIR spectrometer (PerkinElmer Life
and Analytical Sciences, Shelton, CT, USA). Samples were mixed with dry crystalline KBr in a
1:100 (sample: KBr) ratio and pellets were prepared. A spectrum was collected for each sample
within the wave number region 4000-400 cm-1.

LogP
Predicted value of LogP was obtained using the ACD/I-Lab web service (ACD/LogP
8.02).

pH Stability
Solution stability of hesperidin was determined at various pH (1.2, 3, 5, 7.4, and 9) and
temperature (25 and 40 ºC) conditions. Buffers were prepared according to USP. Stability studies
were initiated with the addition of 25 µL of a 1 mg/mL hesperidin stock solution to 5mL of the
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respective buffer previously equilibrated to either 25 or 40 ºC. Aliquots (200 µL) were collected
at 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 14, 30 and 60 days and were stored at -80 ºC until further analysis.
Samples were analyzed using HPLC technique as described under the analytical method section.

Stability in Ocular Tissue Homogenates
Ocular tissues isolated from New Zealand albino rabbits were used for the metabolism
studies. Animals were euthanized with an overdose of pentobarbital administered through the
marginal ear vein. Eyes were enucleated immediately and washed with ice-cold Dulbecco’s
Phosphate Buffered Saline (DPBS pH 7.4) to remove traces of blood. Vitreous humor was
collected through an incision in the sclera. Sclera was isolated with the retinal pigmented
epithelium (RPE) attached. The RPE/choroid section was then carefully separated from
underlying sclera. This procedure takes approximately 10-15 min. The pooled RPE/choroid
tissue was homogenized (TISSUMISER, Fisher Scientific, USA) in 2 mL ice-cold Isotonic
Phosphate Buffer Saline (IPBS), pH 7.4, and then centrifuged at 4ºC (accuSpin 17R, Fisher
Scientific, USA). Supernatant was collected and estimated for total protein content by the
method of Bradford (Sigma - Aldrich, USA) (100). Final protein concentration was adjusted to
1mg/mL by diluting with IPBS and used for the hydrolysis studies. Vitreous humor was used as
such without any dilution or homogenization.
Reactions were initiated by adding 20 µL of drug solution (1 mg/mL) to 2mL of the
supernatant. The reactions were carried out in a water bath at 37ºC. Samples (100 µL) were
withdrawn at predetermined time intervals and the enzymatic degradation process was arrested
with the addition of an equal volume of ice-cold methanol:acetonitrile mixture (60:40). Rate of
hydrolysis in IPBS pH 7.4 at 37 ºC was used as a control. Samples were analyzed using an HPLC
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technique as described under the analytical method section. Experiments were carried out in
triplicate.

Corneal Permeation Studies
Permeation of hesperidin was studied using a side-bi-side diffusion apparatus
(PermeGear, Inc.). Corneas isolated from New Zealand Albino male rabbits were used for these
studies. Rabbits were euthanized, and eyes were collected as described earlier. Cornea was
isolated with a ring of sclera around it, which helps in mounting between diffusion cells. Corneas
were washed in DPBS and mounted on the side-bi-side diffusion apparatus (standard 9 mm cells
were used) (Fig. 3.1A) with the epithelial side facing the donor cell for apical to basolateral
transport (A-B), and with the endothelial side facing the donor cell for basolateral to apical
transport (B-A). Temperature of the cells was maintained at 34 ºC with the help of a circulating
water bath. In all cases, 3 mL of transport buffer (DPBS containing 5 % HP-β-CD) or drug
solution (150 µM of hesperidin in DPBS with 5 % HP-β-CD) was added to the apical side of the
cornea while 3.2 mL was added to the basal side, to maintain the natural hydrostatic pressure.
Aliquots (200 µL) were removed at predetermined time points (15, 30, 45, 60, 90, 120, 150 and
180 min) from the receiver side and the volume withdrawn was replaced with an equal volume of
transport buffer. Samples were stored at -80ºC until further analysis.
Similar procedures were followed to determine transcorneal permeability of
[14C]mannitol (55mCi/mmol) and [3H]diazepam (70Ci/mmol), both at 0.5 µCi/mL concentration.
Five milliliters of scintillation cocktail (Fisher Scientific, USA) was added to each sample and
radioactivity was measured using Liquid Scintillation Analyzer (PerkinElmer Life and Analytical
Sciences, Model Tri-Carb 2900TR, Shelton, CT, USA).
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Figure 3.1: Illustration depicting mounting of ocular tissue on regular side-bi-side diffusion cells
(A) and on Valia-Chein Side-bi-Side diffusion cells (B)

Permeation across Sclera and Retinal Pigmented Epithelium (RPE)
Transscleral permeation studies were carried out using the 5mm diameter Valia-Chein
side-bi-side diffusion cells from PermeGear, Inc. (Fig. 3.1B). After carefully isolating sclera
alone, or sclera with RPE/choroid, the tissues were mounted in a manner such that outer surface
of the sclera, known as the episclera, faced the donor side (Fig. 1B; half-cell a) and the inner side
of sclera, or the RPE side, faced the receiver chamber (Fig.1B half-cell b) for the transport
studies in the sclera to choroid/RPE direction (S to R direction). Donor solution was added to the
RPE/choroid side (Fig.1B half-cell b) for transport in the RPE/choroid to scleral direction (R to S
direction). Temperature of the cells was maintained at 37ºC with the help of a circulating water
bath. 150 µM of hesperidin in DPBS with 5 % HP-β-CD was placed in donor chamber and
DPBS with 5 % HP-β-CD was placed in receiver chamber. Aliquots (200 µL) were removed at
predetermined time points (15, 30, 45, 60, 90, 120, 150 and 180 min) from the receiver side and
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replaced with an equal volume of transport buffer. Samples were stored at -80ºC until further
analysis.
Similar procedures were followed to determine permeability of [14C]mannitol (55
mCi/mmol) and [3H]diazepam (70 Ci/mmol), both at 0.5 µCi/mL concentration, across
sclera/choroid/RPE. Five milliliters of scintillation cocktail (Fisher Scientific, USA) was added
to each sample and radioactivity was measured using Liquid Scintillation Analyzer.

Analytical Method
Hesperidin content in samples collected from the solubility, stability and permeability
studies was estimated using an analytical method based on reversed phase HPLC. An HPLC
system equipped with Waters 600 pump controller, 2470 dual wavelength UV detector,
refrigerated 717 plus auto-sampler and Agilent 3394B integrator was used. The detector was
operated at 284nm. Mobile phase consisted of 20mM monobasic potassium phosphate (pH
adjusted to 2.5 with orthophosphoric acid) and acetonitrile in a ratio of 75:25 and flow rate was
maintained at 1mL/min. A Waters Symmetry Shield C18 column was used.
Analytical method for the determination of hesperetin content was also developed. The
method for hesperetin was similar to that for hesperidin, except for the mobile phase, which, in
this case, was a 50:50 mixture of acetonitrile and 20mM monobasic potassium phosphate (pH
adjusted to 2.5 with orthophosphoric acid).

Data Analysis
Cumulative amount (Mn) transported was calculated using Equation 1 and Steady state
(SS) fluxes (µg/min/cm2) were determined from the slope of the cumulative amount of drug
transported vs. time graph and expressed as per unit of surface area as described by Equation 2.
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Where, Mn is the cumulative amount of the drug in the receiver chamber at nth sampling
time point (n=1, 2, 3, 4, 5, 6, 7 and 8 corresponding to 15, 30, 45, 60, 90, 120, 150 and 180 min
sampling points), Vr is the volume of the medium in the receiver chamber, VS is the volume of
the sample withdrawn at the nth time point, Cr(n) is the concentration of the drug in the receiver
chamber medium at nth time point, A is the surface area of the tissue exposed to the permeant
(surface area of cornea and sclera/RPE exposed is 0.636 and 0.192 cm2, respectively). Note that
when n=1, the second part of the right hand side of Equation 1 becomes zero since concentration
in the receiver chamber, Cr, is zero at time zero.
Membrane permeability (cm/s) values were determined by normalizing the steady state
fluxes to the donor concentration, Cd according to Equation (3).
Permeability (Papp) = Flux/Cd

(Eq. 3)

All experiments were carried out at least in triplicate. Unpaired t-test and ANOVA was
used for statistical analysis. In all the cases a p value less than 0.05 was considered to denote
statistically significant difference.
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RESULTS AND DISCUSSION

Diabetic retinopathy and macular edema are serious sight threatening conditions. While
involvement of several mechanisms in the pathogenesis of this disease has been suggested, a
drug candidate capable of blocking multiple pathways remains to be identified, as yet. Current
treatment options, apart from controlling blood glucose and lipid levels, include corticosteroids,
anti-vascular endothelial growth factor, laser photocoagulation, and vitrectomy. However, long
term treatment with these drugs is associated with toxicity and corticosteroids may lead to
cataract formation and increased intraocular pressure (101). Hesperidin appears to modulate
multiple pathways associated with diabetic retinopathy and macular edema but a suitable ocular
delivery mechanism is lacking. In this study, feasibility of developing an ophthalmic solution
dosage form of hesperidin was investigated
Solubility is an important factor affecting drug permeability across biological
membranes. Solubility of hesperidin in different pH buffers and in water is presented in Table
3.1. The compound was observed to be very poorly soluble in water and exhibited an aqueous
solubility value of 4.95 µg/mL (7.5x10-6 M) at 25 °C. Hesperidin did not demonstrate pH
dependent solubility within the pH range of 1.2 – 9. However, solubility of hesperidin at pH
values greater than 9 was significantly higher (data not shown) but was accompanied with
degradation. These results are in agreement with the studies reported by Serra et al., wherein the
pKa of hesperidin has been reported to be 10±0.2 for the two phenolic hydroxyl groups and
greater than 11.5 for all of the alcoholic hydroxyl groups (26).
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Table 3.1: Solubility of hesperidin as a function of pH (200 mM buffer concentration) and in
water. The solubility studies were carried out at 25ºC for a period of 24h. Values are expressed
as mean ± SD (n=3).

pH

Saturation Solubility (µg/mL)

1.21

4.15 ± 0.34

3.11

8.44 ± 0.47

5.12

5.96 ± 1.92

7.48

5.26 ± 0.31

9.11

8.93 ± 0.73

Water

4.93 ± 0.99

In an attempt to improve hesperidin’s aqueous solubility, effect of ethanol, surfactants
and HP-β-CD, was evaluated. Ethanol and surfactants such as Tween 80 and TPGS (d-alphatocopheryl polyethylene glycol 1000 succinate) were ineffective. However, HP-β-CD markedly
improved hesperidin’s solubility. Cyclodextrins are a group of cyclic oligosaccharides that have
been shown to improve solubility of a multitude of poorly soluble compounds, through the
formation of inclusion complexes. Among the different cyclodextrins available, HP-β-CD has
been reported to be safe for use in ocular preparations (102, 103), even when used at
concentrations as high as 45 % (104).
A linear increase in aqueous solubility of hesperidin was observed with increasing
concentrations of HP-β-CD (Fig. 3.2 and Table 2.2) suggesting formation of a 1:1 inclusion
complex between hesperidin and HP-β-CD. It is interesting to note that hesperidin’s solubility
was increased approximately 100-fold in the presence of 20 % HP-β-CD. The solubility limit of
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the complex was not reached within the concentration range of HP-β-CD used in this study.
Stoichiometry, binding constant (K) and aqueous saturation solubility (S0) were determined from
a plot of solubility as a function of HP-β-CD concentration using Equation 4, according to the
method proposed by Higuchi and Connors. Hesperidin binding constant was calculated to be
625±78 M-1 (R2=0.975±0.023, slope=0.0052±0.0006).

K

=

Slope
(Eq. 4)

S0 (1 − Slope)

Further evidence of the formation of an inclusion complex was obtained from thermal
and spectral analysis. The DSC thermograms are presented in Figure 3.3. DSC scans of pure
hesperidin showed an endothermic peak at 259 °C, corresponding to the melting point of the
compound. Physical mixture of the drug and HP-β-CD, in a 1:1 molar ratio, also exhibited the
endothermic peak associated with hesperidin. However, the peak was not observed in the
complex, prepared by dissolving both the components in methanol (1:1 molar ratio) followed by
evaporation. This suggests molecular encapsulation of drug inside the cyclodextrin cavity. FTIR
scans complemented the DSC data (Fig. 3.4). Hesperidin spectra demonstrate a strong absorption
band at 1644 cm-1, corresponding to its carbonyl stretching vibration. This characteristic
carbonyl stretching vibration was shifted to 1652 cm-1 in the complex and was much broader,
suggesting the formation of complex. Thus, chemical, thermal and spectral analysis, taken
together, strongly supports the formation of an inclusion complex.
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Table 3.2: Aqueous solubility of hesperidin (25°C, 24h equilibration) in the presence of various

concentrations of HP-β-CD. Values are expressed as mean ± SD (n=3).

Hesperidin Solubility
(µg/mL)

0

4.95 ± 0.99

1

42.97 ± 4.28

9

2.5

83.34 ± 6.34

18

5

169.90 ± 25.36

37

7.5

219.03 ± 15.62

48

10

252.77 ± 8.81

55

15

348.55 ± 5.28

76

20

431.97 ± 0.43

95

Hesperidin Solubility
(moles/L)

Concentration of
HP-β-CD (%w/v)

Fold Increase in
solubility

0.0008
0.0006
0.0004
0.0002
0
0

0.05

0.1

0.15

0.2

HP-β-CD concentration (moles/L)

Figure 3.2: Phase solubility of hesperidin in the presence of HP-β-CD, at 25ºC, following 24h
equilibration. Values are expressed as mean ± SD (n=3)
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Figure 3.3: DSC thermograms of the pure hesperidin and HP-β-CD, physical mixture of
hesperidin and HP-β-CD (1:1 molar ratio) and the complex.

Figure 3.4: FTIR spectra of the HP-β-CD, hesperidin and the complex.
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Phase solubility studies pointed towards the formation of the complex in a 1:1 molar
ratio, which is consistent with an earlier report by Tommasini et al., (105). However, the
observed intrinsic solubility of hesperidin (7.5x10-6 M) in the current study was less than the
value (3.6x10-5 M) reported by Tommasini et al., Also, the estimated binding constant in the
previous study was 60 M-1. The observed differences, between the earlier report and the current
study, with respect to these two parameters, may be attributed to the experiment protocol. While
Tommasini et al., sonicated the excess drug containing cyclodextrin solution for a period of
15min and then allowed equilibration for a period of 4 days, in the current study sonication was
not a part of the protocol and equilibration period allowed was only 24 h.
Hesperidin, a flavonoid glycoside, can be converted into its aglycone, hesperetin, through
chemical or enzymatic processes. Stability studies in aqueous solutions did not demonstrate any
decrease in hesperidin content up to 2 months, the final time point tested, in the pH range and
temperature conditions employed. The only exception was pH 9 samples. In this case,
degradation rate constant and half-lives, at 25 and 40°C were observed to be 0.03 and 0.15 day-1,
and, 23 and 4.5 days, respectively (Fig. 3.5). This signifies that hesperidin may undergo alkaline
hydrolysis at higher pH and temperature conditions.
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Figure 3.5: Stability of hesperidin in pH 9 buffer at 40ºC. Values are expressed as mean ± SD
(n=3)

Hesperidin undergoes enzymatic degradation by beta-glucosidases to yield hesperetin.
Literature reports suggest that beta-glucosidases are expressed in the ocular tissues, especially in
the RPE (106, 107). Ideally, one would like to maintain the drug in the unmetabolized form at
the target tissue for maximizing therapeutic effect. With respect to hesperidin, however, both
hesperidin and its aglycone hesperetin are pharmacologically active. Even then, it is important to
know the rate of generation of hesperetin, from hesperidin, in the ocular tissues as the two
compounds would exhibit different pharmacokinetic profiles. For example, hesperetin is more
lipophilic than hesperidin and is known to be a much better substrate of the efflux protein P-gp,
which is also known to be expressed on the RPE (108). Consequently, conversion of hesperidin
to hesperetin may impact therapeutic activity. Taking this into consideration, stability of
hesperidin in ocular tissue homogenates was determined. Hesperetin generation, or decrease in
hesperidin concentrations, in the homogenates was not observed even after 15h. Further studies
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investigating generation of hesperetin in the ocular tissues in vivo, and their in vivo
pharmacokinetic profile following topical and intravitreal administration, are in progress.
Oral hesperidin administration for ocular indications may not be very effective. Local
delivery of hesperidin for ocular diseases may prove to be a much more viable option, compared
to oral administration. To our knowledge, hitherto, permeability of hesperidin across ocular
tissues has not been determined. In this study, ocular tissues isolated from New Zealand albino
rabbits, a model widely used for ophthalmic drug delivery studies, were used to evaluate
feasibility of penetration of hesperidin into the back-of-the eye following topical administration.
The predicted Log P value of hesperidin was determined to be 1.78±0.72 using ACD/I-Lab
software, which indicated that the compound is fairly lipophilic. Diffusion studies were carried
out for 3h, to determine in vitro permeability coefficients across cornea, sclera and
sclera/choroid/RPE. Stability studies of hesperidin in aqueous buffered solutions and tissue
homogenates demonstrated that drug was stable in these matrices for the entire duration of the
diffusion experiments. Since hesperidin demonstrates poor aqueous solubility, 5% HP-β-CD was
incorporated in the transport buffer.
Trans-epithelial electrical resistance (TEER) was monitored (Multimeter, Agilent
Technologies, USA) throughout the duration of the corneal permeation studies, 3h, to evaluate
the integrity of tissue in the presence of 5 % HP-β-CD. TEER values for corneas exposed to
transport buffers with or without HP-β-CD were found to be 5±0.3 KΩcm2 throughout,
demonstrating lack of any effect of HP-β-CD on ocular tissue integrity at this concentration. The
observed TEER is in agreement with previously reported TEER values for rabbit cornea (109).
In addition, diffusion of [14C]mannitol, a paracellular marker, and [3H]diazepam, a transcellular
marker, were also evaluated. The mean percent cumulative amount of the [14C]mannitol
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transported per hour across the cornea remained the same, for the duration of the experiment at
1±0.15. In case of diazepam also, mean percent cumulative amount of [3H]diazepam transported
per hour across the cornea remained steady at 1.62±0.04. These results taken together,
demonstrate that integrity and viability of the corneal tissues are maintained during the
experimental protocol.
Mean cumulative amount of hesperidin transported across ocular tissues as a function of
time is depicted in Figure 3.6 and the permeability coefficients have been presented in Figure
3.7. Steady state diffusion was achieved within 5min. Less than 2 % decrease in hesperidin
concentration in the donor solution was observed during the total time course of the experiments
signifying maintenance of sink conditions.
Hesperidin’s permeability across the rabbit cornea was 1.11±0.86x10-6 cm/s consistent
with other compounds with similar LogP values (110). Although, P-gp has been reported to play
an important role in transcorneal drug absorption (108), corneal permeability of hesperidin in the
apical to basolateral (A-B; 1.11±0.86x10-6 cm/s) and basolateral to apical (B-A; 1.16±0.05x10-6
cm/s) directions did not differ statistically, indicating lack of involvement of any carriermediated process (efflux or influx) in the corneal permeation process, at the concentration
studied. These results are consistent with an earlier study by Kobayashi et al., (25) with Caco-2
cell monolayers demonstrating similar hesperidin permeability in the A-B and B-A directions.
The authors concluded that hesperidin permeates through paracellular route and absence of
active transport process. Moreover, hesperidin behaves as a neutral molecule in the pH range of
1-10 (26) indicating lack of involvement of any anion or cation transporters.
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Figure 3.6: Mean cumulative amount of hesperidin transported across ocular tissues as a
function of time. Values are expressed as mean ± SD (n=4)

Transport studies across sclera and sclera/choroid/RPE were carried out using ValiaChein cells (PermeGear, Inc. USA). To our knowledge, these cells are being adapted for
studying permeability across the RPE for the first time. The scleral tissue tends to fold-up into its
natural elliptical shape while mounting on the regular flat face cells. This creates mounting
problems, especially the risk of damaging the RPE layer. On the other hand, it is very easy to
mount the sclera/choroid/RPE tissue on the Valia-Chein cells. To check the validity of the new
experimental set up, acyclovir (ACV) transport across sclera with RPE was carried out from the
S to R (sclera to RPE) direction. The observed permeability was 2.5x10-6 cm/s. Although there
are no prior reports for trans-RPE permeability of ACV, Kansara et al., (111) reported that the
permeability of ganciclovir (GCV) in the S to R direction was 1.61x10-6 cm/s. GCV and ACV
are very similar structurally, and with respect to their physicochemical characteristics. Moreover,
the permeability of ACV and GCV across the rabbit cornea are reported to be very similar
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(3.5x10-6 and 4.1x10-6 cm/s, respectively) (112, 113), indicating that their membrane permeation
characteristics are also comparable. The close approximation of the permeability of ACV
obtained using the Valia-Chien cells with that of GCV in the Franz diffusion cells, indicate that
the RPE structure was intact during the experimental protocol. Moreover, The mean percent
cumulative amount of

[14C]mannitol and [3H]diazepam transported per hour across the

sclera/choroid/RPE tissues were 0.1±0.04 and 0.08±0.02, respectively, similar to the values
reported by Kansara et al., (111). The above results indicate that sclera/choroid/RPE tissue
maintains its integrity during the experimental protocol.
Permeability of hesperidin across the sclera alone (10.2±2.1x10-6 cm/s) was almost 10fold higher than that across sclera with RPE (Fig. 3.6 and 3.7) and that across the cornea. These
results thus substantiate the concept that RPE presents a significant barrier to the transscleral
diffusion process following systemic as well as topical administration. However, topical
instillation should generate significantly higher concentration gradients across the RPE and thus
higher retinal hesperidin concentrations.
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Figure 3.7: Permeability (cm/s) of hesperidin across various ocular tissues. A-B denotes
permeation in the apical to basolateral direction. S-R and R-S denotes permeation in the sclera to
RPE direction and RPE to sclera direction. Values are expressed as mean ± SD (n=4).

The barrier properties of the RPE may be as a result of efflux pump involvement or high
lipophilicity of the therapeutic agent. The RPE is reported to express P-gp (108), which can
modulate drug clearance from the vitreous humor. To delineate the role of efflux mechanisms on
trans-RPE drug delivery, permeability of hesperidin across RPE in both directions i.e.
sclera→choroid→RPE (S-R) and RPE→choroid→sclera (R-S) was measured and were found to
be 0.82±0.68x10-6 cm/s and 1.52±0.78x10-6 cm/s, respectively (Fig. 3.6 and 3.7). The difference
in permeability in the S-R and R-S directions, under the experimental conditions employed, was
statistically insignificant suggesting lack of any efflux mechanism.
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CONCLUSION

In conclusion, results from this study suggest that hesperidin solubility can be markedly
improved by complexation with HP-β-CD and that hesperidin exhibits sufficient chemical and
enzymatic stability in aqueous solutions and biological matrices, respectively. Additionally,
ocular tissue permeation characteristics of hesperidin are not limited by efflux mechanisms.
Thus, topical delivery of hesperidin in the form of ophthalmic solutions/suspensions appears
feasible. A pH range of 6.5 - 8.5 is considered to be optimal for ophthalmic formulations.
Considering the favorable permeability, solubility and stability profiles, it would be reasonable to
formulate hesperidin based ophthalmic solutions at pH 7.4. Further investigation into penetration
of hesperidin into the back-of-the eye ocular tissues, following topical and systemic
administration is warranted.

Courtesy: Reprinted with kind permission from Springer New York LLC. Majumdar S,
Srirangam R. Solubility, stability, physicochemical characteristics and in vitro ocular tissue
permeability of hesperidin: a natural bioflavonoid. Pharm Res. 2009; 26(5):1217-25.
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CHAPTER 4 : SOLUBILITY, STABILITY, PHYSICOCHEMICAL
CHARACTERISTICS AND IN VITRO OCULAR TISSUE PERMEABILITY
OF HESPERETIN

ABSTRACT

The purpose of this investigation was to determine solubility, stability, and in vitro
permeability characteristics of hesperetin across excised rabbit corneas. Aqueous and pH
dependent solubility was determined using standard shake flask method. Solution stability was
evaluated as a function of pH (1.2 - 9) and temperature (25 and 40°C). Permeability of hesperetin
was determined across the isolated rabbit cornea utilizing a side-bi-side diffusion apparatus, in
the apical to basolateral (A-B) and basolateral to apical (B-A) directions. Hesperetin displayed
asymmetrical transcorneal transport with a 2.3-fold higher apparent permeability in the B-A
direction compared to the A-B direction. The transport process was observed to be pH
dependent. Surprisingly, however, the involvement of efflux transporters or proton-coupled
carrier-systems was not evident in this asymmetric transcorneal diffusion process. The passive
and pH dependent corneal transport of hesperetin could probably be attributable to corneal
ultrastructure, physicochemical characteristics of hesperetin and the role of transport buffer
components.
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INTRODUCTION

In order for a drug to be effective in the treatment of ocular diseases, therapeutic
concentrations need to be achieved and maintained at the target site. Ocular drug levels may be
achieved through topical, periocular, intravitreal, systemic or oral administration. Following
administration, the therapeutic moiety has to cross the relevant ocular physiological barriers like
the cornea, sclera, choroid and retinal pigmented epithelium (RPE), depending on the route of
drug application and the target site. To diffuse across these ocular tissues, the drug molecule
should demonstrate adequate permeability characteristics, which in turn depends on the
physicochemical properties of the compound.
Hesperetin has been reported to be a substrate of efflux proteins as well as proton
dependent influx transporters, although there are conflicting reports (25, 114-116). The corneal
tissue is reported to express several efflux transporters such as P-glycoprotein (P-gp), multi-drug
resistant proteins (MRP) and breast cancer resistant proteins (BCRP) (108, 117). Additionally,
peptide transporters, amino acid transporters, monocarboxylic acid transporters (MCTs) are
amongst the identified influx transporters present on the corneal epithelium (108). Incidentally
one report suggested the involvement of an MCT type transporter in the transcellular transport of
hesperetin (25).
The current project was undertaken to evaluate the in vitro permeability characteristics of
hesperetin across the isolated rabbit cornea. Additionally, solubility, stability, and
physicochemical properties of hesperetin were also determined.
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MATERIALS AND METHODS

Materials
Hesperetin, verapamil, MK-571, erythromycin and 2-hydroxypropyl beta cyclodextrin
(HP-β-CD) (1300 MW 0.6 substitution) were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Sodium azide, ouabain, probenecid, 2, 4, dinitrophenol (2, 4 DNP) were obtained from
Fisher scientific (Fairlawn, NJ, USA). All other solvents and chemicals were also purchased
from Fisher scientific (Fairlawn, NJ, USA) and used as such.

Ocular Tissues
Corneas were isolated from euthanized adult male, albino, New Zealand rabbits weighing
between 2 - 2.5 Kg (Myrtle’s Rabbitry, Thompson Station, TN, USA). All experiments using
rabbits conformed to the Association of Research in Vision and Ophthalmology (ARVO)
statement on the use of Animals for use in Ophthalmic and Vision Research and followed the
University of Mississippi Institutional Animal Care and Use Committee approved protocol (07024).

Solubility Studies
Aqueous solubility of hesperetin was determined using the standard shake flask method
wherein an excess quantity of drug was added to 5 mL of the solvent in tightly capped glass
vials. Samples were constantly agitated at 75 rpm, at room temperature (25 °C), for 24 h in
reciprocating water bath (Fisher Scientific, USA) for uniform mixing. At the end of 24 h,
samples were centrifuged (accuSpin 17R, Fisher Scientific, USA) and the supernatant was
aliquoted and analyzed for drug content. Solubility was determined in water and in buffers (pH
1.3 to 9) prepared following procedures described in the United States Pharmacopoeia.
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Additionally, effect of surfactants (Tween® 80, Cremophor® EL, D-alpha-tocopheryl
polyethylene glycol 1000 succinate (Vitamin E-TPGS), and sodium lauryl sulphate; all at 1 %
w/v concentration) and HP-β-CD on the solubility of hesperetin was evaluated. HP-β-CD
concentrations used for the phase solubility studies were 1, 2.5, 5, 7.5, 10, 15 and 20 % w/v in
water.

Solution Stability
Stability of hesperetin in aqueous solution was determined at various pH (1.3, 3, 5, 7.4,
and 9) and temperature (25 and 40 °C) conditions. Buffers were prepared following USP
procedures. Stability studies were initiated with the addition of hesperetin stock solution to 5 mL
of the respective buffer previously equilibrated to either 25 or 40 °C. The final concentrations of
hesperetin in these solutions were 5 µg/mL. Aliquots (200 µL) were collected at predetermined
time points and were stored at −80 °C until further analysis. Samples were analyzed using HPLC
technique as described under the analytical method section.

LogP and pKa
Predicted value of LogP and pKa were obtained using ACD/I-Lab Web Service
(ACD/LogP 8.02) and (ACD/pKa 8.03), respectively.

Transcorneal Permeation Experiments
Experiments were performed following previously described procedures (118). Briefly,
studies were carried out using a side-bi-side diffusion apparatus (PermeGear, Inc. USA). Rabbits
were euthanized with an overdose of sodium pentobarbital injected through the marginal ear
vein. Eyes were collected immediately and washed with Dulbecco’s Phosphate Buffered Saline
(DPBS) and the corneas were isolated with a ring of sclera around it, to help in mounting
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between the diffusion cells. Corneas were washed in DPBS and mounted on the side-bi-side
diffusion apparatus (standard 9 mm cells were used) with the epithelial side facing the donor cell
for apical to basolateral transport (A–B), and with the endothelial side facing the donor cell for
basolateral to apical transport (B–A). Temperature of the cells was maintained at 34 °C with the
help of a circulating water bath. In all cases, unless otherwise mentioned, 3 mL of transport
buffer (DPBS, pH 7.4, containing 0.5 % w/v HP-β-CD) or drug solution (150 µM hesperetin in
DPBS, pH 7.4 or 6, with 0.5 % w/v HP-β-CD) was added to the apical side of the cornea while
3.2 mL of the drug solution or transport buffer, respectively, was added to the basal side, to
maintain the natural hydrostatic pressure. Aliquots (200 µL) were removed at predetermined time
points (15, 30, 45, 60, 90, 120, 150 and 180 min) from the receiver side and the volume
withdrawn was replaced with an equal volume of transport buffer. Samples were stored at −80
°C until further analysis.

pH Dependent Transport
Donor solution pH was decreased to 6 from 7.4 using dilute HCl solution. Effect of pH
on transcorneal diffusion was evaluated in both A-B and B-A directions.

Inhibition Experiments
Hesperetin’s corneal permeation was determined in the presence of inhibitors of various
transport systems. Permeation of hesperetin in the A-B direction was studied in the presence of
100 µM verapamil, 100 µM erythromycin, 500 µM 2,4 DNP, 1 mM sodium azide, and 1 mM
ouabain. Transport in the B-A direction was carried out in the presence of 100 µM verapamil,
100 µM erythromycin, 50 µM chrysin, 1 mM probenecid, 50 µM MK 571, 1 mM sodium azide,
and 1 mM ouabain. In the studies using sodium azide and ouabain, corneas were presoaked in the
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respective transport media (with inhibitors but no drug) for 30 min before the initiation of the
transport studies. Transcorneal permeation of hesperetin, in A-B direction, in the presence of 2, 4
DNP transport was studied across a pH gradient, with the donor solution pH adjusted to 6 and the
receiver solution pH at 7.4.

Concentration Dependent Transport
Permeation of hesperetin in the A-B direction as a function of drug concentration (from
25 to 500 µM), was determined. Transcorneal permeation protocols as described earlier were
followed.
Transcorneal Permeation in the Presence of Tween® 80
To see the effect of components of transport medium on asymmetrical transport of
hesperetin, transcorneal permeation was carried out in the presence of 0.25 and 0.5 % w/v
Tween® 80 in DPBS (pH 7.4), instead of HP-β-CD, in both A-B and B-A directions.
Transcorneal permeation protocols as described earlier were followed.

Corneal Integrity

In order to ascertain that the integrity of the corneas were maintained under the
experimental conditions employed, control studies were carried out using acyclovir (ACV; 1
mM), as a marker compound. Corneal permeability, both A-B and B-A, of ACV was determined
in the presence of hesperetin and components of the transport medium (0.5% HP-β-CD or
Tween® 80). In these studies samples were analyzed for both ACV and hesperetin content and
the transcorneal permeability values for both were determined.
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Permeation across Sclera and Retinal Pigmented Epithelium (RPE)
Transscleral permeation studies were carried out according to previously described
procedures12. Briefly, diffusion studies were carried out using the 5 mm diameter Valia-Chein
side-bi-side diffusion cells from PermeGear, Inc. Rabbit eyes were collected as described in the
earlier section. Subsequently, sclera alone, or sclera with RPE/choroid was carefully isolated and
the tissues were mounted in a manner such that outer surface of the sclera, known as the
episclera, faced the donor side and the inner side of sclera, or the RPE side, faced the receiver
chamber for the transport studies in the sclera to choroid/RPE direction (S to R direction). Donor
solution was added to the RPE/choroid side for transport in the RPE/choroid to scleral direction
(R to S direction). Temperature of the cells was maintained at 37°C with the help of a circulating
water bath. Donor solution was composed of 150 µM hesperetin in DPBS pH 7.4 with 0.5% HPβ-CD. DPBS with 0.5% HP-β-CD was used as the receiver solution. Aliquots (200 µL) were
removed at predetermined time points (15, 30, 45, 60, 90, 120, 150 and 180 min) from the
receiver side and replaced with an equal volume of transport buffer. Samples were stored at
−80°C until further analysis.

Analytical Method
Hesperetin content in the samples was estimated using an analytical method based on
reversed phase HPLC. An HPLC system equipped with Waters 600 pump controller, 2470 dual
wavelength UV detector, refrigerated 717 plus auto-sampler and Agilent 3394B integrator was
used. The detector was operated at 284 nm. Mobile phase consisted of 20 mM monobasic
potassium phosphate (pH adjusted to 2.5 with orthophosphoric acid) and acetonitrile in a ratio of
50:50 and the flow rate was maintained at 1 mL/min. A Waters Symmetry Shield C18 column
was used. ACV content was determined following previously published methods (119).
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Data Analysis
Parameters associated with drug diffusion across the cornea like rate, flux and apparent
permeability coefficient were calculated following previously described methods (118). Briefly,
Steady state (SS) fluxes (µg/min/cm2) were determined from the slope of the cumulative amount
of drug (M) transported vs. time (t) graph and expressed as per unit of surface area (A) as
described by Equation 1.

Flux (J) =

(dM/dt)
Eq - 1

A

Membrane permeability (cm/s) values were determined by normalizing the steady state
fluxes to the donor concentration, Cd according to Equation 2.

Permeability (Papp) = Flux/Cd

Eq-2

Statistical analysis was carried using JMP software (Version 5.0.1). ANOVA was used to
see the difference among different groups and a student t-test for the difference between two
groups. A p value less than 0.05 is considered statistically significant.
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RESULTS

Solubility Studies
Saturation solubility of hesperetin in water was found to be 15.72 ± 0.58 µg/mL and was
pH dependent. Solubility increased with an increase in solution pH. Presence of surfactants also
improved hesperetin’s aqueous solubility. Solubility of hesperetin in water, various buffers and
surfactant solutions is presented in Table 4.1.

Table 4.1: Saturation solubility of hesperetin in water, buffers (200 mM), and surfactant
solutions (1 % w/v). Samples were kept under constant agitation for 24 h at 25 °C in a shaking
water bath. Values are represented as mean ± SD (n=3).

Solvent

Saturation Solubility
(µg/mL)

Water

15.72 ± 0.58

Buffer (pH 1.3)

8.56 ± 1.31

Buffer (pH 3.0)

11.32 ± 0.60

Buffer (pH 5.0)

9.33 ± 1. 31

Buffer (pH 7.4)

19.58 ± 3.32

Buffer (pH 9.0)

500.26 ± 69.75

Tween® 80 solution

269.21 ± 10.92

Cremophor® EL solution

255.21 ± 64.68

Vitamin E-TPGS solution

340.49 ± 19.65

SLS solution

300.82 ± 16.80
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Hesperetin’s solubility was dramatically increased in the presence of HP-β-CD. Phase
solubility studies were conducted as a function of increasing concentrations of HP-β-CD. A plot
of HP-β-CD concentration against the saturation solubility of hesperetin yielded an AL type
phase solubility curve (Fig. 4.1). Association constant (K), complexation efficiency (CE) and
regression coefficient (R2) were found to be 991 ± 4 M-1, 0.079 ± 0.005 and 0.9953 ± 0.0043,
respectively.

Solubility (Moles/L)

0.012
0.01
0.008
0.006
0.004
0.002
0
0

0.05

0.1

0.15

Concentration of HP-β-CD (Moles/L)
Figure 4.1: Phase solubility of hesperetin in the presence of 2-hydroxypropyl beta cyclodextrin
(HP-β-CD). The study was carried out at a temperature of 25 °C for 24 h. Values are represented
as mean ± SD (n=3).

Stability in Aqueous Solutions
Aqueous solution stability was tested as a function of pH and temperature. Hesperetin
was observed to be stable in pH 1.2, 3 and 5 buffers for 3 months (last time point tested).
However, apparent first order degradation was observed in pH 7.4 and 9 solutions and the
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degradation rates were temperature dependent. The apparent first order degradation rate
constants (K) and estimated half-lives are presented in table 4.2.

Table 4.2: Solution stability of hesperetin as a function of pH and temperature. Values are
represented as mean ± SD (n=3).

pH

Temperature (°C)

K (day-1)

t1/2 (days)

7.4

25

0.010 ± 0.0003

72 ± 2

7.4

40

0.041 ± 0.0007

17 ± 0.3

9

25

0.021 ± 0.0007

34 ± 1

9

40

0.121 ± 0.012

6 ± 0.6

Log P and pKa
Using ACD/LogP and ACD/pKa softwares, hesperetin’s logP was estimated to be 2.90 ±
0.39 and pKa values were calculated to be 9.65, 8.5, and 7.55 for the hydroxyl groups positioned
at 3', 5, and 7, respectively.

Transcorneal Permeability

Transport in the Apical to Basolateral (A-B) and the Basolateral to Apical (B-A) Directions:

Hesperetin’s apparent permeability coefficients across the isolated rabbit cornea are
presented in table 4.3. In this case, both donor and receiver chamber pH was maintained at 7.4.
Apparent permeability of hesperetin in the B-A direction was significantly higher, by about 2.3fold, than that in the A-B direction.
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Table 4.3: Apparent permeability coefficients of hesperetin across the isolated rabbit cornea.
Transport was carried out in a side-bi-side diffusion apparatus at a temperature of 34 °C. Donor
solution contained 150 µM hesperetin. Values are represented as mean ± SD (n=4).

Apparent Permeability
Direction and pH of Diffusion Media
Coefficient (cm/s)
Apical (pH 7.4) to basolateral (pH 7.4) direction

4.31 ± 0.73 X 10-6

Basolateral (pH 7.4) to apical (pH 7.4) direction

10.12 ± 1.92 X 10-6

Apical (pH 6.0) to basolateral (pH 7.4) direction

16.65 ± 3.72 X 10-6

Basolateral (pH 6.0) to apical (pH 7.4) direction

15.89 ± 3.38 X 10-6

Inhibition Studies
Asymmetric transport of hesperetin across the cornea, in the absence of a proton gradient,
could be due to the involvement of influx / efflux transporters. In order to establish / identify the
involvement of a carrier system, hesperetin transport was carried out in the presence of
inhibitors/substrates of various nutrient transporters. The pH of the receiver and donor chamber
solutions were maintained at 7.4. Verapamil (a known P-gp substrate) or erythromycin (a known
P-gp/MRP inhibitor), did not produce a significant difference in the permeability of hesperetin,
in either direction. The metabolic inhibitors ouabain (a Na+/K+ ATPase inhibitors) and sodium
azide (an uncoupler of oxidative phosphorylation) also did not demonstrate any effect on the
transcorneal permeation of hesperetin. Additionally, B-A transport of hesperetin was studied in
the presence of inhibitors of other nutrient transport systems. MK571 (a specific MRP inhibitor),
chrysin (a specific BCRP inhibitor) or probenecid (a specific OCT inhibitor) did not effect
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transcorneal hesperetin permeability. Furthermore, diffusion in the B-A direction was studied in
a sodium free media, to check for the involvement of a sodium dependent transporter. In this

Permeability x 106 (cm/s)

case also a significant change in apparent permeability was not observed (Fig. 4.2 and 4.3).
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Verapamil
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Figure 4.2: Transcorneal permeability of hesperetin (HT) (150 µM) in the apical to basolateral
(A-B) direction alone and in the presence of various drug transporter inhibitors. Values are
represented as mean ± SD (n=4).
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Figure 4.3: Transcorneal permeability of hesperetin (HT) (150 µM) in the basolateral to apical
(B - A) direction alone and in the presence of various drug transporter inhibitors and in a sodium
free media. Values are represented as mean ± SD (n=4).

pH Dependent Transport

Donor solution pH was decreased from 7.4 to 6, and transport was evaluated in both A-B
and B-A directions. In the presence of a proton gradient, hesperetin exhibited a higher apparent
permeability in both A-B (a 4-fold increase) and B-A (a 1.5-fold increase) directions, compared
to its apparent permeability in the absence of a proton gradient (donor and receiver solution pH:
7.4) in the A-B and B-A directions. Since, hesperetin demonstrated greater permeability in the
presence of a proton gradient, transport studies were repeated in the presence of a protonophore,
2, 4 DNP. A significant change in transcorneal hesperetin transport was however, not evident.
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Concentration Dependent Transport:
Hesperetin’s transport in the A-B direction as a function of donor concentration was
studied to further investigate the asymmetrical transport characteristics. Both donor and receiver
solution pH was maintained at pH 7.4. A linear increase in the flux with an increasing
concentration of hesperetin was observed in the concentration range tested (Fig. 4.4).

Flux (µg/cm2.min)

0.06
0.05
0.04
0.03
R² = 0.9794

0.02
0.01
0
0

200
400
Concentration (µM)

600

Figure 4.4: Concentration dependent transcorneal flux of hesperetin in the apical to basolateral
direction. Values are represented as mean ± SD (n=4).

Transcorneal Permeation in the Presence of Tween® 80:
Hesperetin’s apparent permeability coefficients across the cornea in the presence of 0.25
% w/v Tween® 80 were found to be 5.37 ± 1.3 X 10-6 and 7.85 ± 1.6 X 10-6 cm/s in the A-B and
B-A directions, respectively. In the presence of 0.5 % w/v Tween® 80 apparent permeability
coefficients were found to be 2.80 ± 0.6 X 10-6 cm/s in the A-B direction and 3.60 ± 0.8 X 10-6
cm/s in the B-A direction. Thus, in the presence of 0.25 % and 0.5 % w/v Tween® 80, a 1.5-fold
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and a 1.3-fold difference, respectively, exists between the A-B and B-A apparent permeability
values.

Corneal Integrity
Corneal permeability of ACV in plain DPBS was observed to be 2.86 ± 0.86 x 10-6 and
3.28 ± 0.91 x 10-6 cm/s in the A-B and B-A directions, respectively. The difference in the
permeability values was not statistically different. In the presence of hesperetin and HPβCD or
hesperetin and Tween® 80, a significant difference between the A-B and B-A permeability
values of ACV was also not evident, indicating that the corneal integrity was not compromised
under the experimental conditions employed. While ACV did not show any difference in the AB and B-A corneal permeability values, a significant difference (2.3-fold and 1.4-fold in the
presence of HP-β-CD and Tween 80, respectively) was observed with respect to the corneal
permeability of hesperetin.

Transscleral Permeability
Transscleral permeability studies were conducted using Valia-Chein diffusion cells. A
significant difference in hesperetin’s permeability in the S-R and R-S direction was not observed
(Fig. 4.5). Permeability of hesperetin across the sclera alone was much higher (6-fold) compared
to permeability across the sclera with RPE attached (sclera-choroid-RPE).
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Figure 4.5: Transscleral permeability of hesperetin (150 µM) across rabbit sclera and sclerachoroid-RPE. S–R and R–S denotes permeation in the sclera to RPE direction and RPE to sclera
direction, respectively. Values are represented as mean ± SD (n=4).
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DISCUSSION

Hesperetin has the potential to treat multiple ocular diseases like diabetic retinopathy,
diabetic macular edema and cataract, by virtue of its wide-ranging pharmacological activities
(70, 81, 120, 121). However, drug delivery to the eye is a challenging task and successful
ophthalmic formulation development requires an understanding of the physicochemical and
permeability characteristics of a drug molecule. The current research project was undertaken to
delineate the in vitro permeation profile of hesperetin across isolated rabbit corneal tissue.
Hesperetin demonstrated very poor aqueous solubility and exhibited a pH dependent
solubility profile. While a significant difference in solubility was not observed in the acidic pH
range (1.3, 3, and 5), under alkaline conditions solubility increased with an increase in solution
pH (Table 4.1). Hesperetin possesses three phenolic hydroxyl groups (Fig. 2.2), and thus
behaves like a weak acid. However, all the predicted pKa values are above 7.5, suggesting
hesperetin will dissociate under alkaline pH conditions. Consistent with this, higher aqueous
solubility was observed in the basic pH range. Presence of HP-β-CD significantly increased
aqueous solubility of hesperetin and this is in agreement with earlier reports (105). A linear
increase in solubility with increasing concentrations of HP-β-CD (Fig. 4.1) indicates that HP-βCD is probably forming a 1:1 molar complex with hesperetin. From the phase solubility studies,
the complexation efficiency for hesperetin and

HP-β-CD was found to be relatively high

compared to hesperidin (118), its parent compound. This could be due to the much higher
lipophilicity of hesperetin (logP 2.9) compared to hesperidin (logP 1.78). Hesperetin was found
to be stable in the acidic buffers (pH 1.2 - 5). However, hesperetin’s concentration was found to
decrease with time with an increase in solution pH and temperature (pH 7.4 – 9) (Table 4.2).
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Transcorneal diffusion of hesperetin was studied using an in vitro side-bi-side diffusion
apparatus. The studies were carried out using DPBS (pH 7.4) containing 0.5 % w/v HP-β-CD as
the transport medium. Hesperetin exhibited asymmetric permeability across the isolated rabbit
cornea, with the apparent permeability in the B-A direction being 2.3-fold greater than that in the
A-B direction. Higher B-A apparent permeability could indicate the involvement of the efflux
transporters (e.g. MRP, P-gp and BCRP) expressed on the corneal epithelium (108, 117). Earlier
studies, however, present confounding evidence with respect to the interaction of hesperetin with
efflux transporters (25, 114, 116, 122). Kobayashi et al., demonstrated that a proton-coupled and
energy dependent transporter was responsible for this higher A-B flux across the Caco-2 cells
(25). Other researchers, however, reported symmetrical transport of hesperetin across Caco-2
cells (116) and that hesperetin’s A-B transport was unaltered in the presence of specific
inhibitors of different ABC transporters, signifying that hesperetin moves through the Caco-2
cell monolayer by passive diffusion (114, 122).
In the current study, the apparent transcorneal permeability profile of hesperetin
suggested possible involvement of efflux transporters in the permeation process. However, a
significant increase in the A-B transport of hesperetin in the presence of verapamil and
erythromycin (P-gp and MRP inhibitors) or sodium azide and ouabain (metabolic inhibitors) was
not evident (Fig. 4.2). To further investigate the role of influx drug transporters in hesperetin’s
asymmetric transcorneal transport, B-A transport was studied in the presence of verapamil,
erythromycin, MK-571 (P-gp/MRP inhibitors), probenecid (OATP inhibitor), chrysin (BCRP
inhibitor), sodium azide, and ouabain. Hesperetin’s B-A transport remained unaltered in all cases
(Fig. 4.3). These results suggest that the B-A diffusion of hesperetin is not facilitated by any of
the transporters tested, and that the transport process is energy and sodium independent since
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both sodium azide and ouabain produced an insignificant effect on transcorneal drug transport.
Moreover, transporter involvement typically yields a curvilinear or saturable concentration
dependent flux. However, in the present study, transcorneal hesperetin flux, in the A-B direction,
increased linearly with increasing concentrations of hesperetin (Fig. 4.4), within the
concentration range tested. The above results, taken together, strongly suggest that corneal
influx/efflux transporters do not interact with hesperetin and are not responsible for the observed
asymmetric transcorneal transport of hesperetin.
It is evident from the pH dependent solubility studies, and the pKa value (9.65, 8.5, and
7.55) of the drug molecule, that hesperetin undergoes ionization and would thus exhibit pH
dependent permeability rates. To evaluate the effect of ionization on transcorneal hesperetin
permeability, the studies were repeated with the donor solution pH adjusted to 6. The receiver
solution pH was maintained at 7.4. This resulted in a significant increase in hesperetin’s apparent
permeability in both A-B and B-A directions (Table 4.3), although the increase in the A-B
direction was significantly greater than the increase in the B-A direction. At a lower pH value
(pH 6), greater than 95% of the drug exists in the unionized state (pKa 7.55), which would
explain the higher permeability of hesperetin. The higher A-B flux of the drug could also be
because of a proton-coupled transporter. However, in the presence of a protonophore, 2, 4 DNP,
a significant change in the apparent A-B permeability was not evident, eliminating the
involvement of a proton-coupled carrier system.
To evaluate the effect of the transport medium (especially HP-β-CD), apparent
transcorneal permeability of hesperetin was evaluated using DPBS (pH 7.4) containing 0.25% or
0.5% w/v Tween® 80 instead of HP-β-CD. Transport in the B-A direction was 1.5 and 1.3-fold
higher compared to the A-B direction, in the presence of 0.25 and 0.5 % w/v Tween® 80,
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respectively. This study further supports the observation that transport of hesperetin across the
rabbit cornea is asymmetrical, especially at lower concentrations of the surfactant. Transcorneal
permeability coefficient of hesperetin in the presence of 0.25 % w/v Tween® 80 was 2-fold
greater than that in the presence of 0.5 % w/v Tween® 80. This is probably because of increased
micellar entrapment of the drug (same drug concentration but increased surfactant levels). This is
consistent with other studies reporting a decrease in apparent permeability with increasing
surfactant concentration (123).
Considering, hesperetin exhibits asymmetrical transport across the rabbit cornea in the
absence of a proton gradient and symmetrical transport in the presence of a proton gradient, and
that the corneal influx or efflux transporters are not involved in the process, the following
hypothesis could probably explain the observed results. Figures 4.6 and 4.7 illustrate the theory
schematically.
The three physical barriers associated with transcorneal diffusion are the epithelium, the
stroma and the endothelium. Drug transport across these different corneal layers can be
represented by Fick’s first law of diffusion.
According to Fick’s first law of diffusion
dM
dt

=

DSKp (Cd - Cr)

Eq-4

h

Where, dM/dt is the mass transfer rate, D is the diffusion coefficient, S is the surface
area, Kp is the apparent partition coefficient, Cd is the concentration of hesperetin in the donor
compartment, Cr is the concentration of hesperetin in the receiving compartment, (Cd - Cr) is the
concentration gradient, and h is the membrane or barrier thickness.
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Figure 4.6: Schematic representation of the transport of hesperetin across rabbit corneal layers in
the apical to basolateral (A-B) direction. Thicker arrows denote the higher flux.

Figure 4.7: Schematic representation of the transport of hesperetin across rabbit corneal layers in
the basolateral to apical (B-A) direction. Thicker arrows denote the higher flux.
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Consider
‘DSKp/h’ as ‘K’ and
(Cd-Cr) equals Cd (as Cd>>Cr).
When hesperetin is permeating in the A-B direction, the net mass transfer rate can be described
by equation 5
dM
dt

A  B  K1 CUI

Dn

K2 CI

Dn

K3 CUI

Ep

K4 CUI

St

K5 CI

St

K6 CUI

End

Eq-5

where K1, K2, ……and K6 are the rate constants associated with the diffusion of the drug;
[CUI] represents concentration of unionized hesperetin; [CI] represents concentration of ionized
hesperetin. The subscripts Dn, Ep, St and End represent concentration of the drug in donor
chamber, corneal epithelial cells, corneal stroma and corneal endothelial cells, respectively.
Hesperetin is known to cross biological barriers by both paracellular as well as
transcellular pathways (114). In the A-B direction, the corneal epithelium, comprised of multiple
layers of epithelial cells packed tightly together, is the first barrier encountered. When the donor
solution is maintained at pH 7.4, hesperetin (pKa 7.55) exists in both the unionized (UI) and
ionized (I) states and only the unionized fraction would diffuse transcellularly into the epithelial
cells (represented by K1 [CUI]Dn of equation 5). Paracellular diffusion of the ionized form
(represented by K2 [CI]Dn of equation 5) would be negligible due to the presence of the corneal
epithelial tight junctions. A fraction of the unionized hesperetin diffusing into the corneal
epithelial cells, then partitions out into the stroma, which is composed of about 90 % water
(represented by K3 [CUI]Ep of equation 5). In view of the fact that the logP of hesperetin is 2.9, it
is reasonable to conclude that the diffusivity (D) of the drug across the epithelial cell membrane
into the stroma will be very low and thus only a very small fraction of the unionized hesperetin
would partition into the stroma from the epithelial layer (i.e. K3 [CUI]Ep will be very low).
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Equilibrium between the ionized and unionized fractions would be established in the stroma (pH
7.2 - 7.4). From the stroma the unionized fraction of hesperetin would move into the endothelial
cell membrane at a rate represented by K4 [CUI]St of equation 5. Ionized hesperetin, a small
molecule, can also diffuse from the stroma across the intercellular junctions of the corneal
endothelial cell layer (represented by K5 [CI]St of equation 5), which are leaky in nature (110),
into the receiver solution. The final component of the overall diffusion process would be the
movement of drug into the receiver solution from the endothelial cells (represented by K6
[CUI]End of equation 5) which would be facilitated by, HP-β-CD or Tween® 80, solubilizing
components of the receiver solution.
Thus, with respect to transcorneal A-B transport, the epithelial tight junctions, blocking
the diffusion of ionized hesperetin (K2 [CI]Dn), and poor partitioning of the unionized hesperetin
from the corneal epithelial layer into the stroma (K3 [CUI]Ep) act as the rate limiting steps in the
transcorneal diffusion process. The above is schematically represented in Figure 4.5.
On the other hand when hesperetin is diffusing in the B-A direction, the net mass transfer
rate can be described by equation 6
dM
dt

B-A= K7[CUI]Dn+ K8[CI]Dn+ K9[CUI]End+ K10[CUI]St+ K11[CI]St+ K12[CUI]Ep

Eq-6

where, K7, K8, ……and K12 are the rate constants associated with diffusion of the drug;.
This has been schematically described in Fig. 4.6.
In the B-A direction the endothelial cells do not present a formidable barrier to the
diffusion of the unionized (represented by K7 [CUI]Dn of equation 6) or ionized (represented by
K8[CI]Dn of equation 6) hesperetin fractions into the corneal stroma because of a decreased
transcellular diffusion length (single layered endothelial cells compared to the multilayered
corneal epithelium) and the lack of endothelial cell tight junctions, respectively. This is
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consistent with several studies that demonstrate transport across the corneal endothelial cells is
much higher than that across the epithelial cells for several drugs (110). In the stroma, since the
pH is 7.4, equilibrium between the ionized and unionized hesperetin fractions is established.
Considering the less restricted access of the ionized form to the stroma in the B-A direction,
stromal hesperetin concentrations will be significantly higher than that achieved in the A-B
direction.
(([CUI] + [CI])St)B-A >> (([CUI] + [CI])St)A-B

Eq-7

The unionized hesperetin then readily partitions into the corneal epithelial cells, from the
stroma, because of its lipophilic nature (represented by K10 [CUI]St of equation 6). In contrast to
the A-B direction, wherein the drug does not easily partition out from the epithelial layers into
the stroma, in this case, because of higher logP, diffusivity will be high and overall
K10 [CUI]St >> K3 [CUI]Ep

Eq-8

From the epithelial cells, drug partitioning into the receiver chamber will be facilitated by
HP-β-CD or Tween® 80, present in the receiver solution (represented by K12 [CUI]Ep of equation
6). Moreover, the paracellular transport of hesperetin across the corneal epithelium in the B-A
direction (represented by K11 [CI]St of equation 6) could also be significantly higher than that in
the A-B direction because of the structural organization of the tight-junctions (39). Thus,
K11 [CI]St >> K2 [CI]Dn or
K11 [CI]Dn >> K2 [CI]Dn (refer to eq-7)
This is also consistent with the report from Pezron et al., wherein the authors observed a
higher flux of zinc insulin in the B-A direction compared to A-B direction across Calu-3 cell
monolayers. It was found that efflux by a transporter (P-gp), enzymatic degradation or the
abundant insulin transporters on the basolateral side were not responsible for this asymmetric
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transport of insulin. The authors hypothesized that at the apical surface diffusion of insulin
monomers is restricted by the presence of tight junction complexes, however, on the basolateral
side insulin oligomers can diffuse into the intercellular spaces freely and dissociate and diffuse
readily as monomers to the apical surface (124).
Considering better transcellular and paracellular diffusion rates in the B-A direction, the
overall permeability in the B-A direction is greater. Differently stated, when hesperetin is
diffusing in the B-A direction, the stroma is exposed to higher drug concentrations, thus
narrowing down the diffusion path length by acting as a donor. On the other hand, in the A-B
direction, the stroma holds relatively much lower fractions of hesperetin because of the larger
barrier role of the epithelial cell layer in this case. Thus, low drug flux is observed in this
direction. This hypothesis explaining the asymmetrical transcorneal diffusion of hesperetin is
consistent with the reports of Schultz, which documents that passive asymmetric transport
through the biological membranes is possible, and that this could be attributed to the structural
heterogeneity of the biological membrane (125).
When the donor solution pH was decreased to pH 6, however, transcellular diffusion of
hesperetin in the A-B direction increased dramatically (4.5-fold increase) due to a significantly
higher concentration gradient of the unionized species. As a result more drug partitioned into the
corneal epithelium and thus into the stroma and thus higher net diffusion in the A-B direction
was observed. Moreover, unionized (uncharged) hesperetin molecules would demonstrate better
paracellular diffusion characteristics than the negatively charged species (126). Thus, in the A-B
direction, with the donor solution at pH 6, both transcellular as well as paracellular diffusion
rates would increase.
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On the other hand, when the donor solution was at pH 6, the B-A transport increased less
markedly (1.5-fold) since trans-endothelial diffusion of hesperetin was anyway higher to start
with. The slight increase observed would be because of increased transcellular diffusion of the
unionized form and also improved paracellular diffusion of the unionized hesperetin molecule
(both across endothelial and epithelial cell junctions). On the whole, transcellular diffusion rates
would overshadow the paracellular diffusion component of hesperetin in the unionized state.
Consequently A-B and B-A transport becomes equal when the donor solution pH is maintained
at pH 6, i.e. the molecule exists in the unionized state.
It also appears that the composition of the transport medium could significantly affect the
transcorneal transport symmetry. The difference between the A-B and B-A flux was significantly
greater when HP-β-CD was used as the solubilizer. Considering the geometrical configuration,
number of hydrogen bonding sites and the molecular weight of HP-β-CD, there is very little
chance that HP-β-CD could penetrate into the stroma from the basolateral side. On the other
hand the ability of Tween® 80 to diffuse into the stroma through the endothelial cells may be
much greater because of its comparatively linear structure. Presence of a solubilizer in the stroma
would significantly enhance K3[CUI]Ep, and thus decrease the difference between the A-B and BA diffusion rates. At 0.25% w/v the concentration of Tween® 80 generated in the stroma would
be significantly lower than that obtained with 0.5% Tween® 80. Consequently, with 0.25%
Tween® 80 a greater directional diffusion was observed compared to that with 0.5% Tween® 80.
There could be an argument that at higher surfactant concentrations the biological membranes
would be damaged. To check for this ACV, a molecule that traverses the corneal membrane
primarily by diffusion across the paracellular pathway, was included as an internal marker. In the
same experimental set-up, while ACV demonstrated symmetrical transport across the cornea,
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hesperetin demonstrated asymmetrical transport. This demonstrates that a change in corneal
integrity was not responsible for the directionality in the observed transcorneal permeation of
hesperetin. Moreover, a decrease in the overall transcorneal hesperetin flux, at 0.5% Tween® 80,
further indicates lack of surfactant induced membrane damage.
In recent years the transscleral route has gained a lot of attention as a means of treating
posterior segment diseases(127). In vitro transscleral permeation studies of hesperetin revealed
that it is capable of permeating across these ocular barriers. It was observed that the drug
permeates across the sclera easily. However the choroid-RPE acts as a significant barrier to the
movement of the drug. Significant differences in hesperetin’s permeability as a function of
direction, i.e. S-R and R-S were not observed, signifying the lack of involvement of any carrier
mediated system (Fig. 4.5). Earlier studies (128, 129) demonstrate that the sclera is permeable to
higher molecule weight compounds also. Therefore, HP-β-CD, a component of the diffusion
media with a molecular weight of 1300 Daltons, is capable of diffusing across the sclera, into the
sclera/choroidal stroma. Thus, with respect to transscleral diffusion, since HP-β-CD can cross
the sclera and reach the Bruch’s-choroid membrane, the diffusion path length is the same in both
directions and comprises of the RPE and Bruch’s membrane. As a result, a difference in
permeability in the S-R and R-S direction is not evident Additionally, it is interesting to note
that hesperetin’s transscleral permeability is higher than that of its parent compound hesperidin,
which may be due to higher lipophilicity of hesperetin compared to hesperidin(118). It has been
reported that RPE favors the diffusion of lipophilic molecules(130).
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CONCLUSION

In conclusion, hesperetin is capable of permeating across the corneal tissue but exhibits
asymmetric transport with the permeability in the A-B direction being significantly lower than
that in the B-A direction. Unique structural features of the cornea and the transport medium
components and solution pH, rather than the involvement of influx/efflux transporters, are
probable reason behind the higher corneal permeability of the drug in the B-A direction.

Courtesy: Reprinted with kind permission from Elsevier BV. Srirangam R, Majumdar S. Passive
asymmetric transport of hesperetin across isolated rabbit cornea. Int J Pharm. 2010; 394 (1-2):
60-7.
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CHAPTER 5 : INTRAVITREAL KINETICS OF HESPERIDIN,
HESPERETIN AND HESPERIDIN G: EFFECT OF DOSE AND
PHYSICOCHEMICAL PROPERTIES

ABSTRACT

The objective of this study was to delineate the vitreal pharmacokinetics of hesperidin
and hesperetin and the hydrophilic derivative hesperidin G (glucosyl hesperidin), following
intravitreal administration in anaesthetized rabbits. Concentration changes in the vitreous humor
were monitored using microdialysis sampling procedure. All three molecules were administered
intravitreally at three dose levels (50 µL injection volume containing 1.5, 4.5 and 15 µg of the
drug, resulting in a final vitreal concentration of 1, 3 and 10 µg/mL). Vitreal microdialysis
samples were collected every 20 minutes over a period of 10 h. All three molecules exhibited
linear pharmacokinetics, within the dose range tested, since AUC and Cmax increased linearly
with increasing dose and a significant difference in the elimination parameters, like clearance or
half-life, was not observed. The vitreal elimination half-life of these three compounds was
observed to correlate with the molecular weight and lipophilicity of the molecules. The findings
from this study provide practical information that will be useful in the future design of ocular
drug delivery strategies for the bioflavonoids.
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INTRODUCTION

Diabetic retinopathy and diabetic macular edema are the leading causes of acquired
blindness, especially in Western countries (55). Hesperidin, a flavanone glycoside and its
aglycone, hesperetin have beneficial effects in the prevention or treatment of diseases of the
posterior segment of the eye, like diabetic retinopathy, diabetic macular edema and other ocular
disorders, because of their favorable pharmacological properties. These molecules can act as
potential antioxidants, can increase the ocular blood flow and minimize ischemic injury to the
retina, can decrease vascular permeability, and act as a neuroprotectant, anti-inflammatory agent
and anticancer agent (118, 131, 132). Hesperidin G (glucosyl hesperidin) is a water soluble
derivative of hesperidin (Figure 5.1). In hesperidin G, a glucose molecule is attached to the
rutinose moiety of hesperidin. This improved hesperidin’s solubility several folds (133).
Hesperidin G is also reported to have some beneficial effects (134-136). It suppressed the
oxidative stress in the vasculature and thereby ameliorated endothelial dysfunction and
hypertension in spontaneously hypertensive rats. However, the observed pharmacological effects
could be because of conversion of hesperidin G into hesperidin and hesperetin by the intestinal
or hepatic metabolic enzymes (137).
Ameer et al., (19) reported that hesperidin’s oral bioavailability is very low (<25%). Over
and above all the barriers to systemic bioavailability, in order to exert a therapeutic effect in
diabetic retinopathy, these compounds must penetrate into the neural retina from the systemic
circulation. For this, they need to permeate across the blood-retinal barrier (BRB), formed by the
retinal pigmented epithelium (RPE) and the endothelial cells of the retinal blood vessels. The
diffusion limiting capabilities of the BRB has been well established for both hydrophilic (limited
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by tight junctions) as well as lipophilic (through efflux mechanism) compounds. Thus, following
oral administration very little, if any, amounts can reach the neural retina.

Figure 5.1: Chemical structure of hesperidin G (glucosyl hesperidin)

Intravitreal therapy has brought about a paradigm shift in the management of posterior
segment ocular diseases. Currently, it is approved by the US FDA to target submacular choroidal
neovascularization in patients with AMD (36, 138). Considering back-of-the eye drug delivery,
the major advantage of IVI is that it generates higher concentrations of the therapeutic agent in
the vitreous with minimal or negligible systemic exposure. These injections have been used to
deliver many types of medications into the vitreous cavity, for example anti-infective (antibiotic,
antifungal, and antiviral), anti-inflammatory (nonsteroidal anti-inflammatory, steroids, and
immunomodulators), anticancer and anti-VEGF agents. However, IVIs may introduce further
complications, such as the progression of endophthalmitis and cataract due to repeated injections.
Additionally, repeated injections may cause extreme patient discomfort and may lead to
complications such as vitreal hemorrhage, infection, and lens or retinal injury (36, 138). In spite
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of the above, IVIs still represent the most effective route of delivery for the back-of-the eye
diseases.
The duration of effect of an intravitreally administered drug depends on the retention of
the injected drug at the site of administration. Disposition of the intravitreally administered drug
from the vitreous humor mainly depends on the physicochemical properties of the molecule and
metabolism by ocular metabolizing enzymes. A scientific understanding of the elimination
kinetics of the drug from posterior chamber and its relationship with physicochemical properties
such as molecular weight, lipophilicity and solubility is essential for the development of
intravitreal drug delivery technologies with desired pharmacokinetic properties (36, 138-140).
The three molecules hesperidin, hesperetin, and hesperidin G, differ in their
physicochemical properties and molecular weight. Hesperetin has the lowest molecular weight
(C16H14O6, 302.27 g/mole) followed by hesperidin (C28H34O15, 610.57 g/mole) and hesperidin G
(C34H44O20, 772.70 g/mole). Hesperidin G is significantly more hydrophilic than the other two
molecules with a log P of < -3.2 while hesperidin and hesperetin have a log P of 1.78 and 2.9,
respectively (118, 132). Thus, the specific objective of the current project was to evaluate the
dose dependent vitreal disposition kinetics of the selected three compounds and to evaluate the
role of log P, solubility and molecular weight on the vitreal elimination kinetics. In this study,
vitreal microdialysis was used to estimate the concentration of the compounds in the vitreous
humor. It is an invasive sampling technique, which involves surgical implantation of the probes
into the organ/tissue of choice. It has become an important tool for dynamic in vivo sampling and
in recent times has been effectively used in characterizing intraocular disposition of drugs in both
the anterior and the posterior chambers of the eye (42-44, 141).
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MATERIALS AND METHODS

Animals
New Zealand male white rabbits were procured from Myrtle’s Rabbitry (Thompson
Station, TN). Experiments conformed to the tenets of the Association for Research in Vision and
Ophthalmology (ARVO) statement on the Use of Animals in Ophthalmic and Vision Research
and followed the University of Mississippi Institutional Animal Care and Use Committee
(IACUC) approved protocol. Each experiment was conducted at least in quadruplicates.

Materials
Microdialysis probes (CMA/20; 20,000 Da molecular mass weight and 10 mm shaft)
were obtained from CMA/Microdialysis Inc. (North Chelmsford, MA). Hesperidin and
hesperetin were purchased form Sigma-Aldrich (St. Louis, MO). Hesperidin G was obtained as a
gift sample from Hayashibara International Inc. (Broomfield, CO). Ketamine hydrochloride and
xylazine were procured from Fort Dodge Animal Health (Fort Dodge, IA) and Lloyd
Laboratories (Shenandoah, IA), respectively. Pentobarbital was obtained from Virbac AH, Inc.
(Fort Worth, TX). All other chemicals and solvents (HPLC grade) used were purchased from
Thermo Fisher Scientific (Waltham, MA) and used as such.

In vitro Probe Recovery
Microdialysis probe recovery was determined following a previously published
report(44). Briefly, recovery values were obtained by placing the probe in an isotonic phosphatebuffered saline (IPBS) solution (pH 7.4) at 37°C, containing a known concentration (1, 3, 10
µg/mL) of the compound; hesperidin, hesperetin or hesperidin G. The probe was perfused with
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sterile IPBS at different flow rates (1.8, 3 and 4 µL/min), and the dialysate was collected every
20 min, to choose optimal conditions. Relative recovery was calculated using eq. 1:
Recoveryin vitro = Cd/Cs

(1)

where Cd is the concentration of the respective compound in the dialysate and Cs is the
concentration in IPBS. The concentration of the respective compound in the vitreous humor
samples was calculated by dividing the dialysate concentration by the in vitro recovery factor
obtained as described above.
The recovery factor for each probe is individually determined before and after the
experiment and the in vivo samples obtained from each probe is uniquely coded. The mean
recovery factor for that particular probe is then used to obtain the actual vitreous humor levels
from the vitreous humor sample concentrations. If a significant difference in the recovery factor
is observed between the in vitro recovery values obtained at the beginning and at the end of each
experiment, data from that probe is not considered. Determination of the recovery factors were
carried out for each individual compound separately. In order to validate the microdialysis probe
recovery factor estimation in IPBS (pH 7.4), in vitro recovery was also determined in pooled
rabbit vitreous humor (collected at the end of other experiments involving New Zealand white
rabbits, from the same or other protocols). The same probes were used in both media. The
concentration used for the compounds in these studies was 1 µg/mL.

Probe Implantation
Probe implantation was done following previously published reports (44). Briefly, rabbits
(weighing 2–2.5 kg) were anesthetized using ketamine (35 mg/kg)/xylazine (3.5 mg/kg)
administered intramuscularly and were maintained under anesthesia throughout the duration of
the experiment (ketamine/xylazine administered intramuscularly every 40 min). Before probe
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implantation, 1% tropicamide was applied topically to dilate the pupil. A 22-guage needle was
then inserted into the posterior chamber of the eye. The point of insertion was approximately 3
mm below the corneal-scleral limbus. The needle was withdrawn, and the vitreal probe was
implanted immediately. The position of the probe was adjusted so that the semipermeable
membrane was in the mid-vitreous section. The probes were continuously perfused with sterile
IPBS (pH 7.4) at a flow rate of 3 µL/min using a CMA/100 microinjection pump
(CMA/Microdialysis Inc.). After probe implantation, animals were allowed to stabilize for a
period of 2 h before the administration of respective compound. Vitreal samples were collected
every 20 min for a period of 10 h post intravitreal administration. Samples were collected in
microcentrifuge tubes and stored at -80°C until further analysis. At the end of the study, animals
were euthanized, under deep anesthesia, with an overdose of sodium pentobarbital administered
through the marginal ear vein.

Intravitreal Administration
Hesperidin, hesperetin or hesperidin G was administered intravitreally (respective dose
(1.5, 4.5 or 15 µg) in 50 µL of IPBS (pH 7.4)). In the case of hesperidin and hesperetin, initial
stock was prepared using 5 % DMSO and further dilutions were made with sterile IPBS (pH
7.4). Final concentration of DMSO in the vitreous humor ranged between 0.005 to 0.05 %.

Analytical Methods
Hesperidin, hesperetin and hesperetin G content in the samples was estimated using an
analytical method based on reversed phase HPLC. An HPLC system equipped with Waters 600
pump controller, 2470 dual wavelength UV detector, refrigerated 717 plus auto-sampler and
Agilent 3394B integrator was used. The detector was operated at 284 nm. Mobile phase
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consisted of 20 mM monobasic potassium phosphate (pH adjusted to 2.5 with ortho-phosphoric
acid) and acetonitrile in a ratio of 75:25 for hesperidin and glucosyl hesperidin while a ratio of
50:50 was used for hesperetin. The flow rate was maintained at 1 mL/min. A Phenomenex Luna,
250 X 4.6 mm, 5µ, C18(2) column was used. Samples were injected (30 µL) on to the column as
such. Calibration curve concentrations used were 0.02, 0.2, 0.5, 1.0, 5.0, 10.0, 15.0 µg/mL for
hesperetin and 0.05, 0.2, 0.5, 1.0, 5.0, 10.0, 15.0 µg/mL for hesperidin and hesperidin G. The
calibration curve had to have a correlation coefficient (r2) of 0.99 or better. Accuracy and
precision was analyzed using four QC samples, at 0.02, 0.2, 1.0, 10.0 for hesperetin and 0.05,
0.2, 1.0, 10.0 for hesperidin and hesperidin G. The acceptance criterion for each back-calculated
standard concentration was 15% deviation from the nominal value except at LLOQ, which was
set at 20%.

Data Analysis
Vitreal pharmacokinetic parameters were determined using WinNonlin® software
(version 5.2; Pharsight, Mountain View, CA). Data was modeled according to one-compartment
and two-compartment pharmacokinetic models. Akaike Information Criterion (AIC) and
Schwarz Bayesian Criterion (SBC) were used for the selection of the most appropriate model.
Additionally, the goodness of fit was assessed graphically by evaluation of the agreement
between the observed and the predicted concentrations and on the correlation coefficient (R2) for
observed vs. predicted values. Statistical analysis was carried out using JMP software (Version
5.0.1). ANOVA was used to check for difference among different groups and Student t-test was
used to evaluate difference between two groups. A p value less than 0.05 is considered
statistically significant.
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RESULTS AND DISCUSSION

Hesperidin and its aglycone, hesperetin are potential candidates for the prevention or
treatment of diseases of the posterior segment of the eye like diabetic retinopathy and diabetic
macular edema (118, 131, 132). Effective concentrations of hesperidin and hesperetin for various
pharmacological activities have been reported by several researchers. These compounds
exhibited dose dependent activities in different in vitro (1-100 µM) (60, 72, 85, 91, 142-144) and
in vivo studies (10-80 mg/Kg BW) (92, 120, 145-147). Hesperidin G is also reported to have
some beneficial effects (134-136). However, the observed pharmacological effects could be
because of conversion of hesperidin G into hesperidin and hesperetin by the metabolic enzymes
present in the intestine or liver (137).
Analytical method for estimating the concentration of these compounds was validated.
Inter-day and intra-day accuracy and precision (CV %) were within 80 -120 % of nominal
concentration at LLOQ and 85 -115 % at remaining quality control levels (Table 5.1). LLOQ for
hesperidin and hesperidin G was found to be 0.05 µg/mL and for hesperetin 0.02 µg/mL. In this
study, microdialysis sampling technique was used for sampling the vitreous humor. Initial
experiments were carried out to optimize flow rate and recovery factor. It was observed that with
an increase in perfusate flow rate, recovery factor decreased. An optimum flow rate of 3 µL/min
was used for the in vivo studies (Table 5.2). The mean recovery values reported signify the mean
in vitro recovery of the probe over a period of 3 consecutive sampling points (20 minutes per
point over 3 hours) for the same probe. The in vitro microdialysis recovery factor was not
affected by the sample concentration (1, 3, and 10 µg/mL) for the three molecules; hesperidin,
hesperetin and hesperidin G.
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Table 5.1: Intra-day and inter-day accuracy and precision data of quality control standards in

IPBS (pH 7.4).

Measured Concentration (µg/mL)
Compound

Hesperetin

Hesperidin

Hesperidin
G

Theoretical
Concentration
(µg/mL)
0.02 (LLOQ)

Intra-day variation
Inter-day variation
Mean
CV
Accuracy Mean
CV
Accuracy
(N=6)
(%)
(%)
(N=4)
(%)
(%)
0.02
7.42
99.17
0.02
8.66
101.46

0.20 (LQC)

0.202

2.66

100.75

0.202

2.85

100.75

1.00 (MQC)

1.01

5.91

101.00

1.02

5.51

101.00

10.00 (HQC)

10.01

1.43

100.10

9.97

2.17

99.68

0.05 (LLOQ)

0.051

6.1

101.00

0.51

5.69

101.00

0.20 (LQC)

0.203

3.53

101.58

0.203

3.13

101.46

1.00 (MQC)

1.00

5.37

99.67

1.01

5.31

100.33

10.00 (HQC)

10.03

1.95

100.30

10.02

1.69

100.20

0.05 (LLOQ)

0.052

9.61

103.33

0.052

8.35

103.42

0.20 (LQC)

0.204

4.91

101.92

0.199

3.98

99.65

1.00 (MQC)

1.02

6.36

102.17

1.02

5.75

101.58

10.00 (HQC)

10.02

1.34

100.20

10.01

1.93

100.15
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Table 5.2: In vitro microdialysis recovery factor of hesperidin, hesperetin and hesperidin-G at
different perfusate (IPBS, pH 7.4) flow rates. The 3 µL/min was considered to be optimum,
taking recovery factor and sample volume into consideration. Solution of these compounds was
prepared in IPBS (pH 7.4) and to validate this, recovery was determined by adding these
compounds to the vitreous humor, freshly obtained from male, New Zealand, white rabbits.
Values represent mean ± SD (n=4).

Recovery Factor

Flow rate
(µL/min)

Hesperidin

Hesperetin

Hesperidin-G

IPBS (pH 7.4)

1.8

0.45 ± 0.05

0.39 ± 0.05

0.48 ± 0.05

IPBS (pH 7.4)

3

0.37 ± 0.04

0.28 ± 0.03

0.39 ± 0.04

Vitreous Humor

3

0.35 ± 0.05

0.25 ± 0.04

0.37 ± 0.06

IPBS (pH 7.4)

4

0.28 ± 0.03

0.22 ± 0.04

0.30 ± 0.03

Medium

Although the use of IPBS (pH 7.4) is well recognized as a substitute for the vitreous
humor for characterizing the in vitro probe recovery factor, in our studies we further validated
the in vitro microdialysis set up. Recovery was determined from the vitreous humor, spiked with
hesperidin, hesperetin or hesperidin G (1 µg/mL final concentration). The recovery factor
obtained from IPBS was found to be consistent with that obtained from the vitreous humor for all
the three molecules (Table 5.2). Thus, IPBS was used for estimating the probe recovery factor,
before and after each experiment, for each compound.
Vitreal kinetics of hesperidin and hesperetin and a water soluble derivative of hesperidin,
hesperidin G, were determined at three dose levels (1.5, 4.5 or 15 µg in 50 µL injection volume)
following intravitreal administration in rabbits. The vitreal concentration-time profiles of
hesperidin, hesperetin and hesperidin G at the three dose levels are presented in Figures 5.2, 5.3
and 5.4, respectively.
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Mean Log Concentration (µg/mL)

100.0
Hesperidin-1.5 µg
Hesperidin-4.5 µg
Hesperidin-15 µg

10.0

1.0

0.1
0

100

200

300

400

500

600

Time (min)

Figure 5.2: Mean vitreal log concentration vs. time profile of hesperidin following intravitreal
administration of hesperidin at three doses (1.5, 4.5 and 15 µg resulting in vitreal concentration
of 1, 3 and 10 µg/mL, respectively). Injection volume was 50 µL. Values represent Mean ± SD
(n=4).
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Mean Log Concentration (µg/mL)

100.00
Hesperetin 1.5 µg
Hesperetin 4.5 µg

10.00

Hesperetin 15 µg
1.00

0.10

0.01
0

200

400
Time (min)
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Figure 5.3: Mean vitreal log concentration vs. time profile of hesperetin following intravitreal
administration of hesperetin at three doses (1.5, 4.5 and 15 µg resulting in vitreal concentration
of 1, 3 and 10 µg/mL, respectively). Injection volume was 50 µL. Values represent Mean ± SD
(n=4).
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Mean Log Concentration (µg/mL)

100.0
Hesperidin G-1.5 µg
Hesperidin G-4.5 µg
Hesperidin G-15 µg
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Figure 5.4: Mean vitreal log concentration vs. time profile of hesperidin G following intravitreal
administration of hesperidin G at three doses (1.5, 4.5 and 15 µg resulting in vitreal
concentration of 1, 3 and 10 µg/mL, respectively). Injection volume was 50 µL. Values represent
Mean ± SD (n=4).

The vitreal concentration vs. time profile of hesperidin and hesperidin G suggested a twocompartment pharmacokinetic model. Data was modeled according to one-compartment and
two-compartment pharmacokinetic models. Akaike Information Criterion (AIC) and Schwarz
Bayesian Criterion (SBC) were used for the selection of the most appropriate model, in addition
to visual (graphical) estimation. Model selection criteria also indicated a two-compartment
pharmacokinetic model for hesperidin and hesperidin G vitreal concentration-time profile, at all
the dose levels tested. Thus, i.v. bolus two-compartment pharmacokinetic model was used for
calculating the different pharmacokinetic parameters. However, in case of hesperetin, vitreal
concentration vs. time profiles at the three doses suggested a one-compartment pharmacokinetic
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model. Additionally, AIC and SBC criteria also confirmed one-compartment pharmacokinetic
model as the best fit. Thus, i.v. bolus one-compartment pharmacokinetic model was used for
calculating the pharmacokinetic parameters. Vitreal pharmacokinetic parameters of hesperidin,
hesperetin and hesperidin G are presented in Tables 5.3, 5.4 and 5.5, respectively.

Table 5.3: Calculated pharmacokinetic parameters of hesperidin at three doses (1.5, 4.5 and 15
µg resulting in vitreal concentration of 1, 3 and 10 µg/mL, respectively) following intravitreal
administration. Injection volume was 50 µL. Values represent mean (SD) (n=4).

Intravitreal dose (µg)

Parameter

Units

AUC

min.µg/mL

751 ± 88

1575 ± 164

4835 ± 861

Cmax

µg/mL

3.26 ± 1.35

10.82 ± 1.12

25.23 ± 3.02

CL

mL/min

0.0027 ± 0.0003

0.0029 ± 0.0003

0.0032 ± 0.0005

CLD2

mL/min

0.0058 ± 0.0010

0.0054 ± 0.0026

0.0130 ± 0.0026

Vss

mL

1.48 ± 0.42

1.29 ± 0.21

2.07 ± 0.35

V2

mL

0.75 ± 0.62

0.87 ± 0.21

1.46 ± 0.40

Alpha

1/min

0.0267 ± 0.0077

0.0249 ± 0.0109

0.0358 ± 0.0084

Beta

1/min

0.0016 ±0.0004

0.0017 ± 0.0003

0.0014 ± 0.0004

Alpha_HL

min

28 ± 7

31 ± 11

20 ± 5

Beta_HL

min

386 ± 116

407 ± 58

466 ± 98

MRT

min

545 ± 106

448 ± 55

668 ± 184

1.5

4.5

100

15

Table 5.4: Calculated pharmacokinetic parameters of hesperetin at three doses (1.5, 4.5 and 15
µg resulting in vitreal concentration of 1, 3 and 10 µg/mL, respectively) following intravitreal
administration. Injection volume was 50 µL. Values represent mean (SD) (n=4).

Intravitreal dose (µg)
4.5

Parameter

Units

AUC

min.µg/mL

179 ± 58

475 ± 70

1746 ± 146

Cmax

µg/mL

1.02 ± 0.20

4.51 ± 0.57

14.67 ± 1.99

CL

mL/min

0.0093 ± 0.0040

0.0096 ± 0.0015

0.0086 ± 0.00070

VVH

mL

1.52 ± 0.29

1.01 ± 0.13

1.04 ± 0.16

T1/2

min

110 ± 28

89 ± 14

83 ± 10

1.5

15

Table 5.5: Calculated pharmacokinetic parameters of hesperidin G at three doses (1.5, 4.5 and
15 µg resulting in vitreal concentration of 1, 3 and 10 µg/mL, respectively) following intravitreal
administration. Injection volume was 50 µL. Values represent mean (SD) (n=4).

Parameter

Units

AUC
Cmax
CL

min.µg/mL
µg/mL
mL/min

Intravitreal dose (µg)
1.5
4.5
15
688 ± 47
1811 ± 269
6167 ± 168
3.79 ± 1.06
20.16 ± 6.12
32.05 ± 4.39
0.0022 ± 0.0002
0.0025 ± 0.0004
0.0024 ± 0.0002

CLD2

mL/min

0.011 ± 0.002

0.003 ± 0.001

0.007 ± 0.001

Vss

mL

1.41 ± 0.14

1.05 ± 0.013

1.25 ± 0.16

V2

mL

1.00 ± 0.07

0.81 ± 0.05

0.78 ± 0.16

Alpha

1/min

0.045 ± 0.019

0.028 ± 0.011

0.027 ± 0.007

Beta

1/min

0.0014 ± 0.0002

0.0015 ± 0.0002

0.0017 ± 0.0003

Alpha_HL

min

17 ± 6

29 ± 16

27 ± 8

Beta_HL

min

495 ± 66

468 ± 82

414 ± 70

MRT

min

648 ± 90

418 ± 21

517 ± 80
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Following intravitreal administration of a compound, it will be distributed within the
vitreous humor and into the surrounding ocular tissues (retina, choroid, lens and aqueous humor),
from where elimination may take place (140). Distribution of an intravitreally administered drug
is governed by 1) the gel structure of the vitreous humor, 2) the time taken by the compound to
set up equilibrium with the peripheral ocular tissues. The vitreous humor is composed of water
(~ 98-99%) and solids (~ 1%, mainly collagen and glycosaminoglycans) (148). This solid
content is responsible for maintaining the gel structure and acts as a molecular barrier to the
diffusion of administered compounds with factors such as molecular weight and interactions
between the drug and collagen through H-bonds for example, playing significant roles.
Establishing of equilibrium between the peripheral ocular tissues and vitreous humor largely
depends on the partition coefficient of the respective compounds (36). In our study hesperetin is
observed to follow a one-compartment pharmacokinetic model (Fig. 5.3), indicating rapid
distribution within the vitreous gel. Additionally, volume of the vitreous humor in the rabbits is
around 1.5 mL and correspondingly, hesperetin volume of distribution (VVH) is in the range of 1
– 1.5 mL (Table 3). The other two larger molecules with higher molecular weight, hesperidin and
glucosyl hesperidin, exhibited a two-compartment pharmacokinetic model (Fig. 5.2 and 5.4),
probably because of slower distribution within the vitreous humor and into peripheral ocular
tissues (RCS, lens and aqueous humor). The Vss for these compounds is close to 1-2 mL and
peripheral volume of distribution (V2) ranged between 075-1.5 mL. It was also reported that,
distribution of large molecules depends on the convection, generated by pressure and
temperature difference between anterior chamber and the retinal surface (36).
It has been established that hepatic/intestinal beta-glucosidase and/or alpha-rhamnosidase
converts hesperidin into hesperetin and hesperetin then undergoes phase-II metabolism to yield
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hesperetin-glucoronides and hesperetin-sulphates. Additionally hesperetin can be converted into
eriodictyol (9, 149, 150). In the case of hesperidin G, alpha-glucosidase converts hesperidin G
into hesperidin. All these enzymes are reported to be present in the various ocular tissues,
however, the expression levels are low compared to that present in the liver (151-153). In our
study levels of metabolites, if any, following intravitreal administration of these compounds were
not detected. This could be because of small sample volumes and/or low metabolite
concentrations generated. In a majority of the cases, elimination of a drug molecule from the
body has been assumed to follow first order kinetics. Nevertheless, it is also possible that
elimination may display nonlinear pharmacokinetics. In such cases ‘concentration’ or 'dose'
dependent kinetics are observed (154). In this study, all three compounds exhibited linear
pharmacokinetics, within the dose range tested as indicated by a linear increase in the AUC and
Cmax with administered dose (Fig. 5.5A and 5.5B) without a significant difference in the
elimination parameters like clearance and elimination half-life across the doses (Tables 5.3, 5.4
and 5.5).
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Hesperidin G
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Figure 5.5: Linear increase in vitreal pharmacokinetic parameters Cmax (A) AUC (B) following
intravitreal administration of hesperidin, hesperetin, and hesperetin G at three doses. Values
represent mean ± SD (n=4).
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Elimination of intravitreally administered drug can take place by two major routes (36,
139, 140). Direct pathway; the vitreous humor is enclosed by the retina, therefore the most direct
pathway is through this tissue. The other route of elimination would be passage of the drug
forward via the anterior elimination route through the aqueous humor (36). Taken together, the
results of this study indicate that, among the three molecules, hesperetin is eliminated more
rapidly, lowest elimination half-life (T1/2: 83.41 – 110.66 min) and highest clearance rate (CL:
0.0086 - 0.0096 mL/min), from the vitreous humor, followed by hesperidin (T1/2: 385.68 –
466.15 min; CL: 0.0027 - 0.0032 mL/min) and hesperidin G (T1/2: 413.83 – 495.07 min; CL:
0.0024 - 0.0025 mL/min) (Tables 5.3, 5.4 and 5.5). This is probably because of higher
lipophilicity (Log P: 2.9) and lower molecular weight (MW: 302.27) of hesperetin compared to
hesperidin (Log P: 1.79; MW: 610.57) and hesperidin G (Log P: -3.2; MW: 772.70). Therefore,
hesperetin can easily permeate across the retinal barrier. Furthermore, our previous in vitro
permeation studies across isolated rabbit retina-choroid-sclera (RCS) indicated that the apparent
permeability of hesperetin in the retina to scleral (R-S) direction (2.52 ± 0.51 X 10-6 cm/s) is
higher compared to hesperidin (1.51 ± 0.78 X 10-6 cm/s) (132). The terminal elimination of a
molecule from the vitreous humor is significantly dependent on the molecular weight (36).
However, the difference between hesperidin and glucosyl hesperidin with respect to elimination
half-life and clearance is not significant, indicating the role of H-bonding, polar surface area and
other molecular characteristics on transretinal elimination.
The other important information that can be drawn from this study, from a drug delivery
perspective, is that these compounds are exhibiting short half-life in the vitreous humor. Thus, in
order to maintain the therapeutic levels for longer duration frequent administration would be
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necessary. Thus, development of a sustained or controlled ocular drug delivery system is
warranted.

CONCLUSION

Overall, in this study vitreal pharmacokinetics of hesperidin, hesperetin and hesperidin G
were evaluated. All three molecules exhibit a linear vitreal pharmacokinetic profile within the
dose range tested. Additionally, it was observed that vitreal kinetics of these molecules is
dependent on their lipophilicity and molecular weight. The results provide practical information
that will be useful in the future design of ocular drug delivery platforms for these molecules.
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CHAPTER 6 : OCULAR DELIVERY OF HESPERIDIN AND
HESPERETIN FOLLOWING INTRAVENOUS AND TOPICAL
ADMINISTRATION

ABSTRACT

The objective of this study was to determine the ocular bioavailability of hesperidin and
hesperetin following systemic and topical administration in rabbits. Microdialysis was employed
to estimate the vitreal bioavailability and blood samples were collected to estimate systemic
exposure. Vitreal samples did not demonstrate any detectable levels of hesperidin/hesperetin on
intravenous administration. In the systemic circulation these compounds were rapidly
metabolized into their glucuronides, which are extremely hydrophilic in nature. Considering the
characteristics of the blood-retinal-barriers; very little, if any, of these hydrophilic metabolites
can cross the ocular barrier to reach the vitreous humor. Following topical administration,
concentrations of hesperidin/hesperetin were observed in all ocular tissues tested at 1 and 3 h
post dosing, with hesperetin showing higher levels compared to hesperidin. However, very low
levels were observed in the posterior segment. Inclusion of a penetration enhancer,
benzalkonium chloride, improved the back-of-the eye hesperetin levels. Thus, in future studies
penetration into the back-of-the eye with the aid of suitable formulation approaches is warranted.
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INTRODUCTION

Currently, hesperidin is used as a dietary supplement to improve blood flow and for its
vasoprotective properties, and is available as an oral dosage form. Ameer et al., (155) reported
that following oral administration, hesperidin is absorbed across the gastrointestinal tract, but
cumulative urinary recovery indicates low bioavailability (< 25%). Several factors limit oral
bioavailability of hesperidin, including poor water solubility and precipitation in an acidic
environment.
Drug delivery to the eye, in comparison to other parts of the body, poses significant
challenges because of the presence of various barriers which are inherent and unique to the
anatomy and physiology of the eye. The general routes of administration for ocular drug delivery
include topical, periocular, intravitreal, systemic and oral routes. A topically administered drug
may penetrate into the posterior chamber tissues, such as the retina, through corneal or
noncorneal routes (28). Transcorneal absorption represents the major route of penetration for
most therapeutic agents. However, several studies demonstrate that the noncorneal route is also a
significant route, wherein the drug molecule is supposed to penetrate into the intraocular tissues
via diffusion across the conjunctiva and sclera (28, 156). For an orally administered drug, it has
to first reach the systemic circulation and then into the eye. To move from the blood into the
ocular tissue, the molecule needs to permeate across the blood-retinal barrier (BRB), formed by
the retinal pigmented epithelium (RPE) and the endothelial cells of the retinal blood vessels. The
diffusion limiting capabilities of the BRB has been well established for both hydrophilic (limited
by tight junctions) as well as lipophilic (through efflux mechanism) compounds (157).
The major goal of this project is to achieve therapeutically optimal hesperidin/hesperetin
concentrations at the target site, i.e. posterior segment of the eye. Till now no one has
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investigated the ocular bioavailability of hesperidin and its aglycone hesperetin through any
route of administration. In this study, our major objective was to evaluate two routes of
administration, systemic and topical, for the delivery of hesperidin and hesperetin to the posterior
segment of the eye using the rabbit model. Additionally, the feasibility of the oral route for
ocular delivery of the bioflavonoids may be judged from the results obtained from the
intravenous administration study. Thus, the aim of this study was to determine plasma and vitreal
kinetics of hesperidin and hesperetin following systemic and topical administration. The amount
of the compounds reaching the posterior segment of the eye, especially vitreous humor, was
monitored using vitreal microdialysis sampling technique.
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MATERIALS AND METHODS

Animals
Studies were conducted using male New Zealand white rabbits, procured from Myrtle’s
Rabbitry (Thompson Station, TN). Experiments conformed to the tenets of the Association for
Research in Vision and Ophthalmology (ARVO) statement on the Use of Animals in Ophthalmic
and Vision Research and followed the University of Mississippi Institutional Animal Care and
Use Committee (IACUC) approved protocol (11-006). Each experiment was conducted at least
in quadruplicates.
Materials
Hesperidin, hesperetin, beta-glucuronidase (Type HP-2, from Helix pomatia) and
microsomes (obtained from rat liver, pooled) were purchased form Sigma-Aldrich (St. Louis,
MO). Ketamine hydrochloride and xylazine were procured from Fort Dodge Animal Health (Fort
Dodge, IA) and Lloyd Laboratories (Shenandoah, IA), respectively. Pentobarbital was obtained
from Virbac AH, Inc. (Fort Worth, TX). Microdialysis probes (CMA/20; 20,000 Da molecular
mass weight and 10 mm shaft) were obtained from CMA/Microdialysis Inc. (North Chelmsford,
MA). All other chemicals and solvents (HPLC grade) used were purchased from Thermo Fisher
Scientific (Waltham, MA) and used as such.
In vitro Probe Recovery
Microdialysis probe recovery was performed following a previously published report
(44). Briefly, recovery values were determined by placing the probe in an isotonic phosphatebuffered saline (IPBS) solution (pH 7.4) at 37 °C, containing a known concentration of the
compound (hesperidin or hesperetin). The probe was perfused with sterile IPBS at a flow rate of
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3 µL/min, and the dialysate was collected every 20 min. Relative recovery was calculated using
eq. 1:
Recoveryin vitro = Cd/Cs

(1)

where Cd is the concentration of the respective compound in the dialysate and Cs is the
concentration in IPBS. The concentration of the compounds in the vitreous humor samples was
calculated by dividing the dialysate concentration by the respective, probe specific, in vitro
recovery factor obtained as described above. The recovery of each probe was determined before
and after each experiment.
Intravenous Administration Study
Probe Implantation:
Probe were implanted following previously published reports (44). Briefly, rabbits
(weighing 2–2.5 kg) were anesthetized using ketamine (35 mg/kg)/xylazine (3.5 mg/kg)
administered intramuscularly, and were maintained under anesthesia throughout the duration of
the experiment (ketamine/xylazine administered intramuscularly every 40 min). Before probe
implantation, 1% tropicamide was applied topically to dilate the pupil. A 22-guage needle was
then inserted into the posterior chamber of the eye. The point of insertion was approximately 3
mm below the corneal-scleral limbus. The needle was withdrawn and the vitreal probe was
implanted immediately. The position of the probe was adjusted so that the semipermeable
membrane was in the mid-vitreous section. The probes were continuously perfused with sterile
IPBS (pH 7.4) at a flow rate of 3 µL/min using a CMA/100 microinjection pump
(CMA/Microdialysis Inc.). After probe implantation, animals were allowed to stabilize for a
period of 2 h before the administration of the respective compounds. Vitreal samples were
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collected every 20 min for a period of 10 h. Samples were collected in microcentrifuge tubes and
stored at -80°C until further analysis. At the end of the study, animals were euthanized, under
deep anesthesia, with an overdose of sodium pentobarbital administered through the marginal ear
vein.
Intravenous Administration of hesperidin/hesperetin:
After anaesthetizing the rabbits, a 21–25 gauge catheter was placed in the central ear
artery for plasma sampling. Once the catheter was placed appropriately, heparin solution was
injected into the catheter to prevent clotting of the line. Subsequently, the microdialysis probe
was implanted and following its stabilization period 0.5 mL of hesperidin or hesperetin solution,
formulated in dimethyl sulfoxide : propylene glycol: IPBS (pH7.4) (40:40:20), was administered
intravenously through the marginal ear vein (20 mg/kg BW). Four animals were studied for each
compound. Blood samples were withdrawn and then collected in heparinized vials at
approximately 0, 10, 15, 30, 60, 90, 120, 240, 360 and 480 min post dosing. Plasma was
separated from the whole blood by centrifugation at 13,000 rpm for 10 min at 4 ºC (accuSpin
Micro 17R, Thermo Fisher Scientific (Waltham, MA, USA)) and was stored at -80 ºC until
further analysis.
Topical Administration Study:
In our previous studies we found that these compounds were highly insoluble in water
(118, 132). Thus, hesperidin solution (1 % w/v) for topical instillation was prepared by
dissolving it in 100 µL of 1 N sodium hydroxide and adding this solution to 10 % HP-β-CD
(prepared in IPBS, pH 7.4, containing 0.1 % HPMC). Final pH was adjusted to 7.4 using 1 N
hydrochloric acid. The hesperetin solution was prepared by dissolving it in 100 µL of 1 N
sodium hydroxide and adding this solution to 10 % HP-β-CD or 10 % RM-β-CD (prepared in
112

IPBS, pH 7.4, containing 0.1 % HPMC) and the final pH was adjusted to 7.4 using 1 N
hydrochloric acid. In the case of hesperetin an additional solution formulation, which included
0.05% benzalkonium chloride (BAK), was also tested.
Rabbits were anaesthetized as described in the microdialysis probe implantation section
and were maintained under anesthesia throughout the duration of the experiment. Following
anesthesia, hesperidin or hesperetin solution (100 µL of 1 % w/v) was administered topically into
the cul-de-sac of one eye of the rabbit and held for 30 sec. Later, rabbits were sacrificed at 1 and
3 h post dosing, eyes were collected and ocular tissues (cornea, iris-ciliary body, lens, retinachoroid, sclera, aqueous humor and vitreous humor) were isolated, weighed and stored at -80 °C
until further analysis.
Analytical Methods
Liquid Chromatography/Mass spectrometry (LC-ESI-TOF):
The liquid chromatography system used was an Agilent Series 1100 comprising of the
following modular components: quaternary pump, a vacuum solvent microdegasser, an
autosampler with 100-well tray. The mass spectrometric analysis was performed by using the
LC-ESI-TOF (Model #G1969A, Agilent Technologies, Palo Alto, CA, USA) equipped with an
ESI source. All acquisitions were performed under positive ionization mode with a capillary
voltage of 3000 V. Nitrogen was used as the nebulizer gas (35 psig) as well as the drying gas at
11 L/min at a temperature of 350 ºC. The voltage of PMT, fragmentor and skimmer was set at
850V, 100V and 60V respectively. Full scan mass spectra were acquired from m/z 200-1000.
Data acquisition and processing was done using the AnalystTM QS software (Agilent
Technologies, Palo Alto, CA, USA).

113

Chromatographic separation was achieved on a synergi Hydro-RP; 100 x 2.0 mm I.D.; 4
µm particle size (Phenomenex, Torrance, CA, USA). The column was equipped with a guard
column (Supelco, Bellefonte, PA, USA). The mobile phase consisted of ammonium formate (20
mM) with 0.1 % formic acid (A), and acetonitrile with 0.1 % formic acid (B) at a flow rate of 0.3
mL/min, with the following gradient elution: 0 min, 95 % A/5 % B to 100 % B over 10 min.
Each run was followed by a 5 min wash with 100 % B and an equilibration period of 11 min with
95 % A/5 % B. The total run time for analysis was 10 minutes. Sample (10 µL) was injected and
peaks were assigned with respect to the mass of the compounds and comparison of the retention
times. This method involved the use of the [M+H]+ ions in the positive ion mode with extractive
ion monitoring (EIM). In the positive ion mode, the protonated species [M+H]+ at m/z 611. 1991
for hesperidin, 303.0869 for hesperetin and 581.19 for naringin (internal standard) were observed
(Fig 6.1).
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Figure 6.1: Selected ion chromatogram and mass spectra of standard compounds (1 µg/mL)

Plasma Sample Analysis:
Hesperidin and hesperetin have been previously reported to undergo Phase-II metabolism
to form hesperetin-glucuronide (158, 159). However, hesperetin-glucuronide standard is
commercially not available; therefore the plasma samples were run in duplicates with and
without the addition of 40 µL of 15,000 units/mL of beta-glucuronidase (HP-2 type solution
from Helix Pomatia) in 0.1 mM acetate buffer (pH 5.0). Following the addition of the betaglucuronidase, samples were incubated at 37 °C for 2 h, to convert the conjugated metabolite to
parent hesperetin. Later, 30 µL of internal standard (naringin 10 µg/mL) was added to both
samples and mixed thoroughly. To this mixture 330 µL of acetonitrile:methanol (50:50) was
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added to precipitate the proteins and centrifuged (accuSpin micro 17R, Thermo Fisher Scientific)
at 12,000 rpm for 20 min at 4 °C. Supernatant was collected and analyzed for the
hesperidin/hesperetin using LC-MS. Calibration standards (1-1000 ng/mL) were prepared by
spiking known amount of hesperidin/hesperetin, with internal standard, into blank rabbit plasma.
Ocular Tissue Sample Analysis:
To a weighed quantity of the respective ocular tissue (cornea, iris-ciliary, lens, sclera,
choroid-retina) 60 µL of the internal standard (naringin 10 µg/ mL) was added and mixed
thoroughly. To this, 3 mL of acetonitrile:methanol (50:50) mixture was added and homogenized
using a Tissuemiser (Thermo Fisher Scientific). The homogenate was centrifuged (accuSpin
micro 17R, Thermo Fisher Scientific) at 12,000 rpm for 20 min at 4 °C. Supernatant was
collected and analyzed for content using LC-MS. Calibration standards (1-1000 ng/mL) were
prepared by spiking a known amount of hesperidin/hesperetin, with internal standard, into
respective blank rabbit ocular tissue homogenate.
Microdialysis Sample Analysis:
Hesperidin and hesperetin content in the microdialysis samples obtained from the
intravenous administration study was analyzed using an HPLC method. An HPLC system
equipped with Waters 600 pump controller, 2470 dual wavelength UV detector, refrigerated 717
plus auto-sampler and Agilent 3394B integrator was used. The detector was operated at 284 nm.
Mobile phase consisted of 20 mM monobasic potassium phosphate (pH adjusted to 2.5 with
ortho-phosphoric acid) and acetonitrile in a ratio of 75:25 and 50:50 for hesperidin and
hesperetin, respectively. The flow rate was maintained at 1 mL/min. A Phenomenex Luna, 250 X
4.6 mm, 5µ, C18(2) column was used. Samples were injected (30 µL) on to the column as such.
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Calibration standards were in the range of 0.02 - 15.0 µg/mL for hesperetin and 0.05 - 15.0
µg/mL for hesperidin.
Data Analysis
Pharmacokinetic parameters were determined using WinNonlin® (version 5.2; Pharsight,
Mountain View, CA). Terminal slopes of the vitreous concentration-time profile were estimated
by log-linear regression, and the apparent elimination rate constant (k) was derived from the
slope. Elimination half-life (t1/2) was calculated from the equation
t1/2 = 0.693/k.
The area under the vitreal concentration-time curve from time 0 to time t was calculated
by the linear trapezoidal method and extrapolated to infinity according to eq. 2:
AUC(0-α)= AUC(0-t)+(Clast/k)
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RESULTS

Intravenous Administration:
Hesperidin and hesperetin are reported to form hesperetin-glucuronide in vivo and we
wanted to estimate the concentration of this metabolite in the plasma samples. However,
hesperetin-glucuronide standard is commercially not available, thus experimental conditions for
the conversion of hesperetin-glucuronide in the plasma to hesperetin with the aid of the deconjugating enzyme, beta-glucuronidase, were optimized. For this, hesperetin-glucuronides were
initially formed using rat liver microsomes. Formation of the glucuronides and their conversion
to hesperetin was confirmed analytically. A similar procedure has been adapted for the
estimation of hesperetin-glucuronide content in the plasma samples in several other reports (160,
161).
Hesperidin Systemic Pharmacokinetics: Hesperidin was administered intravenously at a dose
of 20 mg/Kg BW to anesthetized rabbits. Plasma samples without beta-glucuronidase treatment
did not show any levels of hesperetin. Only hesperidin levels were observed in these samples.
However, plasma samples treated with the beta-glucuronidase enzyme exhibited levels of
hesperetin along with the parent hesperidin. This indicates that, following systemic
administration, hesperidin exists in the plasma as the parent hesperidin and as its Phase-II
metabolite, hesperetin-glucuronide. It should be noted that the hesperetin levels obtained in the
enzyme treated plasma samples actually represents the levels of the metabolite, hesperetinglucuronide.
Observed plasma concentration-time profiles of hesperidin and the metabolite hesperetinglucuronide (estimated in the plasma as hesperetin) is presented in Figure 6.2. Systemic
pharmacokinetic parameters of hesperidin and regenerated hesperetin were calculated using non118

compartmental analysis (NCA) and have been presented in Table 6.1. It is apparent from the
observed results that, hesperidin’s plasma half-life (6.74 h) is relatively short and that the plasma
levels decrease rapidly. The metabolite, hesperetin-glucuronide, also demonstrated a very short

Mean Plasma Concentration
(ng/mL)

half-life, around 5.16 h. Systemic clearance of hesperidin was found to be 6.69 ± 0.58 L/h/Kg.
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Figure 6.2: Mean plasma concentration-time profile of hesperidin and hesperetin-glucuronide
(estimated as hesperetin after the treatment of the plasma samples with beta-glucuronidase to
convert hesperetin-glucuronide to hesperetin), generated in vivo, in the rabbits following
intravenous administration of hesperidin at 20 mg/Kg body weight (N=4).
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Table 6.1: Calculated pharmacokinetic parameters from the plasma concentration-time profile of
hesperidin and hesperetin-glucuronide (estimated as hesperetin after the treatment of the plasma
samples with beta-glucuronidase to convert hesperetin-glucuronide to hesperetin), following
intravenous administration of hesperidin at 20 mg/Kg. Non-compartmental analysis was
followed for calculating PK parameters. Values represent mean ± SD (N=4)

PK Parameter

Hesperidin

Hesperetinglucuronide

Half-life (h)

6.74 ± 0.79

5.16 ± 1.56

C0 (ng/mL)

4559 ± 1004

AUC last (h.ng/mL)

2516 ± 157

1205 ± 132

AUC inf (h.ng/mL)

3004 ± 236

1382 ± 135

Vd (L/Kg)

64.58 ± 3.70

CL (L/h/Kg)

6.69 ± 0.58

MRT (h)

4.22 ± 0.67

3.63 ± 1.27

Hesperetin Systemic Pharmacokinetics
Hesperetin was administered intravenously at a dose of 20 mg/Kg to the anesthetized
rabbits. Blood samples were collected to estimate the systemic availability of hesperetin and its
metabolite, hesperetin-glucuronide. The first set of plasma samples that were analyzed directly,
without treatment with the beta-glucuronidase enzyme, showed hesperetin concentrations. The
hesperetin concentrations in the second set, where the plasma samples were treated with the betaglucuronidase enzyme, were significantly higher compared to first sample set. This suggests that
hesperetin undergoes metabolism in vivo and forms hesperetin-glucuronide. Thus, on treating
these plasma samples with the beta-glucuronidase enzyme, higher levels of hesperetin were
observed. To get the concentration of the metabolite, hesperetin-glucuronide, concentration of
hesperetin in first set of samples were subtracted from the second set. The plasma concentration-
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time profile of hesperetin and its metabolite, hesperetin-glucuronide is presented in Figure 6.3.
Pharmacokinetic parameters were calculated using non-compartmental analysis and have been
presented in Table 6.2. The biological half-life (4.6 h) and MRT (3.17 h) of the metabolite,
hesperetin-glucuronide, was found to be similar to that observed upon hesperidin administration
(5.16 and 3.63 h, respectively).
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Figure 6.3: Mean plasma concentration-time profile of hesperetin (from direct analysis) and
hesperetin-glucuronide (estimated as hesperetin after the treatment of the plasma samples with
beta-glucuronidase to convert hesperetin-glucuronide to hesperetin) following intravenous
administration of hesperetin at a dose of 20 mg/Kg in rabbits (N=4).
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Table 6.2: Calculated pharmacokinetic parameters from plasma concentration-time profile of
hesperetin (from direct analysis) and hesperetin-glucuronide (estimated as hesperetin after the
treatment of the plasma samples with beta-glucuronidase to convert hesperetin-glucuronide to
hesperetin) following intravenous administration of hesperetin at 20 mg/Kg. Non-compartmental
analysis was followed for calculating PK parameters. Values represent mean ± SD (N=4).

PK Parameter

Hesperetin

Hesperetinglucuronide

Half-life (h)

5.32 ± 0.62

4.61 ± 0.62

C0 (ng/mL)

2220 ± 518

AUClast (h.ng/mL)

906 ± 89

1648 ± 418

AUCinf (h.ng/mL)

1055 ± 111

1855 ± 513

Vd (L/Kg)

145.60 ± 8.84

CL (L/h/Kg)

19.09 ± 1.99

MRT (h)

3.60 ± 0.21

3.17 ± 0.39

Vitreal Bioavailability:
Vitreal microdialysis was carried out to estimate the amount of hesperidin or hesperetin
reaching the vitreous humor following intravenous administration. However, these samples did
not exhibit any detectable levels of the compounds, indicating that their vitreal bioavailability is
negligible through systemic route.
Topical Administration:
Experiments were carried out in anesthetized rabbits and the eyes were collected at 1 and
3 h post administration. The ocular tissues were isolated and analyzed for hesperidin or
hesperetin. Levels of hesperidin and hesperetin observed in the ocular tissues following topical
administration are presented in Fig 6.4. and Fig 6.5., respectively. Hesperidin and hesperetin
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levels were observed in all the ocular tissues tested. However, low concentrations were observed
in the retina-choroid and vitreous humor, the targeted sites.
In another set of studies, effect of the solubilizers (HP-β-CD and RM-β-CD) and
penetration enhancer/preservative (benzalkonium chloride (BAK)) on hesperetin’s ocular
penetration following topical administration was studied. The results from these experiments
have been presented in Table 6.3 and 6.4. Hesperetin concentrations achieved in the retina with
HP-β-CD (2.62 µg/g of tissue) was not significantly different from that observed with RM-β-CD
(2.5 µg/g of tissue) based formulations. However, higher hesperetin levels were obtained in the
vitreous humor with HP-β-CD compared to RM-β-CD. The effect of BAK was more pronounced
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Figure 6.4: Levels of hesperidin observed in the rabbit ocular tissues at 1 h and 3 h following
topical administration of hesperidin (100 µL of 1 % w/v solution containing HP-β-CD (10 %
w/v), HPMC (0.1 % w/v), 1 N NaOH (0.05 % v/v) and 1 N HCl (0.05 % w/v) IPBS pH 7.4
(q.s.)). Values represent mean ± SD (N=4).

123

12.607

10.535

3h

15.533

1h

20

0.193

0.836

1.509

0.007

0.013

5

0.99

10

3.345

4.657

15

2.624

Mean Concentration (µg/g)

25

Irisciliary

Aqueo
us
Humor

Cornea

Sclera

Vitreo
us
Humor

Choroi
dRetina

0

Figure 6.5: Levels of hesperetin observed in the rabbit ocular tissues at 1 h and 3 h following
topical administration of hesperetin (100 µL of 1 %w/v solution containing HP-β-CD (10 %
w/v), HPMC (0.1 % w/v), 1 N NaOH (0.05 % v/v) and 1 N HCl (0.05 % w/v) IPBS pH 7.4
(q.s.)). Values represent mean ± SD (N=4). Values represent mean ± SD (N=4).
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Table 6.3: Hesperetin concentrations observed in the rabbit ocular tissues at 1 h following
topical administration of 100 µL of hesperetin solution (1 %w/v) containing HP-β-CD (10 %
w/v), HPMC (0.1 % w/v), 1 N NaOH (0.05 % v/v), 1 N HCl (0.05 % w/v), benzalkonium
chloride (BAK) (0 or 0.05 % w/v) IPBS pH 7.4 (q.s.). Values represent mean ± SD (N=4).

HP-β-CD

HP-β-CD : BAK

Fold difference

Aqueous Humor

0.84 ± 0.21

1.06 ± 0.21

1.26

Vitreous Humor

0.016 ± .01

0.15 ± 0.03

9.62

Cornea

15.53 ± 8.15

27.05 ± 6.53

1.74

Iris-ciliary

12.61 ± 8.21

27.10 ± 13.61

2.15

Retina

2.62 ± 0.81

18.39 ± 4.86

7.01

Sclera

4.66 ± 2.29

10.25 ± 3.78

2.20

Table 6.4: Hesperetin concentrations observed in the rabbit ocular tissues at 1 h following
topical administration of 100 µL of hesperetin solution (1 %w/v) containing RM-β-CD (10 %
w/v), HPMC (0.1 % w/v), 1 N NaOH (0.05 % v/v), 1 N HCl (0.05 % w/v), benzalkonium
chloride (BAK) (0 or 0.05 % w/v) and IPBS pH 7.4 (q.s.). Values represent mean ± SD (N=4).

Aqueous Humor
Vitreous Humor
Cornea
Iris-ciliary
Retina
Sclera

RM-β-CD
0.06 ± 0.03
0.06 ± 0.02
5.13 ± 1.86
3.46 ± 2.32
2.50 ± 1.04
1.32 ± 0.56

RM-β-CD:BAK
0.23 ± 0.14
0.14 ± 0.02
17.62 ± 7.07
6.40 ± 2.16
5.62 ± 0.15
5.42 ± 1.17
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Fold difference
3.59
2.47
3.02
2.46
2.78
4.80

DISCUSSION

Drug delivery to the deeper ocular tissues poses significant challenges because of the
presence of various barriers. In this current investigation, hesperidin and hesperetin delivery to
the posterior segment of the eye was determined following systemic and topical administration,
in anesthetized rabbits.

Intravenous Administration:
Upon systemic administration, therapeutic agents could reach the posterior segment of
the eye; however, molecules encounter the BRB comprised of the endothelial cells of the retinal
capillaries and the epithelial cells of the RPE. The BRB acts as a significant diffusional barrier, a
characteristic dependent on the physiochemical properties of the diffusing molecule and its
interaction with different influx and efflux transporters expressed on the BRB. It is generally
believed that the BRB favors diffusion of lipophilic molecules (157).
Vitreal microdialysis was carried out to measure the amount of the compound reaching
the vitreous humor following systemic administration. Blood samples were also collected, from
the same rabbits, to measure the systemic exposure of hesperidin/hesperetin and its metabolite.
The phase-II metabolism is the major pathway responsible for the intestinal and hepatic
metabolism of hesperidin, wherein hesperidin is converted to hesperetin and hesperetin then
undergoes glucuronidation (155), which is the major circulating metabolite. Thus, in order to
evaluate the systemic availability, concentrations of both hesperidin/hesperetin and hesperetinglucuronide were measured. Hesperetin-glucuronide concentrations were obtained following
treatment of the plasma samples with beta-glucuronidase to convert it into hesperetin and the
hesperetin levels were then estimated.
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Surprisingly, hesperidin was not detected in the microdialysis samples collected from the
vitreous humor. This could be attributed to several factors. First, in general, ocular
bioavailability from the systemic circulation is limited by the BRB. The barrier property of the
BRB is such that passage of hydrophilic molecules is very limited (162, 163). Since, hesperidin
undergoes rapid systemic metabolism to its hydrophilic metabolite (Fig 6.2), diffusion across the
BRB would be severely restricted. Moreover, the extrapolated mean concentration of hesperidin
at time zero, the maximum concentration following intravenous administration, is around 4.5
µg/mL (Table 6.1). Considering hesperidin’s in vitro permeability (0.82 X 10-6 cm/sec) across
the sclera-choroid-RPE (118), which is an underestimation of the actual in vivo barrier
characteristics, very little, if any, hesperidin levels would be expected in the vitreous humor.
Estimation of these low concentrations might also be limited by the microdialysis recovery factor
In the case of hesperetin, a better permeation across the BRB can be expected, since
hesperetin is more lipophilic (LogP 2.9) compared to that of hesperidin (LogP 1.78). This is also
suggested by its greater in vitro permeability (2.37 X 10-6 cm/sec) across the sclera-choroid-RPE
compared to that of hesperidin’s (0.82 X 10-6 cm/sec). Additionally, in our previous study with
quinidine, having a similar LogP (2.6) and molecular weight (324.417 g/mole), respectable levels
were observed in the vitreous humor upon systemic administration (141). However, in this study,
vitreal samples failed to exhibit any detectable levels of hesperetin. This can be attributed to
several factors. It is apparent from the plasma concentration-time profile of hesperetin that high
plasma hesperetin concentrations are not maintained long enough to drive permeation across the
BRB into the vitreous humor. Again, this could be because of rapid in vivo metabolism of
hesperetin into its glucuronide (Fig. 6.3), which is highly hydrophilic in nature. Therefore,
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permeation of these hydrophilic molecules across the BRB is a limiting factor. It is thus not
surprising that hesperetin concentrations were not detectable in the vitreous humor.
Topical Administration:
Since, in this study, hesperidin and hesperetin are being targeted to the posterior segment
of the eye, penetration of these compounds into the ocular tissues following topical
administration was estimated in the anesthetized rabbits. Effective concentrations of hesperidin
and hesperetin needed for various pharmacological activities have been reported by several
researchers. These compounds exhibited dose dependent activities in different in vitro (1-100
µM) (60, 72, 85, 91, 142-144) and in vivo studies (10-80 mg/Kg BW). Additionally, several
studies indicate that hesperetin is more potent compared to hesperidin (92, 120, 145-147).
Results from the topical administration studies with hesperidin and hesperetin in the
rabbits (Fig 6.4 and 6.5) indicate that higher levels were observed in the cornea, sclera, irisciliary body and aqueous humor for both compounds, consistent with the corneal penetration
pathway. With regard to the posterior segment of the eye (choroid-retina and vitreous humor),
higher concentrations were evident in the choroid-retina in comparison to the vitreous humor.
However, from a therapeutic standpoint, levels of these compounds declined rapidly from almost
all the tissues. For example, in the choroid-retina there was more than 50 % decrease in
concentration within 2 h. From these results and from our previous in vitro ocular permeability
studies, it is apparent that the sclera is not a big barrier and that these compounds are able to
reach the choroid-retina. However, they are not able to efficiently permeate across the BRB.
Comparing the levels of hesperidin and hesperetin obtained in the ocular tissues tested, it
was evident that hesperetin demonstrated greater in vivo permeability (Fig 6.4 and 6.5). This
could be because of physicochemical properties of the administered compound. It is well
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recognized that corneal and choroid-retina transport favors relatively lipophilic molecules. In this
case, hesperetin is more lipophilic (Log P 2.9) compared to hesperidin (Log P 1.78).
Additionally, the molecular size of hesperetin is much smaller compared to hesperidin. These
factors explain the better in vivo permeability of hesperetin.
However, the vitreal levels achieved even with hesperetin is sub-therapeutic. To improve
penetration into the deeper ocular tissues, effect of solubilizers and BAK (as the penetration
enhancer) in the topical formulation was studied (Table 6.3 and 6.4). Cyclodextrins are a group
of cyclic oligosaccharides that have been shown to improve solubility of a multitude of poorly
soluble compounds, through the formation of inclusion complexes. Several reviews have been
published on the applications of cyclodextrins in ocular drug delivery (104, 164). In this study,
hesperetin concentrations achieved in the vitreous humor and the choroid-retina were similar
from HP-β-CD and RM-β-CD based formulations. However, HP-β-CD produced higher levels in
the anterior segment of the eye. BAK has often been investigated as penetration enhancer in
ocular preparations in several studies (165-168). It is believed that BAK improves drug penetration
by acting primarily on the tight junctions. In a study by Okabe et al., 0.05 % of BAK had produced

no substantial histological and electrophysiological changes in the eye and improved the
penetration of tested compounds (165). In this study, inclusion of BAK in the HP-β-CD and RMβ-CD based formulations improved the penetration of hesperetin into the ocular tissues.
Additionally, BAK was observed to be more effective when combined with HP-β-CD rather than
RM-β-CD in terms of fold-increase in hesperetin concentrations generated in the retina-choroid
and the vitreous humor.
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CONCLUSIONS

In conclusion, ocular bioavailability of hesperidin or hesperetin is negligible following
intravenous administration. This could be primarily because of the metabolism of these
compounds into their more hydrophilic derivatives. Based on the intravenous administration
study results, it can be concluded that the ability of these compounds to reach the deeper ocular
tissues following oral administration, considering the high intestinal and hepatic metabolism,
will be very poor. On the other hand, following topical administration significant concentrations
of hesperidin and hesperetin were observed in the ocular tissues. However, very low levels were
evident in the posterior segment ocular tissues tested. Inclusion of the penetration enhancer,
benzalkonium chloride, improved the hesperetin levels in the back-of-the eye tissues. Thus,
further studies attempting to improve penetration into the back-of-the eye, through the topical
administration route, with the aid of formulation approaches is warranted.

130

BIBLIOGRAPHY

131

1.

Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, et al.,. Global data on
visual impairment in the year 2002. Bull World Health Organ2004 Nov;82(11):844-51.

2.

Ryskulova A, Turczyn K, Makuc DM, Cotch MF, Klein RJ, et al.,. Self-reported agerelated eye diseases and visual impairment in the United States: results of the 2002
national health interview survey. Am J Public Health2008 Mar;98(3):454-61.

3.

Foster A, Gilbert C, Johnson G. Changing patterns in global blindness: 1988-2008.
Community Eye Health2008 Sep;21(67):37-9.

4.

Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, et al.,. Prevalence of
age-related macular degeneration in the United States. Arch Ophthalmol2004
Apr;122(4):564-72.

5.

Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, et al.,. The prevalence of
diabetic retinopathy among adults in the United States. Arch Ophthalmol2004
Apr;122(4):552-63.

6.

Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial
growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des2004;10(27):3331-48.

7.

Ali TK, El-Remessy AB. Diabetic retinopathy: current management and experimental
therapeutic targets. Pharmacotherapy2009 Feb;29(2):182-92.

8.

Chiou GC XR. Effects of some natural flavonoids on retinal function recovery after
ischemic insult in the rat. J of ocular Pharmacol and Therap2004;20(2):107-13.

9.

Garg A, Garg S, Zaneveld LJ, Singla AK. Chemistry and pharmacology of the Citrus
bioflavonoid hesperidin. Phytother Res2001 Dec;15(8):655-69.

10.

Beiler. J.M MGJ. Inhibition of hyaluronidase action by derivatives of hesperidin. Journal
of Biological chemistry1948;174:31-4.

11.

Jingli Zhang RAS, Laurence D. Melton Margot A. Skinner. Inhibition of lipid oxidation
by phenolic antioxidants in relation to their physicochemical properties.
pharmacologyonline2007;1:180-9.

12.

Hirata A, Murakami Y, Shoji M, Kadoma Y, Fujisawa S. Kinetics of radical-scavenging
activity of hesperetin and hesperidin and their inhibitory activity on COX-2 expression.
Anticancer Res2005 Sep-Oct;25(5):3367-74.

13.

Ayalasomayajula SP, Amrite AC, Kompella UB. Inhibition of cyclooxygenase-2, but not
cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur J
Pharmacol2004 Sep 13;498(1-3):275-8.

14.

Galati EM, Monforte MT, Kirjavainen S, Forestieri AM, Trovato A, et al.,. Biological
effects of hesperidin, a citrus flavonoid. (Note I): antiinflammatory and analgesic activity.
Farmaco1994 Nov;40(11):709-12.
132

15.

Monforte MT, Trovato A, Kirjavainen S, Forestieri AM, Galati EM, et al.,. Biological
effects of hesperidin, a Citrus flavonoid. (note II): hypolipidemic activity on experimental
hypercholesterolemia in rat. Farmaco1995 Sep;50(9):595-9.

16.

Galati EM, Trovato A, Kirjavainen S, Forestieri AM, Rossitto A, et al.,. Biological
effects of hesperidin, a Citrus flavonoid. (Note III): antihypertensive and diuretic activity
in rat. Farmaco1996 Mar;51(3):219-21.

17.

Tanaka T, Makita H, Ohnishi M, Mori H, Satoh K, et al.,. Chemoprevention of 4nitroquinoline 1-oxide-induced oral carcinogenesis in rats by flavonoids diosmin and
hesperidin, each alone and in combination. Cancer Res1997 Jan 15;57(2):246-52.

18.

Tanaka T, Makita H, Kawabata K, Mori H, Kakumoto M, et al.,. Chemoprevention of
azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids,
diosmin and hesperidin. Carcinogenesis1997 May;18(5):957-65.

19.

Ameer B, Weintraub RA, Johnson JV, Yost RA, Rouseff RL. Flavanone absorption after
naringin, hesperidin, and citrus administration. Clin Pharmacol Ther1996 Jul;60(1):3440.

20.

Gil-Izquierdo A, Gil MI, Tomas-Barberan FA, Ferreres F. Influence of industrial
processing on orange juice flavanone solubility and transformation to chalcones under
gastrointestinal conditions. J Agric Food Chem2003 May 7;51(10):3024-8.

21.

Tsai TH, Liu MC. Determination of extracellular hesperidin in blood and bile of
anaesthetized rats by microdialysis with high-performance liquid chromatography: a
pharmacokinetic application. J Chromatogr B Analyt Technol Biomed Life Sci2004 Jul
5;806(2):161-6.

22.

Mitsunaga Y, Takanaga H, Matsuo H, Naito M, Tsuruo T, et al.,. Effect of bioflavonoids
on vincristine transport across blood-brain barrier. Eur J Pharmacol2000 May
3;395(3):193-201.

23.

Ofer M, Wolffram S, Koggel A, Spahn-Langguth H, Langguth P. Modulation of drug
transport by selected flavonoids: Involvement of P-gp and OCT? Eur J Pharm Sci2005
Jun;25(2-3):263-71.

24.

Breinholt VM, Offord EA, Brouwer C, Nielsen SE, Brosen K, et al.,. In vitro
investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food
Chem Toxicol2002 May;40(5):609-16.

25.

Kobayashi S, Tanabe S, Sugiyama M, Konishi Y. Transepithelial transport of hesperetin
and hesperidin in intestinal Caco-2 cell monolayers. Biochim Biophys Acta2008
Jan;1778(1):33-41.

26.

Serra H, Mendes T, Bronze MR, Simplicio AL. Prediction of intestinal absorption and
metabolism of pharmacologically active flavones and flavanones. Bioorg Med Chem2008
Jan 19.
133

27.

Manach C, Morand C, Gil-Izquierdo A, Bouteloup-Demange C, Remesy C.
Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of
two doses of orange juice. Eur J Clin Nutr2003 Feb;57(2):235-42.

28.

Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv2006
Mar;3(2):275-87.

29.

Grass GM, Robinson JR. Mechanisms of corneal drug penetration. I: In vivo and in vitro
kinetics. J Pharm Sci1988 Jan;77(1):3-14.

30.

Grass GM, Robinson JR. Mechanisms of corneal drug penetration. II: Ultrastructural
analysis of potential pathways for drug movement. J Pharm Sci1988 Jan;77(1):15-23.

31.

Watson PG, Young RD. Scleral structure, organisation and disease. A review. Exp Eye
Res2004 Mar;78(3):609-23.

32.

Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease.
Adv Drug Deliv Rev2001 Oct 31;52(1):37-48.

33.

Fischbarg J. The biology of the eye: Elsevier; 2006.

34.

Balachandran RK, Barocas VH. Computer modeling of drug delivery to the posterior eye:
effect of active transport and loss to choroidal blood flow. Pharm Res2008
Nov;25(11):2685-96.

35.

Lee TW, Robinson JR. Drug delivery to the posterior segment of the eye: some insights
on the penetration pathways after subconjunctival injection. J Ocul Pharmacol Ther2001
Dec;17(6):565-72.

36.

Laude A, Tan LE, Wilson CG, Lascaratos G, Elashry M, et al.,. Intravitreal therapy for
neovascular age-related macular degeneration and inter-individual variations in vitreous
pharmacokinetics. Prog Retin Eye Res2010 May 7;29(6):466-75.

37.

Brubaker R. The flow of aqueous humor in the human eye. Trans Am Ophthalmol
Soc1982;80:391.

38.

Maurice D, Mishima S. Ocular Pharmacokinetics In: Sears ML, editor. Handbook of
experimental pharmacology: pharmacology of the eye1986;69:19–116.

39.

Sreeraj M, Mitra A, Patrick M. Ophthalmic drug delivery systems. 2 ed. Mitra A, editor:
Marcel Dekker, Inc.; 2003.

40.

Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp
Pharmacol Physiol2000 Jul;27(7):558-62.

41.

Järvinen K, Järvinen T, Urtti A. Ocular absorption following topical delivery. Advanced
Drug Delivery Reviews1995;16(1):3-19.

134

42.

Duvvuri S, Rittenhouse KD, Mitra AK. Microdialysis assessment of drug delivery
systems for vitreoretinal targets. Adv Drug Deliv Rev2005 Dec 13;57(14):2080-91.

43.

Macha S, Mitra AK. Ocular pharmacokinetics in rabbits using a novel dual probe
microdialysis technique. Exp Eye Res2001 Mar;72(3):289-99.

44.

Majumdar S, Hippalgaonkar K, Srirangam R. Vitreal kinetics of quinidine in rabbits in
the presence of topically coadministered P-glycoprotein substrates/modulators. Drug
Metab Dispos2009 Aug;37(8):1718-25.

45.

Majumdar S, Kansara V, Mitra AK. Vitreal pharmacokinetics of dipeptide monoester
prodrugs of ganciclovir. J Ocul Pharmacol Ther2006 Aug;22(4):231-41.

46.

Janoria KG, Boddu SH, Natesan S, Mitra AK. Vitreal pharmacokinetics of peptidetransporter-targeted prodrugs of ganciclovir in conscious animals. J Ocul Pharmacol Ther
Jun;26(3):265-71.

47.

Macha S, Duvvuri S, Mitra AK. Ocular disposition of novel lipophilic diester prodrugs of
ganciclovir following intravitreal administration using microdialysis. Curr Eye Res2004
Feb;28(2):77-84.

48.

Plock N, Kloft C. Microdialysis--theoretical background and recent implementation in
applied life-sciences. Eur J Pharm Sci2005 May;25(1):1-24.

49.

Singh R, Ramasamy K, Abraham C, Gupta V, Gupta A. Diabetic retinopathy: an update.
Indian J Ophthalmol2008 May-Jun;56(3):178-88.

50.

Izuta H, Matsunaga N, Shimazawa M, Sugiyama T, Ikeda T, et al.,. Proliferative diabetic
retinopathy and relations among antioxidant activity, oxidative stress, and VEGF in the
vitreous body. Mol Vis2010;16:130-6.

51.

Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the
pathogenesis of age-related macular degeneration. Surv Ophthalmol2000 SepOct;45(2):115-34.

52.

Ohia SE, Opere CA, Leday AM. Pharmacological consequences of oxidative stress in
ocular tissues. Mutat Res2005 Nov 11;579(1-2):22-36.

53.

Erickson KK, Sundstrom JM, Antonetti DA. Vascular permeability in ocular disease and
the role of tight junctions. Angiogenesis2007;10(2):103-17.

54.

Rechtman E, Harris A, Garzozi HJ, Ciulla TA. Pharmacologic therapies for diabetic
retinopathy and diabetic macular edema. Clin Ophthalmol2007 Dec;1(4):383-91.

55.

Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema:
pathophysiology, screening, and novel therapies. Diabetes Care2003 Sep;26(9):2653-64.

56.

Ockrim Z, Yorston D. Managing diabetic retinopathy. BMJ2010;341(c5400):930-5.
135

57.

Kollias AN, Ulbig MW. Diabetic retinopathy: Early diagnosis and effective treatment.
Dtsch Arztebl Int2010 Feb;107(5):75-83; .

58.

Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy:
pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab
Disord2008 Dec;9(4):315-27.

59.

Pietta PG. Flavonoids as antioxidants. J Nat Prod2000 Jul;63(7):1035-42.

60.

Chen MC, Ye YY, Ji G, Liu JW. Hesperidin upregulates heme oxygenase-1 to attenuate
hydrogen peroxide-induced cell damage in hepatic L02 cells. J Agric Food Chem2010
Mar 24;58(6):3330-5.

61.

Ratty AK, Das NP. Effects of flavonoids on nonenzymatic lipid peroxidation: structureactivity relationship. Biochem Med Metab Biol1988 Feb;39(1):69-79.

62.

Malterud KE, Rydland KM. Inhibitors of 15-lipoxygenase from orange peel. J Agric
Food Chem2000 Nov;48(11):5576-80.

63.

Balakrishnan A, Menon VP. Antioxidant properties of hesperidin in nicotine-induced
lung toxicity. Fundam Clin Pharmacol2007 Oct;21(5):535-46.

64.

Chen M, Gu H, Ye Y, Lin B, Sun L, et al.,. Protective effects of hesperidin against
oxidative stress of tert-butyl hydroperoxide in human hepatocytes. Food Chem
Toxicol2010 Aug 1;48(10):2980-7.

65.

Kamaraj S, Ramakrishnan G, Anandakumar P, Jagan S, Devaki T. Antioxidant and
anticancer efficacy of hesperidin in benzo(a)pyrene induced lung carcinogenesis in mice.
Invest New Drugs2009 Jun;27(3):214-22.

66.

Pradeep K, Park SH, Ko KC. Hesperidin a flavanoglycone protects against gammairradiation induced hepatocellular damage and oxidative stress in Sprague-Dawley rats.
Eur J Pharmacol2008 Jun 10;587(1-3):273-80.

67.

Wilmsen PK, Spada DS, Salvador M. Antioxidant activity of the flavonoid hesperidin in
chemical and biological systems. J Agric Food Chem2005 Jun 15;53(12):4757-61.

68.

Cho J. Antioxidant and neuroprotective effects of hesperidin and its aglycone hesperetin.
Arch Pharm Res2006 Aug;29(8):699-706.

69.

Aranganathan S, Panneer Selvam J, Nalini N. Hesperetin exerts dose dependent
chemopreventive effect against 1,2-dimethyl hydrazine induced rat colon carcinogenesis.
Invest New Drugs2009 Jun;27(3):203-13.

70.

Choi EJ. Antioxidative effects of hesperetin against 7,12-dimethylbenz(a)anthraceneinduced oxidative stress in mice. Life Sci2008 May 23;82(21-22):1059-64.

136

71.

Kim HJ, Jeon SM, Lee MK, Cho YY, Kwon EY, et al.,. Comparison of hesperetin and its
metabolites for cholesterol-lowering and antioxidative efficacy in hypercholesterolemic
hamsters. J Med Food2010 Aug;13(4):808-14.

72.

Kalpana KB, Srinivasan M, Menon VP. Evaluation of antioxidant activity of hesperidin
and its protective effect on H2O2 induced oxidative damage on pBR322 DNA and RBC
cellular membrane. Mol Cell Biochem2009 Mar;323(1-2):21-9.

73.

Rao YK, Geethangili M, Fang SH, Tzeng YM. Antioxidant and cytotoxic activities of
naturally occurring phenolic and related compounds: a comparative study. Food Chem
Toxicol2007 Sep;45(9):1770-6.

74.

Cos P, Calomme M, Sindambiwe JB, De Bruyne T, Cimanga K, et al.,. Cytotoxicity and
lipid peroxidation-inhibiting activity of flavonoids. Planta Med2001 Aug;67(6):515-9.

75.

Aranganathan S, Nalini N. Efficacy of the potential chemopreventive agent, hesperetin
(citrus flavanone), on 1,2-dimethylhydrazine induced colon carcinogenesis. Food Chem
Toxicol2009 Oct;47(10):2594-600.

76.

Pemp B, Schmetterer L. Ocular blood flow in diabetes and age-related macular
degeneration. Can J Ophthalmol2008 Jun;43(3):295-301.

77.

Liu SX, Chiang CH, Yao QS, Chiou GC. Increase of ocular blood flow by some
phytogenic compounds. J Ocul Pharmacol Ther1996 Summer;12(2):95-101.

78.

Park YH, Chiou GC. Structure-activity relationship (SAR) between some natural
flavonoids and ocular blood flow in the rabbit. J Ocul Pharmacol Ther2004 Feb;20(1):3542.

79.

Xu XR, Park YH, Chiou GC. Effects of dihydrogenation of flavones and number of
hydroxy groups in the molecules on ocular blood flow in rabbits and retinal function
recovery in rats. J Ocul Pharmacol Ther2004 Aug;20(4):311-20.

80.

Park YH, Xu XR, Chiou GC. Structural requirements of flavonoids for increment of
ocular blood flow in the rabbit and retinal function recovery in rat eyes. J Ocul Pharmacol
Ther2004 Jun;20(3):189-200.

81.

Chiou GC, Xu XR. Effects of some natural flavonoids on retinal function recovery after
ischemic insult in the rat. J Ocul Pharmacol Ther2004 Apr;20(2):107-13.

82.

Xiaoting L, Xiangyun Z, Shumei L, Minghua D, Liang X. Effect of hesperidin on
expression of inducible nitric oxide synthase in cultured rabbit retinal pigment epithelial
cells. Adv Exp Med Biol2010;664:193-201.

83.

Mojzis J, Varinska L, Mojzisova G, Kostova I, Mirossay L. Antiangiogenic effects of
flavonoids and chalcones. Pharmacol Res2008 Apr;57(4):259-65.

137

84.

Stoclet JC, Chataigneau T, Ndiaye M, Oak MH, El Bedoui J, et al.,. Vascular protection
by dietary polyphenols. Eur J Pharmacol2004 Oct 1;500(1-3):299-313.

85.

Choi EJ, Kim GD, Chee KM, Kim GH. Effects of hesperetin on vessel structure
formation in mouse embryonic stem (mES) cells. Nutrition2006 Sep;22(9):947-51.

86.

Calderone V, Chericoni S, Martinelli C, Testai L, Nardi A, et al.,. Vasorelaxing effects of
flavonoids: investigation on the possible involvement of potassium channels. Naunyn
Schmiedebergs Arch Pharmacol2004 Oct;370(4):290-8.

87.

Choi IY, Kim SJ, Jeong HJ, Park SH, Song YS, et al.,. Hesperidin inhibits expression of
hypoxia inducible factor-1 alpha and inflammatory cytokine production from mast cells.
Mol Cell Biochem2007 Nov;305(1-2):153-61.

88.

Paysant J, Sansilvestri-Morel P, Bouskela E, Verbeuren TJ. Different flavonoids present
in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its antihyperpermeability effect in the hamster cheek pouch microcirculation. Int Angiol2008
Feb;27(1):81-5.

89.

Yoshida H, Takamura N, Shuto T, Ogata K, Tokunaga J, et al.,. The citrus flavonoids
hesperetin and naringenin block the lipolytic actions of TNF-alpha in mouse adipocytes.
Biochem Biophys Res Commun2010 Apr 9;394(3):728-32.

90.

Fenton JI, Hord NG. Flavonoids promote cell migration in nontumorigenic colon
epithelial cells differing in Apc genotype: implications of matrix metalloproteinase
activity. Nutr Cancer2004;48(2):182-8.

91.

Choi EM, Lee YS. Effects of hesperetin on the production of inflammatory mediators in
IL-1beta treated human synovial cells. Cell Immunol2010;264(1):1-3.

92.

Gandhi C, Upaganalawar A, Balaraman R. Protection against in vivo focal myocardial
ischemia/reperfusion injury-induced arrhythmias and apoptosis by hesperidin. Free Radic
Res2009 Sep;43(9):817-27.

93.

Morand C, Dubray C, Milenkovic D, Lioger D, Martin JF, et al.,. Hesperidin contributes
to the vascular protective effects of orange juice: a randomized crossover study in healthy
volunteers. Am J Clin Nutr Nov 10.

94.

Tunon MJ, Garcia-Mediavilla MV, Sanchez-Campos S, Gonzalez-Gallego J. Potential of
flavonoids as anti-inflammatory agents: modulation of pro-inflammatory gene expression
and signal transduction pathways. Curr Drug Metab2009 Mar;10(3):256-71.

95.

Koyuncu H, Berkarda B, Baykut F, Soybir G, Alatli C, et al.,. Preventive effect of
hesperidin against inflammation in CD-1 mouse skin caused by tumor promoter.
Anticancer Res1999 Jul-Aug;19(4B):3237-41.

138

96.

Jain M, Parmar HS. Evaluation of antioxidative and anti-inflammatory potential of
hesperidin and naringin on the rat air pouch model of inflammation. Inflamm Res2010
May;60(5):483-91.

97.

Sakata K, Hirose Y, Qiao Z, Tanaka T, Mori H. Inhibition of inducible isoforms of
cyclooxygenase and nitric oxide synthase by flavonoid hesperidin in mouse macrophage
cell line. Cancer Lett2003 Sep 25;199(2):139-45.

98.

Nizamutdinova IT, Jeong JJ, Xu GH, Lee SH, Kang SS, et al.,. Hesperidin, hesperidin
methyl chalone and phellopterin from Poncirus trifoliata (Rutaceae) differentially
regulate the expression of adhesion molecules in tumor necrosis factor-alpha-stimulated
human umbilical vein endothelial cells. Int Immunopharmacol2008 May;8(5):670-8.

99.

Sreeraj Macha AKM, Patrick M. Hughes. Ophthalmic drug delivery systems. 2 ed. Mitra
AK, editor: Marcel Dekker; 2003.

100.

Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities
of protein utilizing the principle of protein-dye binding. Anal Biochem1976 May
7;72:248-54.

101.

Holekamp NM, Thomas MA, Pearson A. The safety profile of long-term, high-dose
intraocular corticosteroid delivery. Am J Ophthalmol2005 Mar;139(3):421-8.

102.

Jansen T, Xhonneux B, Mesens J, Borgers M. Beta-cyclodextrins as vehicles in eye-drop
formulations: an evaluation of their effects on rabbit corneal epithelium. Lens Eye Toxic
Res1990;7(3-4):459-68.

103.

Saarinen-Savolainen P, Jarvinen T, Araki-Sasaki K, Watanabe H, Urtti A. Evaluation of
cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an
immortalized human corneal epithelial cell line. Pharm Res1998 Aug;15(8):1275-80.

104.

Loftssona T, Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv
Rev1999 Mar 1;36(1):59-79.

105.

Tommasini S, Calabro ML, Stancanelli R, Donato P, Costa C, et al.,. The inclusion
complexes of hesperetin and its 7-rhamnoglucoside with (2-hydroxypropyl)-betacyclodextrin. J Pharm Biomed Anal2005 Sep 15;39(3-4):572-80.

106.

Wilcox DK. Extracellular release of acid hydrolases from cultured retinal pigmented
epithelium. Invest Ophthalmol Vis Sci1987 Jan;28(1):76-82.

107.

Adler AJ. Selective presence of acid hydrolases in the interphotoreceptor matrix. Exp Eye
Res1989 Dec;49(6):1067-77.

108.

Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and bloodretina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv
Rev2006 Nov 15;58(11):1136-63.

139

109.

Marshall WS, Klyce SD. Cellular and paracellular pathway resistances in the "tight" Cl- secreting epithelium of rabbit cornea. J Membr Biol1983;73(3):275-82.

110.

Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature
analysis for drug delivery to the eye. J Pharm Sci1998 Dec;87(12):1479-88.

111.

Kansara V, Hao Y, Mitra AK. Dipeptide monoester ganciclovir prodrugs for transscleral
drug delivery: targeting the oligopeptide transporter on rabbit retina. J Ocul Pharmacol
Ther2007 Aug;23(4):321-34.

112.

Majumdar S, Hippalgaonkar K, Repka MA. Effect of chitosan, benzalkonium chloride
and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit
cornea. Int J Pharm2008 Feb 4;348(1-2):175-8.

113.

Majumdar S, Nashed YE, Patel K, Jain R, Itahashi M, et al.,. Dipeptide monoester
ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis:
in vitro and in vivo evaluations. J Ocul Pharmacol Ther2005 Dec;21(6):463-74.

114.

Brand W, van der Wel PA, Rein MJ, Barron D, Williamson G, et al.,. Metabolism and
transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers. Drug Metab
Dispos2008 Sep;36(9):1794-802.

115.

Mertens-Talcott SU, De Castro WV, Manthey JA, Derendorf H, Butterweck V.
Polymethoxylated flavones and other phenolic derivates from citrus in their inhibitory
effects on P-glycoprotein-mediated transport of talinolol in Caco-2 cells. J Agric Food
Chem2007 Apr 4;55(7):2563-8.

116.

Serra H, Mendes T, Bronze MR, Simplicio AL. Prediction of intestinal absorption and
metabolism of pharmacologically active flavones and flavanones. Bioorg Med Chem2008
Apr 1;16(7):4009-18.

117.

Vellonen KS, Mannermaa E, Turner H, Hakli M, Wolosin JM, et al.,. Effluxing ABC
transporters in human corneal epithelium. J Pharm Sci2010 Feb;99(2):1087-98.

118.

Majumdar S, Srirangam R. Solubility, stability, physicochemical characteristics and in
vitro ocular tissue permeability of hesperidin: a natural bioflavonoid. Pharm Res2009
May;26(5):1217-25.

119.

Majumdar S, Hingorani T, Srirangam R. Evaluation of active and passive transport
processes in corneas extracted from preserved rabbit eyes. J Pharm Sci2010
Apr;99(4):1921-30.

120.

Choi EJ, Ahn WS. Neuroprotective effects of chronic hesperetin administration in mice.
Arch Pharm Res2008 Nov;31(11):1457-62.

121.

Hwang SL, Yen GC. Neuroprotective effects of the citrus flavanones against H2O2induced cytotoxicity in PC12 cells. J Agric Food Chem2008 Feb 13;56(3):859-64.

140

122.

Brand W, Padilla B, van Bladeren PJ, Williamson G, Rietjens IM. The effect of coadministered flavonoids on the metabolism of hesperetin and the disposition of its
metabolites in Caco-2 cell monolayers. Mol Nutr Food Res2010 Jan 28.

123.

Chiu YY, Higaki K, Neudeck BL, Barnett JL, Welage LS, et al.,. Human jejunal
permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco2 cells. Pharm Res2003 May;20(5):749-56.

124.

Pezron I, Mitra R, Pal D, Mitra AK. Insulin aggregation and asymmetric transport across
human bronchial epithelial cell monolayers (Calu-3). J Pharm Sci2002 Apr;91(4):113546.

125.

Schultz JS. Passive asymmetric transport through biological membranes. Biophys J1971
Nov;11(11):924-43.

126.

Schanker L. Passage of drugs across body membranes. Pharmacol Rev1962;14:501-30.

127.

Barocas VH, Balachandran RK. Sustained transscleral drug delivery. Expert Opin Drug
Deliv2008 Jan;5(1):1-10.

128.

Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability. Effects of
age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis
Sci1995 Aug;36(9):1893-903.

129.

Ambati J, Canakis CS, Miller JW, Gragoudas ES, Edwards A, et al.,. Diffusion of high
molecular weight compounds through sclera. Invest Ophthalmol Vis Sci2000
Apr;41(5):1181-5.

130.

Kim SH, Lutz RJ, Wang NS, Robinson MR. Transport barriers in transscleral drug
delivery for retinal diseases. Ophthalmic Res2007;39(5):244-54.

131.

Majumdar S, Srirangam R. Potential of the bioflavonoids in the prevention/treatment of
ocular disorders. J Pharm Pharmacol2010 Aug;62(8):951-65.

132.

Srirangam R, Majumdar S. Passive asymmetric transport of hesperetin across isolated
rabbit cornea. Int J Pharm2010 Jul 15;394(1-2):60-7.

133.

Hijiya H, Miyake T, inventors; Kabushiki Kaisha Hayashibara, Okayama, Japan,
assignee. alpha-glycosyl hesperidin, and its preparation and uses. United States patent
5652124. 1997 07/29/1997.

134.

Yamamoto M, Suzuki A, Hase T. Short-term effects of glucosyl hesperidin and
hesperetin on blood pressure and vascular endothelial function in spontaneously
hypertensive rats. J Nutr Sci Vitaminol (Tokyo)2008 Feb;54(1):95-8.

135.

Yamamoto M, Suzuki A, Jokura H, Yamamoto N, Hase T. Glucosyl hesperidin prevents
endothelial dysfunction and oxidative stress in spontaneously hypertensive rats.
Nutrition2008 May;24(5):470-6.
141

136.

Ohtsuki K, Abe A, Mitsuzumi H, Kondo M, Uemura K, et al.,. Glucosyl hesperidin
improves serum cholesterol composition and inhibits hypertrophy in vasculature. J Nutr
Sci Vitaminol (Tokyo)2003 Dec;49(6):447-50.

137.

Yamada M, Tanabe F, Arai N, Mitsuzumi H, Miwa Y, et al.,. Bioavailability of glucosyl
hesperidin in rats. Biosci Biotechnol Biochem2006 Jun;70(6):1386-94.

138.

Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents.
Retina2009 Jul-Aug;29(7):875-912.

139.

Maurice D. Review: practical issues in intravitreal drug delivery. J Ocul Pharmacol
Ther2001 Aug;17(4):393-401.

140.

Tojo KJ, Ohtori A. Pharmacokinetic model of intravitreal drug injection. Math
Biosci1994 Sep;123(1):59-75.

141.

Hippalgaonkar K, Srirangam R, Avula B, Khan IA, Majumdar S. Interaction between
topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on
vitreal kinetics. Drug Metab Dispos2010 Oct;38(10):1790-7.

142.

Kuntz S, Wenzel U, Daniel H. Comparative analysis of the effects of flavonoids on
proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur J
Nutr1999 Jun;38(3):133-42.

143.

Kalpana KB, Devipriya N, Srinivasan M, Menon VP. Investigation of the radioprotective
efficacy of hesperidin against gamma-radiation induced cellular damage in cultured
human peripheral blood lymphocytes. Mutat Res2009 May 31;676(1-2):54-61.

144.

Choi IY, Kim SJ, Jeong HJ, Park SH, Song YS, et al.,. Hesperidin inhibits expression of
hypoxia inducible factor-1 alpha and inflammatory cytokine production from mast cells.
Mol Cell Biochem2007 Nov;305(1-2):153-61.

145.

Akiyama S, Katsumata S, Suzuki K, Ishimi Y, Wu J, et al.,. Dietary hesperidin exerts
hypoglycemic and hypolipidemic effects in streptozotocin-induced marginal type 1
diabetic rats. J Clin Biochem Nutr2010 Jan;46(1):87-92.

146.

Stoclet JC, Chataigneau T, Ndiaye M, Oak MH, El Bedoui J, et al.,. Vascular protection
by dietary polyphenols. Eur J Pharmacol2004 Oct 1;500(1-3):299-313.

147.

Balakrishnan A, Menon VP. Antioxidant properties of hesperidin in nicotine-induced
lung toxicity. Fundam Clin Pharmacol2007 Oct;21(5):535-46.

148.

Bishop PN. Structural macromolecules and supramolecular organisation of the vitreous
gel. Prog Retin Eye Res2000 May;19(3):323-44.

149.

Brand W, Boersma MG, Bik H, Hoek-van den Hil EF, Vervoort J, et al.,. Phase II
metabolism of hesperetin by individual UDP-glucuronosyltransferases and

142

sulfotransferases and rat and human tissue samples. Drug Metab Dispos2010
Apr;38(4):617-25.
150.

Breinholt VM, Offord EA, Brouwer C, Nielsen SE, Brosen K, et al.,. In vitro
investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food
Chem Toxicol2002 May;40(5):609-16.

151.

Lentrichia B, Bruner W, Kean E. Glycosidases of the retinal pigment epithelium. Invest
Ophthalmol Vis Sci1978;17(9):884.

152.

Hawkins LA, Garg HS, Awasthi YC, Srivastava SK. Distribution of lysosomal
hydrolases in human and bovine ocular tissues. Curr Eye Res1981;1(9):497-500.

153.

Duvvuri S, Majumdar S, Mitra AK. Role of metabolism in ocular drug delivery. Curr
Drug Metab2004 Dec;5(6):507-15.

154.

Gibaldi M, Perrier D. Nonlinear pharmacokinetics. In: Gibaldi M, Perrier D, editors.
Pharmacokinetics. 2 ed. New York: M. Dekker Inc., ; 1975. p. 271-315.

155.

Ameer B, Weintraub RA, Johnson JV, Yost RA, Rouseff RL. Flavanone absorption after
naringin, hesperidin, and citrus administration. Clin Pharmacol Ther1996 Jul;60(1):3440.

156.

Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol2002
Aug;47 Suppl 1:S41-52.

157.

Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: challenges and
opportunities. Expert Opin Biol Ther2003 Feb;3(1):45-56.

158.

Kanaze FI, Bounartzi MI, Georgarakis M, Niopas I. Pharmacokinetics of the citrus
flavanone aglycones hesperetin and naringenin after single oral administration in human
subjects. Eur J Clin Nutr2007 Apr;61(4):472-7.

159.

Erlund I, Meririnne E, Alfthan G, Aro A. Plasma kinetics and urinary excretion of the
flavanones naringenin and hesperetin in humans after ingestion of orange juice and
grapefruit juice. J Nutr2001 Feb;131(2):235-41.

160.

Matsumoto H, Ikoma Y, Sugiura M, Yano M, Hasegawa Y. Identification and
quantification of the conjugated metabolites derived from orally administered hesperidin
in rat plasma. J Agric Food Chem2004 Oct 20;52(21):6653-9.

161.

Gardana C, Guarnieri S, Riso P, Simonetti P, Porrini M. Flavanone plasma
pharmacokinetics from blood orange juice in human subjects. Br J Nutr2007
Jul;98(1):165-72.

162.

Kuppermann BD, Loewenstein A. Drug delivery to the posterior segment of the eye. Dev
Ophthalmol;47:59-72.

143

163.

Loftsson T, Sigurdsson HH, Konradsdottir F, Gisladottir S, Jansook P, et al.,. Topical
drug delivery to the posterior segment of the eye: anatomical and physiological
considerations. Pharmazie2008 Mar;63(3):171-9.

164.

Kaur IP, Chhabra S, Aggarwal D. Role of cyclodextrins in ophthalmics. Curr Drug
Deliv2004 Oct;1(4):351-60.

165.

Okabe K, Kimura H, Okabe J, Kato A, Shimizu H, et al.,. Effect of benzalkonium
chloride on transscleral drug delivery. Invest Ophthalmol Vis Sci2005 Feb;46(2):703-8.

166.

Majumdar S, Hippalgaonkar K, Repka MA. Effect of chitosan, benzalkonium chloride
and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit
cornea. Int J Pharm2008 Feb 4;348(1-2):175-8.

167.

Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura J, et al.,. Modification of ocular
permeability of peptide drugs by absorption promoters. Biol Pharm Bull2000
Dec;23(12):1524-7.

168.

Sasaki H, Nagano T, Yamamura K, Nishida K, Nakamura J. Ophthalmic preservatives as
absorption promoters for ocular drug delivery. J Pharm Pharmacol1995 Sep;47(9):703-7.

144

VITA

Ramesh

Srirangam,

youngest

son

of

Mr.

Madanaiah

Srirangam

and

Mrs.

Laxmikanthamma Srirangam, was born on March 3rd, 1979 in Warangal, India. He attended high
school at Andhra Pradesh Residential School (APRS) Bandarupally (Warangal), India and
graduated in May 1994. He pursued his Bachelors in Pharmacy from the University College of
Pharmaceutical Sciences, Kakatiya University, Warangal, India and graduated with a first class
distinction in November 2002. He was an outstanding student of his class and received the
prestigious Indian Drug Manufacturers Association (IDMA) – G.P. Nair award. He secured an
"All India 13th rank" (99.72 Percentile) in Graduate Aptitude Test in Engineering and
Pharmaceutical Sciences (GATE) - 2002, an all India entrance test for entry into Masters
education. He received the Master’s degree in Pharmacy with a specialization in Pharmaceutics
at the University College of Pharmaceutical Sciences, Kakatiya University, Warangal, India and
graduated with a first class distinction in August 2002. He is a recipient of Junior Research
Fellowship from All India Council for Technical Education and Training (AICTE) during
Master’s education. After completing his Master’s Degree, he worked at Dr. Reddy’s Lab,
Hyderabad, India for one year.
In August 2006, Mr. Ramesh Srirangam was accepted as a Ph.D. student in the
Department of Pharmaceutics, University of Mississippi. During the course of his doctoral study,
he completed an internship at Novartis Pharmaceutical Corporation, East Hanover, NJ (summer
2010). As a doctoral student he received best poster presentation award at Sigma Xi Student
Research Poster Symposium, held at University of Mississippi (2008). He received NIH pre-

doctoral fellowship twice, awarded by Centers of Biomedical Research Excellence, University of
Mississippi (2007 and 2009). He is a member of Honor Societies Phi Kappa Phi and Rho-Chi,
and American Association of Pharmaceutical Scientists (AAPS). As a graduate student, he
served as the Senator for the Department of Pharmaceutics in Graduate Student Council (20082009), and the Treasurer (2006-2007), Chair-Elect (2008-2009) and Chair (2009-20010) for the
AAPS-University of Mississippi Student Chapter. As a Chair-Elect and Chair organized
PharmForum-2009 and PharmForum-2010, respectively, at University of Mississippi.
He is author and co-author of several peer reviewed publications and presented his
research work at various international conferences. He completed his Ph.D degree in September
2011.

PEER REVIEWED PUBLICATIONS

Book Chapter
•

Srirangam R and Majumdar S. Transscleral drug delivery to the posterior segment of the
eye: Particulate and colloidal formulations and biopharmaceutical considerations. In Drug
Delivery Research. Edited by Dr. Ashim K. Mitra. Publisher: Research Signpost and
Transworld Research Network. (Under Publication)

Research Articles
•

Srirangam R, Hippalgaonkar K and Majumdar S. Intravitreal kinetics of hesperidin,
hesperetin and hesperidin G: effect of dose and physicochemical properties. J. Pharm Sci.
(Under Review)

•

Srirangam R, Hippalgaonkar, K Avula B, Khan IA, and Majumdar S. Ocular
bioavailability of hesperidin and hesperetin following systemic and topical administration
in the rabbits. Pharm. Res. (Communicated)

•

Hippagaonkar K, Srirangam R, Avula B, Khan IA, and Majumdar S. Interaction between
topically and systemically co-administered p-glycoprotein substrates/inhibitors: effect on
vitreal kinetics. Drug Metab Dispos. 2010; 38(10):1790-7.

•

Majumdar S and Srirangam R. Potential of the bioflavonoids in the prevention/treatment
of ocular disorders. J Pharm Pharmacol. 2010; 62 (8): 951-965.

•

Srirangam R and Majumdar S. Passive asymmetric transport of hesperetin across isolated
rabbit cornea. Int J Pharm. 2010; 394(1-2):60-7

•

Majumdar S, Hingorani T, and Srirangam R. Evaluation of active and passive transport
processes in corneas extracted from preserved rabbit eyes. J Pharm Sci 2009; 99(4):19211930

•

Majumdar S, Hippagaonkar K, and Srirangam R. Vitreal kinetics of quinidine in rabbits
in the presence of topically co-administered P-gp substrates/modulators. Drug Metab
Dispos. 2009; 37(8):1718-25

•

Majumdar S, Hingorani T, Srirangam R, Gadepalli RS, Rimoldi JM, and Repka MA.
Transcorneal permeation of L - and D - aspartate ester prodrugs of acyclovir: delineation
of passive diffusion versus transporter involvement. Pharm Res. 2009; 26(5): 1261-9

•

Majumdar S and Srirangam R. Solubility, stability, physiochemical characteristics and in
vitro ocular tissue permeability of hesperidin: a natural bioflavonoid. Pharm Res. 2009;
26(5): 1217-25.

•

Repka MA, Majumdar S, Battu SK, Srirangam R, Upadhye SB. Applications of hot-melt
extrusion for drug delivery. Expert Opin Drug Deliv. 2008; 5(12): 1357-1376 (Most
downloaded article of the journal in year 2009)

•

Lagishetty C, Kallem R, Karthik A, Sundari BT, Srirangam R, Mullangi R, and Srinivas
NR. A rapid and highly sensitive method for the determination of glimepiride in human
plasma by liquid chromatography- electrospray ionization tandem mass spectrometry:
application to a pre-clinical pharmacokinetic study. Biomed Chromatogr. 2008; 22(1):
58-63

•

Yamsani S, Srirangam R, Yamsani MR, and Paradkar AR. Effect of rifampicin
pretreatment on the transport across rat intestine and oral pharmacokinetics of ornidazole
in healthy human volunteers. Drug Metabol Drug Interact. 2007; 22(2-3):151-163

•

Srirangam R, Yamsani S, and Yamsani MR. Effect of ketoconazole on oral
pharmacokinetics of ornidazole – a possible role of P-glycoprotein and CYP3A. Drug
Metabol Drug Interact. 2006; 22(1):67-77

